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Resumo 
Com o aumento da esperança média de vida são várias as doenças incapacitantes que 
surgem no envelhecimento e com grande impacto na qualidade de vida do Homem. 
Podemos incluir nesta categoria as doenças cardiovasculares, neurológicas, 
musculosqueléticas e várias outras doenças de origem maligna. Daí a urgência e 
importância de desenvolver novos tratamentos mais eficientes e capazes de minimizar ou 
até eliminar estas incapacidades. A seguir às lesões do sistema nervoso central (SNC), 
as lesões do sistema nervoso periférico (SNP) são as que têm menor sucesso no que 
respeita à recuperação funcional apesar da melhoria constante das técnicas de 
microcirurgia surgirem com elevada frequência na prática clínica. Uma total compreensão 
quer molecular quer celular, do processo regenerativo do nervo periférico incluindo da 
recuperação funcional e de uma (possível) reinervação do(s) órgão(s) alvo, após uma 
lesão de axonotmese ou de neurotmese, continua a ser um dos principais objectivos da 
biologia e medicina regenerativa. O modelo experimental in vivo mais utilizado em 
estudos de regeneração do nervo periférico tem sido o nervo ciático do rato. Apesar das 
lesões do nervo ciático não serem comuns em Humanos, este modelo experimental é 
muito realista no que respeita ao estudo de nervos mistos ou plurifasciculares com 
axónios de diferentes tamanhos e origens. Nos últimos anos, os avanços na Medicina 
Regenerativa têm sido notáveis, e a comunidade científica tem testemunhado a 
descoberta de novos conceitos com grande impacto na área. Até há alguns anos atrás 
era do entendimento geral que a maioria dos tecidos apresentava uma capacidade 
limitada de regeneração. Hoje em dia é do conhecimento comum que quase todos os 
órgãos e tecidos poderão regenerar, parcial ou totalmente (num cenário ideal) com base 
em terapias celulares e engenharia de tecidos. No que se refere à engenharia de tecidos 
e às terapias celulares, as células estaminais mesenquimatosas (MCSs) têm suscitado 
bastante interesse devido às suas características, nomeadamente, elevada plasticidade, 
capacidade de proliferação e diferenciação, assim como as suas propriedades 
imunossupressoras. As MSCs têm a capacidade de produção de factores tróficos, 
produção de moléculas da matriz extracelular, modulação da resposta imunológica e de 
diferenciação em células de Schwann ou noutras células envolvidas na degenerescência 
Walleriana e regeneração axonal. Estudos recentes demonstram que as MSCs são 
capazes de modificar o microambiente em torno do tecido lesionado, promovendo a 
reparação com melhorias funcionais através da secreção de factores de crescimento, 
conhecido como o efeito paracrino, que estimulam as populações de células existentes 
no local, diminuindo a resposta imune e inflamatória. Estas células têm ganho adeptos 
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devido a vários fatores: i) maior número de células estaminais por volume; ii) não é 
necessária uma compatibilidade antigénica HLA tão exigente como para as células da 
medula óssea, alargando o número de dadores disponíveis, r baixa expressão dos 
antigénios HLA classe I e ausência de expressão dos antigénios HLA classe II; e iii) são 
mais fáceis de obter, processar e criopreservar e a sua colheita é eticamente aprovada e 
legislada pelas leis nacionais e internacionais.  
No presente trabalho pretendeu-se avaliar o efeito terapêutico das MSCs humanas 
(HMSCs), isoladas da geleia de Wharton do cordão umbilical (UC), em lesões de 
axonotmese e neurotmese do nervo ciático do rato. Este manuscrito inclui os resultados 
obtidos com HMSCs indiferenciadas e diferenciadas em células tipo neurogliais, 
infiltradas localmente na lesão ou associadas a diferentes biomateriais, dois dos quais já 
disponíveis no mercado: poly(DL-lactide-ε-caprolactone) (PLC, Vivosorb®), um híbrido de 
quitosano e um selante hemostático composto por colagénio e trombina (Floseal®). Uma 
vez que estes biomateriais já foram previamente estudados pelo nosso grupo de 
investigação em lesões de axonotmese e de neurotmese do nervo ciático, este trabalho 
focou-se no desenvolvimento de um sistema celular seguro e capaz de expansão in vitro 
– as MSCs isoladas da geleia de Wharton do UC. Os estudos in vitro das HMSCs 
indiferenciadas e sujeitas a diferenciação, incluíram avaliação de citocompatibilidade dos 
biomateriais desenvolvidos, caracterização celular por imunocitoquímica, análise de 
cariótipo, citometria de fluxo e perfil metabólico durante a expansão e a diferenciação. Os 
ensaios in vivo recorrendo a lesões de axonotmese e de neurotmese do nervo ciático de 
ratos adultos Sasco Sprague, incluíram uma análise em termos de biocompatibilidade, 
recuperação funcional durante 12 ou 20 semanas respectivamente e análise morfológica 
por histomorfometria. As HMSCs isoladas da geleia de Wharton do UC associadas aos 
diversos biomateriais utilizados, são uma potencial ferramenta para promover a 
recuperação funcional e morfológica, em especial, de nervos sensitivos após 
traumatismo, especialmente em lesões de neurotmese quando não é possível realizar 
uma sutura epineural topo-a-topo sem tensão ou um autoenxerto. Estas células não 
apresentam qualquer controvérsia ética, podem ser colhidas no momento do parto, 
criopreservadas, descongeladas e expandidas para aplicações terapêuticas. Da 
necessidade de um estudo longitudinal e do envolvimento multidisciplinar incluindo o 
desenvolvimento de biomateriais e de sistemas celulares, bem como para ensaios pré-
clínicos recorrendo a modelos animais apropriados, o bem-estar animal e a legislação em 
vigor foram sempre considerados desde o primeiro dia deste trabalho experimental. 
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Abstract 
With the world wide global increase in life expectancy, a variety of disabling diseases with 
large impact on human population are arising. This includes cardiovascular, neurological, 
musculoskeletal, and several other malignancies. Therefore, it is imperative that new and 
more effective treatment procedures are developed to minimize or even rectify these 
changes. After Central Nervous System (CNS) lesions, Peripheral Nervous System (PNS) 
injuries are the ones with minor successes in terms of functional recovery and the most 
frequent in clinical practice. A full understanding of peripheral nerve regeneration process, 
especially what concerns a complete functional recovery and organ reinnervation after 
nerve injury, still remains the principle goal of regenerative biology and medicine. The rat 
sciatic nerve has been the most commonly experimental animal model used in studies 
concerning peripheral nerve regeneration and possible therapeutic approaches. Although 
sciatic nerve injuries themselves are rare in humans, this experimental model provides a 
very realistic testing bench for lesions involving plurifascicular mixed nerves with axons of 
different size and type competing to reach and reinnervate distal targets. Recent 
advances in Regenerative Medicine are remarkable and in the last years the scientific 
community has witnessed the arrival of many new concepts and discoveries. Until a few 
years ago, biological tissues were regarded as unable of extensive regeneration, but 
nowadays organs and tissues appear as capable to be reconstructed, based on “stem 
cells”. Mesenchymal stem cells (MSCs) have become one of the most interesting targets 
for tissue regeneration due to their high plasticity, proliferative and differentiation capacity 
together with their attractive immunosuppressive properties. Cellular systems implanted 
into an injured nerve may produce growth factors or extracellular matrix molecules, 
modulate the inflammatory process and eventually improve nerve regeneration. It has 
been speculated that once MSCs have the potential to differentiate into several tissues, 
they might be responsible for turnover and maintenance of adult tissues. Recent studies 
demonstrated that transplanted MSCs are able of modifying the surrounding tissue 
microenvironment, promoting repair with functional improvement by secretion of growth 
factors (known as paracrine effect), by stimulating the pre-existing stem cell populations 
and by decreasing the inflammatory and immune response. The stem cells obtained from 
the umbilical cord are a promising alternative once: i) the number per volume is higher, ii) 
a complete or high HLA profile match for allogenic use is not necessary due to the low 
expression of HLA class I antigens in addition to the absence of HLA class II expression, 
which permits a great enlargement of the number of available donors iii) the stem cells are 
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easier to obtain, and to be cryopreserved, and their collection is ethically approved by 
national and international laws.  
In the present study, the therapeutic value of human umbilical cord matrix (Wharton’s jelly) 
MSCs (HMSCs) on rat sciatic nerve after axonotmesis and neurotmesis injuries, was 
evaluated. This manuscript includes the results obtained with undifferentiated HMSCs or 
differentiated into neuroglial-like cells locally infiltrated or delivered by different 
biomaterials, two of them already available in the market: poly(DL-lactide-ε-caprolactone) 
(PLC Vivosorb®) membrane, hybrid chitosan developed by our research group, and a 
haemostatic sealant composed of collagen-derived particles and topical bovine-derived 
thrombin (Floseal®). Since these biomaterials were already previously tested by our 
research group in sciatic nerve injuries, this work was focused in the development of a 
safe and in vitro expandable cellular system – the MSCs from the Wharton’s jelly of the 
umbilical cord. The in vitro studies of the scaffolds included cytocompatibility evaluation of 
the biomaterials used and cell characterization by immunocytochemistry, karyotype 
analysis, differentiation capacity into neuroglial-like cells, metabolic profile during 
expansion and differentiation, and flow cytometry. In the present work MSCs were 
expanded and differentiated in vitro in neuroglial-like cells and in vivo testing was carried 
out in Sasco Sprague adult rats. After axonotmesis and neurotmesis injuries and 
therapeutic treatment, follow-up for a complete functional evaluation was performed 
during 12 to 20 weeks, respectively and the repaired nerves processed for stereological 
analysis, allowed a morphologic regeneration evaluation. The MSCs from the Wharton’s 
jelly delivered through tested biomaterials should be regarded as a potentially valuable 
tool to improve clinical outcome especially after trauma to sensory nerves when an 
epineural end-to-end suture without tension or grafting are not possible. In addition, these 
cells represent a non-controversial source of primitive mesenchymal progenitor cells that 
can be harvested after birth, cryogenically stored, thawed, and expanded for therapeutic 
uses. The importance of a longitudinal study concerning tissue engineering of the 
peripheral nerve, which includes a multidisciplinary team able to develop biomaterials 
associated to cell therapies, to perform pre-clinical trials concerning animal welfare and 
the appropriate animal model was always enhanced since the first day of this 
experimental work. 
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Introduction 
Peripheral neuropathy may be inherited or acquired. The inherited are caused by inborn 
mutations. Some genetic mistakes lead to mild neuropathies with little significant 
impairment, starting at early adulthood. Other genetic alterations are more severe and 
frequently appear in infancy or childhood and are known as disorders that are responsible 
for extreme weakening and wasting of muscles in the lower legs and feet, gait 
abnormalities, loss of tendon reflexes, and numbness in the lower limbs, among other 
symptoms. Acquired peripheral neuropathies are grouped into three broad categories: (i) 
caused by systemic disease; (ii) caused by trauma from external agents, and (iii) caused 
by infections or autoimmune disorders affecting nerve tissue. It is recurrent that the 
specific cause is unknown and sometimes iatrogenic. Clinicians usually refer to 
neuropathies with no known cause as idiopathic neuropathies. This thesis is focused in 
peripheral nerve injuries caused by traumatic/physical injuries, which are the most 
common. Sudden trauma, such as motor vehicle accidents, falls, industrial accidents, 
penetrating traumas and sport-related activities cause severe lesions to nerves.  
Even after many years of research, results are very disappointing specially concerning the 
functional recovery of the peripheral nerve (Flores et al., 2000). It is crucial to have a 
complete knowledge of peripheral nerve anatomy before we start any kind of study. The 
perfect knowledge passes through a solid understanding of the various components of 
intraneural arrangements (Flores et al., 2000). Before a deep dive in the peripheral nerve 
regeneration it is vital to have an overview on the anatomy and physiology of the nervous 
system especially on the peripheral nervous system (PNS). 
 
1. Nerve Anatomy 
The nervous system coordinates internal organ functions and responds to external 
environmental stimulus. It is divided into the central nervous system (CNS) and the 
peripheral nervous system (PNS); the last was intensively studied for the past years and 
the basis of the research work of the PhD thesis, described in this manuscript. The PNS 
functions in order to receive and respond to stimuli for and from the brain and spinal cord 
which together form the CNS (McKinley et al., 2008). The cranial nerve, spinal nerve, 
plexuses, ganglia and peripheral nerves all together constitute de PNS (McKinley et al., 
2008).  
The CNS and PNS together have three main functions: collecting information (receptors - 
PNS), processing and evaluating information (sensory system – PNS and CNS) and 
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responding to stimuli (motor system – PNS and CNS) (McKinley et al., 2008). Mainly we 
have two functional divisions for nervous system: sensory nervous system (SNS) and 
motor nervous system (MNS). 
In SNS nerves from PNS diffuse sensory information to specific parts of brain and spinal 
cord and the CNS interprets the information, so is responsible for input. There are two 
components in this system, the somatic sensory and the visceral sensory component. The 
somatic is considered a voluntary mechanism once there is some kind of control on it; this 
includes the somatic and special sense. The visceral is considered involuntary because 
there is no control over it (McKinley et al., 2008). On the other hand, the CNS is 
responsible for the output, so transmitting motor stimuli from de CNS to muscles and 
glands. The peripheral nerve organization has been studied for at least two centuries 
(Stewart, 2003) as described. 
 
 
Figure 1 – Cellular organization within nervous tissue.  
 
1.1. Neurons 
Neurons are the basic functional unit of nervous system. They have a high metabolic rate, 
survival depending on a continuous and abundant supply of glucose and oxygen. They 
have an extensive longevity and may survive since fetal development until elder age. 
They are unable to divide, typically are considered as unmitotic (McKinley et al., 2008). 
Although neurons may appear in many shapes and sizes, they all consist of the following 
common basic structures (Figure 2): 
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Figure 2 – Representation of neuron structure. 
 
 Cell body – or the soma is the control centre, being mainly responsible for 
receiving, transforming and redirecting the nerve impulse. Surrounded by a plasma 
membrane the cell body encloses a nucleus where the high metabolic activity 
occurs. 
 Dendrites – short branching fibres from the cell body. There may be one or more 
for each neuron. The more dendrites a neuron has, higher is the contact surface 
with the surroundings which permits higher input of nerve impulses. This structure 
is essentially responsible for the input of the nerve impulse. 
 Axon – elongated projection from the cell body, also named nerve fibre. A neuron 
may have one or no axon at all. They are responsible for the output of information. 
Neurons may be classified according to their morphological structure (table 1) or function 
(Table 2). The structural classification depends on the number of dendrites extending from 
the cell body. 
 
Table 1: Structural classification of neurons 
Classification Description Function 
Unipolar Neuron 
No dendrites only with a single axon, 
normally with a T shape resulting 
from the fusion of two processes into 
one long axon 
Sensory neuron 
Bipolar Neuron 
Very uncommon with one dendrite 
and one axon 
Special sensor neurons 
found in retina and 
olfactory epithelium 
Multipolar 
Neuron 
Most common with several dendrites 
and mostly one axon 
Interneurons and motor 
neurons 
Adapted from (McKinley et al., 2008) 
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Table 2: Functional Classification of Neurons 
Classification Description Structural 
Sensory 
Conducts nerve impulse from body to 
CNS 
Mostly unipolar and a few 
bipolar 
Motor 
Conducts nerve impulse from CNS to 
muscles and glands 
Multipolar 
Interneuron 
Existing only in CNS; facilitating 
communication between motor and 
sensory neurons 
Multipolar 
Adapted from (McKinley et al., 2008) 
 
Considering function, neurons may be classified as sensory, motor or interneurons. As 
described on table 2. 
 
1.2. Glial Cells 
Glial cells differ from neurons in size, since these are smaller cells, and on mitotic 
capacity, once they are able to divide (McKinley et al., 2008). There are two types of PNS 
glial cells, the satellite flat cells arranged around neural cell bodies in ganglia and the 
neurolemmocytes called Schwann cells (SCs), associated with PNS neurons and 
responsible for myelinating PNS axons and for surrounding the unmyelinated axons. 
Peripheral nerve regeneration is entirely dependent on the SCs, which play a vital role in 
the guidance of axonal growth towards distal end during regenerative process after 
axonotmesis and neurotmesis injuries. They are also responsible for generating an 
appropriate environment in the injured tissue as they produce extracellular matrix (ECM), 
cell adhesion molecules, integrins and neurotrophins and play a fundamental role during 
the Wallerian degeneration (Schmidt et al., 2003). 
 
1.3. Peripheral Nerve System 
The peripheral nerve (Figure 3) is composed of several axons with various sizes which 
are surrounded by connective tissue and nerve components. The outer layer of 
connective tissue is the epineurium that drags all fascicles together, this is the stronger 
sheath. The perineurium surrounds one or more fascicles that for its turn contain 
individual axons and SCs. The endoneurium is the last sheath that surrounds the 
myelinated axon or unmyelinated cluster of nerve fibres associated with SCs. All together 
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form a network that organize and protects the fibres and axons (Flores et al., 2000; 
Eroschenko, 2012). 
 
Figure 3 – Cross section of peripheral nerve 
 
The number and size of fascicles diverge significantly, not only among different nerves but 
also inside the same nerve in different sites along the structure (Stewart, 2003). Nerves 
can be mono, oligo and poly-fascicular. About longitudinal organization of these 
fascicules, two opposite hypothesis have arisen in these last two centuries. The first one 
defines that the fascicules are settled like cables (Figure 4A) and the more recent views is 
that along the structure there is branching, splitting and re-joining of fascicules and parts 
of it, the so called plexiform structure (Figure 4B) (Stewart, 2003). Evidence has shown 
that in truth there is a mixture of both theories.  
 
Figure 4 - Representation of the two hypotheses for fascicular organization of peripheral nerve. (A) 
Cable structure and (B) Plexiform (Stewart, 2003). 
 
A B 
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2. Nerve Injury 
Many people are affected by peripheral nerve injuries (PNI) every year, striking about 
2.8% of trauma patients (Deumens et al., 2010b). A large number of patients remain with 
the incapacity for all their life’s (Madduri et al., 2010), this brings huge disabilities across 
the world. These injuries are of extreme importance since they lead to disturbances in 
functions mediated by the injured nerve (Deumens et al., 2010b) and there for the delay, 
or even preclude the return to work of the patients. PNI also compromise the quality of life 
of patients as it increases the risk of secondary disabilities resulting from falls and 
secondary injuries (Robinson, 2000). Until late 18th century, it was believed that peripheral 
nerves would never regenerate (Siemionow et al., 2010). Since then, many advances 
have been done in this field, but it still remains a clinical challenge. 
 
2.1. Classification 
Peripheral nerve injury may present or not gaps between nerve stamps. Axons extensions 
can regenerate over the gap reconnecting to distal stump  (Siemionow et al., 2010). In the 
absence of an intervention, functional regeneration is restricted due to scars, neuroma 
formation, mismatched fibres or extensive splitting of the re-growing axons; moreover 
peripheral regeneration is often associated to neuropathic pain, which is even more 
limiting for the patient than the incomplete functional recovery (Keilhoff et al., 2011). The 
functional outcome gets worse with the degree of injury and regeneration is weaker if a 
nerve gap or neuroma has been developed leading to total functional impairment 
(Siemionow et al., 2010; Keilhoff et al., 2011). Temporal delay from time of trauma to 
surgical repair is also an important factor for poor functional outcome (Walsh et al., 2009). 
There are two proposed classification for peripheral nerve injuries (Table 3). One 
proposed by  Seddon in 1975 and another proposed by Sunderland in 1978 (Robinson, 
2000). The Seddon classification is more commonly used in literature and among the 
clinical field. The one proposed by Sunderland is a more subdivided scheme and less 
straight forward (Robinson, 2000). 
As described by Seddon, neuropraxia is a minor injury with motor and sensory loss but 
with no evidence of Wallerian degeneration (Robinson, 2000). Axonotmesis lesion 
frequent in crush, nerve stretch and percussion injuries. The axon and myelin sheaths 
disrupt but the surrounding stroma maintains partially or even totally intact. Wallerian 
degeneration occurs but axonal regeneration can follow along the intact endoneurial tube 
(Robinson, 2000). Resuming, neuropraxia and axonotmesis have a good clinical 
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prognosis and a surgical reconstruction is not need in most of the cases. Neurotmesis is 
an injury where the nerve is completely transected, with or without loss of tissue (gap) and 
it may be evidently disorganized by scars, without a surgical reconstruction the axonal 
regrowth is impossible (Robinson, 2000). Normally it is associated with an evident poor 
functional recovery comparing with other injuries, especially if the distance between injury 
and target organ or tissue is quite long (Walsh et al., 2009). 
 
Table 3: Classification system for nerve injuries 
Seddon 
Classification 
Sunderland 
Classification 
 
Pathology 
 
Prognosis 
Neuropraxia First degree 
Myelin injury or 
ischemia 
Excellent recovery in weeks to 
months 
Axonotmesis  
Axon loss 
Variable stromal 
disruption 
Good to poor, depending upon 
integrity of supporting structures and 
distance muscle 
 
Second 
degree 
Axon loss 
Endoneurial tubes 
intact 
Perineurium intact 
Epineurium intact 
Good, depending upon distance 
muscle 
 Third degree 
Axon loss 
Endoneurial tubes 
disrupted 
Perineurium intact 
Epineurium intact 
Poor 
Axonal misdirection 
Surgery may be required 
 
Fourth 
degree 
Axon loss 
Endoneurial tubes 
disrupted 
Perineurium 
disrupted 
Epineurium intact 
Poor 
Axonal misdirection 
Surgery usually required 
Neurotmesis Fifth degree 
Axon loss 
Endoneurial tubes 
severed 
Perineurium 
severed 
Epineurium 
severed 
No spontaneous recovery 
Surgery required 
Prognosis after surgery reserved 
Adapted from (Robinson, 2000) 
 
2.2. Wallerian Degeneration 
PNS axons are very vulnerable to traumas like cross section and crushing. However, 
regeneration of axons is possible depending on the extension of the lesion. It depends on 
3 factors: (i) the amount of damage; (ii) the secretion of growth factors and (iii) the 
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distance between site of injury and the effector organ. This regeneration process is called 
Wallerian degeneration. 
 
Figure 5 - After axonotmesis a traumatic degeneration occurs in the proximal nerve segment and 
the immediate distal portion of the nerve. Within 2 to 4 days, Wallerian degeneration occurs in the 
distal segment of the axon and lasts for 1 to 2 weeks. 
 
After a trauma peripheral nerve regeneration is basically supported by SCs (Keilhoff et al., 
2011), who play a vital role during the Wallerian degeneration (Figure 5) in which the 
distal segment suffers a slow process of degradation. The SCs are responsible for 
removing the debris, which is the primordial step of this process which starts immediately 
after injury and implicates myelin breakdown. The end of the proximal portion seals off by 
membrane fusion and swells. This is a result of cytoplasm flowing from the neuron cell 
body through the axon. The distal portion of the axon and its myelin sheath degenerate, 
SCs and macrophages are recruited to the damaged site in order to phagocyte all myelin 
and cellular debris. These SCs organize themselves into the regeneration columns, called 
the Büngner bands, which guide the axon development as it begins to grow rapidly 
through the regeneration tube at a rate of about 5 mm per day under the influence of 
nerve growth factors released by the SCs. Following Wallerian degeneration the axon 
regenerates and remyelination occurs. Innervation is restored as soon as the axons re-
established contact with its original effector organ or tissue (Flores et al., 2000; McKinley 
et al., 2008; Keilhoff et al., 2011). 
Proliferating SCs produce neurotrophins, cell adhesion molecules, and cytokines which 
support axonal regeneration and recruit more cells into the injured site (Walsh et al., 
2009). Axonal regeneration depends on SCs promotion, so unless nerve contact is rebuilt 
quickly when there is a gap between the nerve stumps, SCs lose their ability to assist 
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regeneration which leads to a poor functional recovery and in most cases, to neuroma 
formation (Keilhoff et al., 2011). 
 
3. Surgical reconstruction of peripheral nerve injuries 
3.1. Microsurgical procedure 
Reconstructive repair strategies are based on nerve injuries from 3rd degree forward, on 
the other hand, 1st and 2nd degree lesions are left to heal spontaneously (Pfister et al., 
2011). At this moment surgery is the only treatment for severe injured nerves, when the 
gap is short and a direct tension-free suture coaptation of the nerve stumps is possible 
(Madduri et al., 2010).  
The rat is the most commonly used animal model for peripheral nerve regeneration 
studies, due to both its widespread availability and the distribution of their nerve trunks 
which is similar to humans (Mackinnon et al., 1985). The rat’s sciatic nerve (Figure 6) has 
an advantage in terms of surgical approach: it provides a nerve trunk with adequate length 
and space at the mid-thigh for surgical manipulation and insertion of grafts or guide tubes. 
For that reason it’s still the most employed experimental model (van Neerven et al., 2012).  
 
 
Figure 6 – Surgical approach to the rat’s sciatic nerve. 
 
An appropriate animal model choice is fundamental for pre-clinical studies and must 
precede any clinical trial. Experimentally induced injuries including focal crush or freeze 
injury that cause axonal interruption but preserves the connective sheaths (axonotmesis), 
complete transection disrupting the whole nerve trunk (neurotmesis) and resection of a 
nerve segment inducing a gap of a certain length, are common procedures in these 
research area ( aur cio et al., 2011).  
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Adequate measures must be done to minimize pain and discomfort, human endpoints for 
animal suffering and distress must be taken in account since animal welfare is an 
important and serious issue. All procedures must be performed with the approval of the 
Local Country Veterinary Authorities in accordance with the European Communities 
Council Directive of November 1986 (86/609/EEC). 
Surgeries are performed using an M-650 operating microscope (Leica Microsystems, 
Wetzlar, Germany). Under deep anaesthesia, the right sciatic nerve is exposed through a 
skin incision extending from the greater trochanter to the distal mid-half of the femur 
followed by a muscle splitting incision. For axonotmesis, after nerve mobilisation, a 
standardized crush injury is performed using a non-serrated clamp (Institute of Industrial 
Electronic and Material Sciences, University of Technology, Vienna, Austria, figure 7A) 
exerting a constant force of 54 N for a period of 30 s, 10 mm above the bifurcation into 
tibial and common peroneal nerves inducing a 3 mm lesion (Figure 7B) (Luís et al., 2007; 
Gärtner et al., 2012a; Gärtner et al., 2012b). 
 
 
Figure 7 – (A) 3mm axonotmesis lesion (B) Non-serrated clamp (Luís, 2008) (Institute of Industrial 
Electronic and Material Sciences, University of Technology, Vienna, Austria). 
 
For neurotmesis a transection injury is performed using straight microsurgical scissors. 
The nerve must be injured at a level as low as possible, generally immediately above the 
terminal nerve ramification. For neurotmesis with a nerve gap (the animal model of 
neurotmesis developed in our studies includes a gap of 10 mm), the proximal and distal 
nerve stumps are inserted 3 mm into the tube guide and held in place, maintaining a 
nerve gap of 10mm (Figure 8A), with two epineural sutures using 7/0 monofilament nylon. 
For neurotmesis without a gap, the nerve is reconstructed with an end-to-end suture 
(Figures 8B), with two epineural sutures using de 7/0 monofilament nylon. Finally the skin 
A B 
3 mm 
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and subcutaneous tissues are closed together with a simple-interrupted suture of a non-
absorbable filament. An antibiotic should always be administered to prevent any 
infections. To prevent autotomy a deterrent substance must be applied to rats’ right foot 
(Kerns et al., 1991; Sporel-Ozakat et al., 1991).  
At this moment of state of art there are three surgical approaches for nerve reconstruction: 
(i) direct repair, (ii) nerve grafting and (iii) nerve transfer. 
 
 
Figure 8 – Nerve reconstruction after neurotmesis lesion (A) nerve gap of 10mm (B) end-to-end 
suture 
 
3.1.1. End-to-end suture  
End-to end suture or direct repair is a suitable approach for reconnecting an injured nerve 
where no gap exists between the ends or when the suture can be performed without 
tension (Pfister et al., 2011). At the best, if there is no scar tissue at the suture point, 
proximal axons will grow through the proliferating SCs into the distal segment promoting 
and directing regeneration. However, this strategy brings some difficulties in reproducing 
the original alignment of the nerve fascicles inducing some tension (Pfister et al., 2011). 
 
 
Figure 9 - Surgical reconstruction, end-to-end reconnection. 
A B 
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3.1.2. Autograft 
To avoid excessive connective tissue formation and tension when re-joining nerve ends a 
bridging material is used. An autologous nerve grafting (nerve autograft) is the selected 
method and the gold standard in these injuries. Autografting is the best choice for severe 
peripheral gaps where direct coaptation is not possible without tension (Madduri et al., 
2010). Autografting carries several limitations; because it depends on the quality, quantity 
and appropriate size of donor’s nerve. Nerve harvesting causes co-morbidity at donor site, 
loss of sensation, neuroma and scar formation, plus an insufficient revascularization of the 
graft may be the frequent reason for unsuccessful functional recovery (Madduri et al., 
2010; Keilhoff et al., 2011). 
 
3.1.3. Allograft 
When autografts are not a possible choice, allografts and nerve conduits may be an 
option, as a good alternative for gaps between 3-10mm. In comparison with artificial nerve 
conduits these grafts have more biocompatibility, are less toxic and are more propitious to 
cell adhesion and growth. Nevertheless, allografts might undergo rejection so they require 
immunosuppressive therapies for at least two years, and carry many difficulties in 
isolation, so this strategy is typically reserved for cases with extensive or even irreparable 
nerve damages (Pfister et al., 2011). 
 
3.1.3.1. Non-autologous and acellular grafts 
Non-autologous tissues have a great value for investigators as an attempt to outline the 
limitations of allografts. Allogeneic tissues from cadaveric donors and xenogeneic tissues 
from animal origin are available in large amounts and do not carry harvesting difficulties. 
Nevertheless rejection and consequent immunosuppression treatment remain as a 
concern and disease transmission may also be a problem to take under consideration 
(Schmidt et al., 2003). To avoid immunorejection ablation of immunogenic components 
during the biomaterial processing is possible. Methods focus on removal or destruction of 
antigen cells maintaining the ECM components viable. Decellularization methods may be 
thermal, radiation or chemical processes (Schmidt et al., 2003) which have been 
demonstrated not to be quite efficient. Thermal technique involves repeated cycles of 
freezing and heating, which has been efficient in cellular immunogenic destruction, leaving 
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however the ECM structure damaged and leading to inflammation. Radiation treatment 
has less damage on ECM, but the removal of cell debris is not complete. Chemical 
process that gives a good cellular clearance and maintain the ECM structure are the 
method with best results (Schmidt et al., 2003). The use of acellular tissues in nerve repair 
may become a good alternative for the future. 
 
4. Tissue engineering  
Many in vivo studies with animal models have proven that nerves are capable to 
regenerate through various types of conduits.  In the mainstream studies with rats, the 
nerve gaps ranged between 10-50mm in length. Concerning to the rat model, the sciatic 
nerve has been consensual for peripheral nerve regeneration studies. Rat and mouse, 
have been one of the most commonly used animal models for peripheral nerve 
regeneration studies due to their widespread availability as well as to the distribution of 
their nerve trunks which is similar to humans (Mackinnon et al., 1985). There are a few 
studies where a 80mm gap was performed in other animal models like sheep (Strasberg 
et al., 1996) and swine (Atchabahian et al., 1998) but the axonal regeneration was very 
weak (Siemionow et al., 2010). Other nerve trunks, especially in the rat forelimb, are 
getting more and more used for experimental research (Papalia et al., 2006) but, the rat 
sciatic nerve is still the far most employed experimental model as it provides a nerve trunk 
with adequate length and space at the midthigh for surgical manipulation and introduction 
of grafts or guides (Rodriguez et al., 2004;  aur cio et al., 2011). Sciatic nerve injuries are 
rare in humans, yet this experimental model provides a very realistic testing bench for 
injuries involving plurifascicular mixed nerves with axons of different size and type 
competing to reach and reinnervate distal targets (Mackinnon et al., 1985). 
 
4.1. Nerve conduits 
The very first reported intent to use of a nerve conduit was in 1881 by Gluck who used a 
decalcified long bone (Ijpma et al., 2008). In 1904 Foramitti defined nerve tubulation as 
“guiding frame for the divided nerves, on which the newly emerging nerve substance can 
grow in the shortest way from the central to the peripheral stump without much resistance, 
and to protect the junction against embedding in callus and scar tissues, and to keep the 
nerve gap open for regeneration from the central into the peripheral stump”. More than a 
century has passed and the concept is still the same (Ijpma et al., 2008). The first nerve 
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regeneration study was performed by Mackinnon and Dellon using monkeys as a animal 
model. They used several length bio-absorbable conduits. It was proven that peripheral 
nerves could regenerate through a 3mm nerve gap with the help of an appropriate nerve 
conduit (Dellon et al., 1988; Mackinnon et al., 1990).  
Artificial nerve conduits (NC) are presented as a promising alternative. Compared with 
autograft they have several advantages to be explored. Quantity is unlimited, size is not a 
restriction, as they can be produced in various sizes and shapes, and there is no donor-
site morbidity. Many studies over the past years have studied different artificial NC, made 
of synthetic and natural material. However, the results still remain unsatisfactory. Yet, 
artificial nerve conduits in the past 30 years have progressed from a research tool to a 
real device to be used in clinical procedures as an alternative to autografts. 
Physical and biological properties (Figure 10), such as permeability, flexibility, swelling, 
degradation, size and biocompatibility and biodegradability of nerve conduit material are 
very important for entubulation repair (de Ruiter et al., 2009;  aur cio et al., 2011). 
Permeability is of extreme importance due to the necessity of oxygen and nutrient 
diffusion into the regeneration site (de Ruiter et al., 2009). Porosity should be high enough 
to provide sufficient space for cell adhesion, extracellular matrix regeneration and the pore 
structure should allow spatial cell distribution throughout the scaffold to facilitate 
homogeneous tissue formation. A proper surface is also of vital importance because it 
must support cell adhesion, viability and tissue cell growth (Chen et al., 2002). 
Furthermore, nerve conduits should exhibit a porous structure with interconnecting pores 
of suitable size to permit a rapid and sufficient vascularization. Penetration of blood vessel 
into the scaffolds and their efficient vascularization after implantation is a major 
precondition for long-term survival of the cells within the tissue construct (Laschke et al., 
2009). Flexibility is also an important property to facilitate de bridging of the gap, although 
this offers fragility to the conduit which may break or tear the suture (de Ruiter et al., 
2009).  
The entubulation technique provides an environment for outgrowing axons and Schwann 
cells, which are indispensable elements for nerve functional recovery (Meek et al., 2008). 
Tissue engineering needs to create a nerve conduit that can minimize fibrosis, permitting 
organized nerve regeneration, being able to guide the nerve fibres to their final organ and 
allowing nutritional supply (Keilhoff et al., 2011).  
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Figure 10 – Ideal physical and biological properties of nerve conduits.  
 
Many research groups have focused their studies on synthetic nerve conduits. Compared 
with absence of surgical intervention, artificial nerve conduits significantly enhance 
regeneration (Bellamkonda, 2006). The first artificial nerve guide tested were non-
reabsorbable silicone tubes, which required a second surgery to remove the synthetic 
material (Nectow et al., 2012). Since then many different biomaterials have been tested 
and reabsorbable materials have the advantage to degrade in site and there is no need 
for second surgery to remove the material after regeneration of the tissues. The ideal 
nerve conduit should be fully degraded at the time of complete regeneration (Meek et al., 
2008). The degradation time is of extreme importance, if it’s too quick before achievement 
of complete regeneration, there will be no support for the definitive connection of the two 
edges. On the other hand if it’s too slow, it may cause compression at the site of 
regeneration inhibiting the whole process (den Dunnen et al., 1995). A large number of 
trials using different materials as nerve conduits in animal models have been performed in 
the last years (Meek et al., 2008). Nerve conduits should be easy to manage during 
surgery and be easily sterilized avoiding modification of physical properties. 
 
4.2. Biomaterials 
The ideal biomaterial for nerve conduit should be easy to: (i) design in different sizes; (ii) 
be sterilized and (iii) insert using microsurgical techniques. It must fulfil several biological 
and physicochemical requirements such as biocompatibility, biodegradability, permeability 
to ions and metabolites for the revascularization of the regenerated nerve, biomechanical 
and surface properties should enable and modulate the cellular system adhesion 
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( aur cio et al., 2011). Biomaterials may be biological or synthetic; the second ones can 
be absorbable and non-absorbable (Schmidt et al., 2003). 
 
4.2.1. Natural 
Natural derived biomaterial have the advantage that as biologically derived materials, they 
stimulate cell adhesion, migration, growth and proliferation, providing a special 
predisposition for regenerating injured nerve tissue. They are also biocompatible, don’t 
induce foreign body reaction and the degradation debris are non-toxic. These interactions 
are mediated by specific receptor-binding sites with ECM molecules such as collagen, 
laminin, fibronectin and others. So, these components have become very important 
candidates for neural scaffolds, either as primordial elements of NC material or as a 
supplement to the NC, in the form of a hydrogel (Deumens et al., 2010a). As mentioned 
before collagen is one of the most popular biological derived materials since it covers 30% 
of total body proteins, it is used either in soft and hard tissue engineering (Meek et al., 
2008; Deumens et al., 2010a). Our research group has tested a type III equine collagen 
and hybrid chitosan in axonotmesis and neurotmesis injuries with very promising results. 
Collagen has demonstrated to be a good delivery vehicle for support cells (Luís et al., 
2008b; Amado et al., 2010; Simões et al., 2010). Chitosan has recently attracted particular 
attention due to its biocompatibility, biodegradability, low toxicity, low cost, wound-healing 
enhancement and antibacterial effects together with its potential use in nerve regeneration 
that have been demonstrated both in vitro and in vivo (Shirosaki et al., 2005). In a 
previous study performed by our group, in vivo results showed that type III chitosan 
(hybrid chitosan) improved both morphological regeneration of nerve fibre and functional 
recovery. Chitosan type III is a hybrid of chitosan which was developed by the addition of 
γ-glycidoxypropyltrimethoxysilane (GPTMS). The addition of GPTMS improves the 
wettability of chitosan surfaces, and therefore it is expected to be more hydrophilic than 
the original chitosan. Chitosan type III was developed to be more porous, with a larger 
surface volume but still preserving mechanical strength and the ability to adapt to different 
shapes. Chitosan and chitosan-based materials have been proven to promote adhesion, 
survival, and neuritis outgrowth of neural cells (Amado et al., 2008; Simões et al., 2010). 
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4.2.2. Synthetic 
4.2.2.1. Non-absorbable 
In the beginning, the first nerve conduits to be used were non-absorbable silicone tubes, 
which required a second surgical intervention to remove the nerve guide (Nectow et al., 
2012). Other non-absorbable materials, such as porous stainless steel and elastomer 
hydrogel, have been reported, yet these materials carry some disadvantages. They 
induce foreign body reaction due to their characteristics, such as inflexibility and fibrous 
tissue formation therefore it is necessary to remove the conduit after recovery has been 
established (Nectow et al., 2012). 
 
4.2.2.2. Absorbable 
Absorbable NCs are the ideal, once after the device has completed its mission; no foreign 
body material will be left behind. Among synthetic biodegradable materials, two types 
attracted particular attention to our research group: Poly(DL-lactide-ε-caprolactone) (PLC) 
(Varejão et al., 2003a; Battiston et al., 2005; Luís et al., 2007a; Luís et al., 2008a; Luís et 
al., 2008b) and poly(lactic-co-glycolic acid) (PLGA) in a proportion 90:10 of the two 
polymers, poly(L-lactide): poly(glycolide) (PLA:PLG) (Luís et al., 2007b; Luís et al., 
2008a). The PLC and the PLGA 90:10 exhibits several different physical-chemical 
properties, for instance PLC is stiffer than PLGA 90:10 due to structural reinforcement of 
the ester bonds and does not degrade so fast. The biodegradation rate of PLGA tubes is 
quicker, estimated to be around 3 months while the complete reabsorption of PLC is 
estimated to be of 16 months approximately (Luís et al., 2007b; Luís et al., 2008a; Geuna 
et al., 2009). The biodegradation rate of PLGA is dependent on the proportion between 
the two polymers, PLA:PLG (Luís et al., 2008a). The degradation products of PLC are 
less acidic, which may cause less damage to the surrounding tissue, and they are 
transparent facilitating the correct positioning of the nerve stumps, while PLGA tubes may 
compromise advantages in terms of microporosity, which may improve nerve repair. In 
vitro studies have shown that the PLGA, hybrid chitosan and PLC are biocompatible with 
nerve cells and may facilitate nerve cell attachment, differentiation and growth (Luís et al., 
2007b; Amado et al., 2008; Luís et al., 2008a; Geuna et al., 2009). In vivo studies have 
demonstrated that PLGA and PLC improve significantly both motor and sensory functions. 
An important difference between both biomaterials was that the structure of the polymer 
was still well preserved, after 20 weeks, in nerves repaired by PLC while for PLGA guides 
the polymer was already substituted by a connective matrix rich in collagen fibres and 
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fibroblasts which looks like a normal epineurium. Nevertheless quantitative assessment of 
the total number of regenerated nerve fibres showed no statistical difference between 
nerves guided with PLC and PLGA (Luís et al., 2007b; Luís et al., 2008a). 
Shin and colleagues reported in 2009 a study in which they compared 3 synthetic 
bioabsorbable conduits with a reversal autograft in sciatic nerve repair. One of the 
synthetic absorbable conduits was also a PLC tube which showed the best results equally 
with the autograft. The other two conduits demonstrated to be less effective (Shin et al., 
2009). In 2008 Meek and Coert published a review with an overlook through the FDA/CE 
approved absorbable conduits (Meek et al., 2008). The next table summarizes the 
characteristic of FDA/CE approved absorbable biomaterials for nerve conduits. 
 
Table 4: FDA/CE approved absorbable nerve conduits 
 NeuraGen NeuroMatrix/NeuroFlex Neurotube Neurolac 
Composition Type I 
collagen 
Type I collagen Polyglycolic 
acid 
Poly(DL-
lactide-ε-
caprolactone) 
Company Integra 
NeuroScience 
Collagene Matrix Inc. Synovis Polyganics BV 
Maximum 
length 
3 cm 2.5 cm 4 cm 3cm 
Diameter 1.5-7 mm 2-6 mm 2.3-8mm 1.5-10mm 
Clinical Data Yes No Yes Yes 
Average 
price 
€1200 €600 (expected) €340 €700-1800 
*Adapted from (Meek et al., 2008) 
 
4.3. Supplements for Nerve Conduits 
It is estimated that tissue engineering association of biomaterials to cellular systems, 
capable of differentiating into neuroglial-like cells, may improve peripheral nerve 
regeneration, in terms of motor, sensory and histomorphometric parameters. 
In regard to supplements for conduits three main studies have been performed by several 
research groups around the world: (i) NC plus growth factors, (ii) NC cultured with SCs 
and (iii) NC cultured with different types of stem cells (Keilhoff et al., 2011). It is known 
that neurotrophic factors are naturally released after a nerve cut, compromising a 
discriminating selection of neuron types (motor or sensory) and increase in axonal 
outgrowth and neuronal survival. For this reason since 1990 growth factors have been the 
focus of many researchers, as supplement to nerve conduits for improvement of nerve 
regeneration, (de Ruiter et al., 2009). Nerve growth factor (NGF), brain-derived 
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neurotrophic factor (BDNF), ciliary neurotrophic factor (CNF) and insulin-like growth 
factor-1 (IGF-1) are some examples of natural growth factors that are produced by SCs 
and released during nerve regeneration (Siemionow et al., 2010). Growth factors have the 
advantage to be soluble and easily incorporated into nerve conduits. In vivo, the method 
for growth factor delivery into injured site has a huge influence over the promotion and 
efficacy of nerve regeneration (Schmidt et al., 2003). For this reason, it is important to 
develop strategies for growth factor delivery. 
Polymer matrices, microspheres, and gene therapy are effective delivery methods. In 
what concerns to nerve regeneration, two delivery devices have been mainly used: 
polymer matrices and microspheres. For instance the nerve guidance channel is an 
example of a polymer matrix delivery system. They have been used as a model system to 
study peripheral nerve repair, by incorporating growth factors into the conduit wall, the 
nerve guidance channel itself becomes a delivery device. This system has a major 
problem; they only provide a finite reservoir of active biomolecular agents. Therefore, 
researchers are looking towards gene therapy techniques for a long-term production of 
active growth factors in situ (Schmidt et al., 2003).  
Floseal® is an example of a ready-to-use commercial haemostatic matrix with potential 
use in Tissue Engineering previously used with success by our research group for bone 
regeneration experiments (Lobato et al., 2005). Floseal® is a haemostatic sealant 
composed of collagen-derived particles and topical bovine-derived thrombin and it has 
been proven to control bleeding in several medical applications, like vascular surgery, 
adenoidectomy, laparoscopy and partial nephrectomy. Floseal® is easily used and it can 
be extruded from a syringe and applied topically to the bleeding area. This haemostatic 
agent has the ability to acquire irregular shapes fitting the wounded site. When the 
Floseal® is in contact with blood the collagen particles are hydrated and swell, restricting 
the blood flow. The thrombin present converts the patient fibrinogen into a fibrin polymer, 
originating a clot around the lesion area of the nerve (Lobato et al., 2005). 
Our research group has tested the PLGA 90:10 and the hybrid chitosan type III tube-
guides covered with N1E-115 differentiated in vitro during 48 hours in the presence of 
dimethylsul-foxide (DMSO), into neural-like cells. The N1E-115 cells derived from mouse 
neuroblastomas differentiate in vitro into neural-like cells and were used as a cellular 
model for stem cells ( aur cio et al., 2011). The purpose to cover the tube-guides with a 
cellular system differentiated in vitro into neural-like cells, was to locally produce 
neurotrophic factors. The role of neurotrophic factors in neural regeneration has been the 
focus of extensive research (Hu et al., 1997; Amado et al., 2008;  aur cio et al., 2011). 
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The influence of these factors in neural development, survival, outgrowth, and branching 
has studied from the molecular level to the macroscopic tissue responses. Neurotrophic 
factors promote a variety of neural responses, like the survival and outgrowth of the motor 
and sensory nerve fibres, and are implicated in peripheral nerve regeneration (Johnson et 
al., 2008; Geuna et al., 2009). N1E-115 cell line established from neuroblastoma, 
undergoes neuronal differentiation in response to dimethylsul-foxide (DMSO), adenosine 
3’;5’-cyclic monophosphate (cAMP), or serum withdrawal (Rodrigues et al., 2005; Amado 
et al., 2010) was a cellular system tested in axonotmesis and neurotmesis lesions to 
locally produce and deliver these neurotrophic factors. Results obtained by our research 
group using N1E-115 cells in vitro differentiated demonstrated that in what concerns to 
promoting axon regeneration there was a modest beneficial effect on functional recovery 
on axonotmesis injury (Luís et al., 2008b) and for neurotmesis study evidences 
demonstrated negative effects on nerve fibre regeneration (Simões et al., 2010; Maur cio 
et al., 2011). The N1E-115 cells present in nerve scaffolds probably compete for the 
nutrient and oxygen provided by local blood supply, these detail in association with the 
effect of space-occupying may have held up the positive effect of local neurotrophic factor 
release leading to a negative outcome on nerve regeneration, (Amado et al., 2008; 
Simões et al., 2010;  aur cio et al., 2011). Therefore, N1E-115 cells proved to be an 
unsuitable cellular system candidate for treatment of nerve injury after axonotmesis and 
neurotmesis, and its clinical application is limited in part due to its neoplastic origin 
( aur cio et al., 2011). 
The dynamic between SCs and axon growth is primordial for axon migration. SCs have a 
crucial role during Wallerian degeneration, producing ECM molecules, expressing cell 
adhesion molecules and secreting growth factors (Evans, 2001). Cultures of SCs have 
some intrinsic difficulties, such as culture time. In addition, and unless they are from 
autologous tissue, they also have the disadvantage, of being immunogenic therefore 
requiring immunosuppressive therapy. Even for autologous tissue they still have 
limitations like donor site morbidity and very little time for culturing autologous cells. Other 
cellular systems apart from SCs, have been proposed for supplement to NCs. Specially 
stem cell systems, since they overcome many of the issues responsible limited SCs 
harvesting. 
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5. Cellular Systems 
 
 
5.1.  
Cellular Systems and Biomaterials for Nerve Regeneration in 
Neurotmesis Injuries 
In: Biomaterials Applications for Nanomedicine. InTech Edited by Rosario 
Pignatello, ISBN 978-953-307-661-4. (2011) 
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5.2.  
Mesenchymal Stem Cells from Extra-Embryonic Tissues for Tissue 
Engineering 
In: Advances in Biomaterials Science and Applications in Biomedicine. InTech 
Edited by Rosario Pignatello ISBN 980-953-307-856-9. (2013) 
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6. Methods for functional recovery analysis after axonotmesis and neurotmesis 
Even after all these studies, the functional outcome in patients still remains limited. The 
results and the understanding of such limitation are greatly dependent on the approaches, 
methods and therapeutic strategies. Choosing the correct experimental model and 
functional assay for peripheral nerve injury is essential. After peripheral nerve injury there 
are neural and mechanical disorders which are the major limitations to study the functional 
meanings of recovery (Nichols et al., 2005). The rat has become the most appellative 
animal model in peripheral nerve regeneration studies. Primarily due to the large 
availability of these animals, and also because of the similarity to humans in the 
distribution of their nerve trunks (Mackinnon et al., 1985). Although sciatic nerve injuries 
themselves are rare in humans, this experimental model provides a very realistic testing 
tool for injuries comprising plurifascicular mixed nerves. The rat sciatic nerve is the most 
experimented model since it provides a nerve trunk with adequate length and space at the 
mid-thigh for surgical manipulation and application of grafts or nerve conduits (Mackinnon 
et al., 1985). To evaluate functional recovery after sciatic nerve injury there are several 
methods available that have been extensively used by our research group.  
 
6.1. Extensor postural thrust  
The Extensor Postural Trust (EPT) or motor reflex function was originally proposed by 
Thalhammer and collaborators in 1995, for the calculation of part of the neurological 
recovery in rats after sciatic nerve injury (Thalhammer et al., 1995). In this neurological 
test, the totality of the rat’s body, with exception of the hind limbs, is wrapped in a surgical 
towel and supported by the thorax (Figure 11). The affected hind limb is then let down 
towards the platform of a digital balance to produce the EPT. As the animal is lowered 
over the platform, he extends the hind limb, anticipating the contact made by the distal 
metatarsus and digits. The force applied (in a scale range 0-500 g) to the digital platform 
balance is recorded in grams (Gärtner et al., 2012a; Gärtner et al., 2012b).  
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Figure 11 - Extensor Postural Trust (EPT) neurological test. 
 
The reduction in this force, representing a reduced extensor muscle tone, is considered a 
deficit of motor function. The same procedure is applied to the contra-lateral, unaffected 
limb. The affected and normal limbs are tested 3 times, with an interval of 2 minutes 
between consecutive trials, and the three values are averaged to obtain a final result. The 
normal (unaffected limb) EPT (NEPT) and experimental EPT (EEPT) values are 
incorporated into an equation (Gärtner et al., 2012a; Gärtner et al., 2012b). 
The percentage of functional deficit (range between 0 and 1), is derived from Equation (1) 
as described in the literature by Koka and Hadlock (Koka et al., 2001): 
 
             
         
    
 
(Equation 1) 
 
6.2. Withdrawal Reflex Latency 
The Withdrawal Reflex Latency (WRL) or hot plate sensory test is a model that allows 
independent motor and sensory testing. The rat is wrapped in a surgical towel above its 
waist and then positioned to stand with the affected hind paw on a hotplate at 56ºC 
(Figure 12). WRL is defined as the time elapsed from the onset of hotplate contact to 
withdrawal of the hind paw. Normal rats withdraw their paws from the hotplate within 4 
seconds or less (Hu et al., 1997). The affected and normal limbs are tested three times, 
with an interval of 2 minutes between consecutive testing to prevent sensitization. The 
mean value is calculated for the three latency times to obtain a final result. The maximum 
time for heat stimulation is set at 12 seconds to avoid skin damage to the foot (Varejão et 
al., 2003a; Varejão et al., 2003b; Gärtner et al., 2012a; Gärtner et al., 2012b). 
 
 
Chapter I 
Introduction 
 
 
Andréa Louise Moutinho Gärtner | 93 
 
 
Figure 12 - Withdrawal Reflex Latency (WRL) sensory test (Luís, 2008). 
 
6.3. Sciatic Functional Index and Static Sciatic Index  
Normal function of the hind limb in the rat is crucial for an accurate gait and posture. After 
a nerve injury posture and function of leg, foot and toe will be affected, changing the 
patterns of paw stepping and placement (de Medinaceli et al., 1982; Nichols et al., 2005). 
Sciatic Functional Index (SFI) is a method in which animals are tested in a confined 
walkway measuring 42-cm long and 8.2-cm wide, with a dark shelter at the end. A white 
paper is placed on the floor of the rat walkway. The hind paws of the rats are pressed 
down onto paint soaked sponge after what they are allowed to walk down the walkway 
leaving its hind footprints on the paper. Often, several walks are required to obtain clear 
print marks of both feet. Prior to any surgical procedure, all rats are trained to walk in the 
walkway, and a baseline walking track is recorded. Subsequently, walking tracks are 
recorded every week until the week-8 postoperatively and then every 2 weeks (Gärtner et 
al., 2012a; Gärtner et al., 2012b). 
 
 
Figure 13 – Measurements taken from the footprints for calculation of SFI value. 
 
Several measurements are taken from the footprints (Figure 13): 
(i) distance from the heel to the third toe, the print length (PL);  
(ii) distance from the first to the fifth toe, the toe spread (TS); and  
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(iii) distance from the second to the fourth toe, the intermediary toe spread (ITS).  
The mean distances of the measurements are used to calculate the following factors SFI 
and SSI (dynamic and static), where the capital letters E and N indicate injured 
(experimental) and non-injured side (normal), respectively. 
 
                        
       
   
 
(Equation 2) 
                                      
         
    
 
(Equation 3) 
                          
       
   
 
(Equation 4) 
  
SFI is calculated as described by Bain et al. (Bain et al., 1989) according to the following 
equation: 
 
    
         
   
      
         
   
     
         
   
     
                                                     
 
(Equation 5) 
 
 
Static footprints are obtained at least during four occasional rest periods. For the sciatic 
static index (SSI) only the parameters TS and ITS, are measured (Bervar 2000): 
 
                                             (Equation 6) 
For both SFI and SSI, an index score of 0 is considered normal and an index of -100 
indicates total impairment. When no footprints are measurable, the index score of -100 is 
given (Dijkstra et al., 2000).  
 
6.4. Kinematic analysis of the rat gait 
As mentioned before the selection of a good functional assay is of extreme importance. 
Nevertheless after neural injury there are other dysfunctions that must be evaluated, and 
for that reason the analysis of the locomotion is of extreme importance. A considerable 
work has been developed in order to establish methods for locomotion analysis in animal 
models. Kinematic parameters are essential tools for the evaluation of functional nerve 
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recovery. The first system to be used for locomotion function analysis was the open field 
locomotion scoring system formulated by Tarlov and Klinger in 1954. After this, many 
reformulations to this scoring system were done (Couto et al., 2008). With the advances in 
high technology, instrumented rat gait methods have been highly used in research. 
Voluntary movement and reflex activity are considered for functional assay analysis. Gait 
functions represent the combination of motor and sensory function and several gait 
parameters are considered with significant relationship for functional evaluation of 
experimental rat model.  
The kinematic two dimensional (2D) approach is the most friendly, since it is simple and 
requires only one camera to record the step cycles (Couto et al., 2008). Locomotion is 
described by a repetitive sequence of limb motion to move the body forward while 
maintaining the stance balance. There are three basic approaches to analyse the gait 
(Perry et al., 1993): (i) subdivision of the cycle according to the variations in reciprocal 
floor contact by the two feet; (ii) using the time and distance qualities of the stride; and (iii) 
identifying the functional significance of the events within the gait cycle and designating 
these intervals as the functional phases of gait. According to the variations in reciprocal 
floor contact by the two feet, as the body moves forward, one limb serves as mobile 
source of support while the other limb advances itself to a new support site. Stance phase 
designates the entire period during which the foot is on the ground and begins with initial 
contact (IC) and Swing phase is the phase of the normal gait cycle during which the foot is 
off the ground. The swing phase follows the stance phase and is divided into (i) initial 
swing, (ii) midswing, and (iii) terminal swing stages. Analysis of the free walking pattern of 
the rat is the mostly used method for assessment of motor function through motion 
analysis. Although locomotor activity in an open field is a stable behavioural test and may 
be used as an index of the behavioural-physiological coping style of an individual rat 
(Basso, Beatie and Bresnahan (BBB) Locomotor Rating Scale), the information obtained 
is qualitative, ranging from 0 to 21 and distinguishing between locomotors features such 
as flaccid paralysis, isolated hind-limb joint movements, weight-supported plantar 
stepping, coordination, and details of locomotion (eg, toe clearance, paw position) (Basso 
et al., 1995; Basso, 2000). 
Ankle kinematics is carried out prior to nerve injury (week 0), and at the end of the follow-
up time. Animals walk on a Perspex track with length, width and height of respectively 
120, 12, and 15 cm. In order to ensure locomotion in a straight direction, the width of the 
apparatus is adjusted to the size of the rats during the experiments. The rats’ gait is 
recorded at a rate of 300 Hz images per second. The camera is positioned at the track 
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half length, where gait velocity is stable, and 1 m distant from the track obtaining a 
visualization field of 14 cm wide. The video images are stored for later analysis using an 
appropriate software APAS® (Ariel Performance Analysis System, Ariel Dynamics, San 
Diego, USA). 2-D biomechanical analysis (sagittal plan) is carried out applying a two-
segment model of the ankle joint, adopted from the model firstly developed by Varejão 
et.al. (Varejão et al., 2004). The rats’ ankle angle is determined using the scalar product 
between two vectors representing the foot and the lower leg. With this model, positive and 
negative values of position of the ankle joint (º) indicate dorsiflexion and plantarflexion, 
respectively. For each step cycle the following time points are identified: initial contact 
(IC), Opposite Toe off (OT), and Heel Rise (HR) and toe-off (TO) and are time normalized 
for 100% of step cycle (Dijkstra et al., 2000; Varejão et al., 2002; Varejão et al., 2003b). 
The normalized temporal parameters are averaged over all recorded trials. A total of six 
walking trials for each animal with stance phases lasting between 150 and 400 ms 
(milliseconds) are considered for analysis, since this corresponds to the normal walking 
velocity of the rat (20–60 cm/s) (Varejão et al., 2003b). 
 
7. Morphological analysis 
It is known that morphological analysis is the most common method for peripheral nerve 
regeneration studies. Actually, the investigation of nerve morphology can give us 
important information on various aspects of the regeneration processes which relate with 
nerve function (Geuna et al., 2009; Raimondo et al., 2009). Quantitative calculation of 
nerve fibres is an essential element to evaluate the effectiveness of experimental 
microsurgical techniques in the repair of severed peripheral nerves. The data obtained 
from histomorphometric analysis like number, density, and size of nerve fibres can provide 
answers to several important questions, about a new microsurgical technique (Geuna et 
al., 2004). Assessment of myelinated nerve fibre-size in peripheral nerves is a common 
element used in peripheral nerve regeneration research (Geuna et al., 2001). Yet, nerve 
function cannot be evaluated using just one parameter by itself (Dellon et al. 1989; 
Kanaya et al., 1996; Geuna et al., 2001), the association of some morphological 
parameters with functional recovery of a repaired nerve has been demonstrated, 
consolidating the importance of the morpho-quantitative assessment in the context of 
experimental nerve studies. The size of a myelinated nerve fibre is measured by several 
geometrical parameters: the diameter, the perimeter and the cross-sectional area. When 
high-resolution optical observation is the same parameters can be measured for the axon, 
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allowing the calculation of myelin thickness (Geuna et al., 2001). It takes about 2-3 hours 
to estimate the density and total number of myelinated fibres in one single nerve (Geuna 
et al., 2000). Therefore an efficient time-saving method is required. 
The method used in this work (designed-based sampling strategy) was developed by 
Geuna and colleagues, it was designed in a fashion to apply stereological principles to 
peripheral nerve quantitative morphology by estimation of the density and total number of 
myelinated fibres (Geuna, 2000; Geuna et al., 2000). Designed-based sampling strategies 
permits that all objects in the sampling space have an equal opportunity of being sampled, 
therefore these is a probability-based sampling strategy (Geuna, 2000). This sampling 
design requires a large amount of sampling in order to obtain a precise estimation. Here 
the fibre tops are used as sampling object instead of the profiles due to the morphological 
variability especially in size, shape and orientation. The dissector principle is used for the 
sampling of myelinated nerve fibres in peripheral nerves in order to obtain unbiased 
estimates of fibre density and total number. The method allows us to identify the top of 
fibres on two-dimensional (2-D) transverse sections of a nerve (Geuna, 2000). In the 
experimental work here described the estimation of, the total number of myelinated fibres, 
the mean diameter of fibre and axon of the regenerated and control nerve fibres was 
done. 
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Aims 
As mentioned before, sciatic nerve injuries themselves are rare in humans; nevertheless 
this experimental model provides a very realistic testing tool for injuries involving 
plurifascicular mixed nerves. The rat sciatic nerve is the most experimented model since it 
provides a nerve trunk with adequate length and space at the mid-thigh for surgical 
manipulation and application of grafts or nerve conduits (Mackinnon et al., 1985). 
Mesenchymal stem cells (MSCs) have become one of the most seducing targets for 
tissue regeneration due to their striking characteristics; high plasticity, proliferative and 
differentiation capacity together with their attractive immunosuppressive properties. MSCs 
present low immunogenicity and high immunosuppressive properties once Human 
Leucocyte Antigen (HLA) class II expression is in very low levels or even absent. 
Research in this field has brought exciting promises in many disorders and therefore in 
tissue regeneration. The differentiation potential of MSCs in multilineage end-stage cells is 
already proven, and their potential for treatment of several diseases is well established 
(Gärtner et al., 2013). The ability of MSCs to deliver trophic mechanisms, including 
secretion of cytokines that might serve both paracrine and endocrine functions have 
resulted in reduction of inflammation, apoptosis and fibrosis in numerous disease, 
transforming this cells into a valuable tool in regenerative medicine (Ankrum et al., 2010). 
MSCs isolation can be performed from several different tissues, including bone marrow, 
adipose tissue, skeletal muscle, umbilical cord matrix and blood, placental tissue, amniotic 
fluid, synovial membranes, dental pulp, fetal blood, liver, and lung (Phinney et al., 2007). 
MSCs isolated from the umbilical cord matrix (Wharton’s jelly) present several 
advantages, such as shorter population doubling time, easy culture in plastic flasks, and 
good tolerance towards the immune system. As a matter of fact, local or systemic 
application of MSCs in non-immunosuppressed animals does not induce acute rejection 
which has been demonstrated in the experimental work discussed in this manuscript. In 
addition these cells have anticancer properties, and absence of tumorigenic activity, they 
are very easy to obtain and to isolate, and do not raise ethical controversies, since they 
are collected from tissues usually discarded at birth (Gärtner et al., 2013). Therefore, this 
cellular system raised deep interest by our research group in order to study the 
therapeutic effect of MSCs associated to several developed and commercially available 
biomaterials in nerve regeneration promotion. 
The rat sciatic nerve was the selected model to test the association of biomaterials with 
human MSCs (HMSCs) isolated from the umbilical cord Wharton’s jelly. For the 
axonotmesis injury the goal was to test the therapeutic value of undifferentiated MSCs 
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associated or not to two different biomaterials, a hybrid chitosan membrane and a PLC 
membrane; and differentiated neuroglial-like MSCs in association with PLC (Table 1). In 
the first study, “Use of hybrid chitosan membranes and human mesenchymal stem cells 
from the Wharton jelly of umbilical cord for promoting nerve regeneration in an 
axonotmesis rat model”, a standardized axonotmesis injury was reconstructed with local 
application of undifferentiated MSCs associated or not to a hybrid chitosan membrane. 
The functional recovery was evaluated during 12 weeks by EPT and WRL tests and the 
morphological analysis was carried out with morphology and stereology analysis. 
In the second study, “Use of poly(DL-lactide-ε-caprolactone) membranes and 
mesenchymal stem cells from the Wharton’s jelly of the umbilical cord for promoting nerve 
regeneration in axonotmesis: In vitro and in vivo analysis”, the induced standardized 
axonotmesis injury was treated with undifferentiated and differentiated neuroglial-like 
MSCs associated with a PLC membrane. Also in this work, the functional recovery was 
evaluated during 12 weeks by EPT, WRL and SFI tests and the morphological analysis 
was carried out with stereology analysis. 
 
Table 1 - Experimental groups performed for the axonotmesis injury study. 
Injury Group Procedure Follow-up Time Publication 
A
x
o
n
o
tm
e
s
is
 
Crush No treatment 12 weeks 1st,2nd 
CrushCell Suspension HMSC 12 weeks 1st,2nd 
CrushChitIIICell 
HMSC + Chitosan Type 
III membrane 
12 weeks 1st 
CrushChitIII 
Chitosan Type III 
membrane 
12 weeks 1st 
CrushPLC PLC membrane 12 weeks 2nd 
CrushCellNonDIFPLC HMSC+PLC membrane 12 weeks 2nd 
CrushCellDIFPLC 
Neural-like HMSC+PLC 
membrane 
12 weeks 2nd 
 
This type of injury (axonotmesis) is the most appropriate to investigate the cellular and 
molecular behaviour of peripheral nerve regeneration, and to accomplish preliminary in 
vivo testing of the cellular system and biomaterials used in tube-guide fabrication for more 
serious injuries of the peripheral nerve like neurotmesis. This particular work also 
permitted us to understand the clinical importance of the use of undifferentiated MSCs or 
differentiated into neuroglial-like cells. 
Axonotmesis is a less severe lesion and has a good clinical prognosis and in most of the 
cases surgical reconstruction is not needed, nevertheless in the absence of an 
intervention, functional regeneration may not be complete, leading to muscle atrophy. It 
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was also our intention to study therapeutic approaches including the use of MSCs 
associated to different bio membranes, to improve the regenerative process in 
axonotmesis lesions to overcome the delayed regeneration frequently observed in this 
kind of injury leading to a poor functional recovery. 
In the third published study “Use of poly(DL-lactide-ε-caprolactone) membranes and 
Mesenchymal Stem Cells for promoting nerve regeneration in a Neurotmesis rat model: in 
vitro and in vivo analysis”, we proposed to study the therapeutic value of undifferentiated 
and differentiated neuroglial-like MSCs associated to a PLC membrane in a more serious 
lesion of the peripheral nerve system that implies reconstructive microsurgery techniques 
– the neurotmesis. The functional recovery was evaluated during 20 weeks by EPT, WRL, 
SFI and ankle cinematic tests and the morphological analysis was carried out with 
stereology analysis.  
At last and also for neurotmesis lesion, the aim of the study “Effects of umbilical cord 
tissue mesenchymal stromal cells (UCX®) on rat sciatic nerve regeneration after 
neurotmesis injuries.”, was to evaluate the therapeutic value of human MSCs from the 
umbilical cord matrix either alone or administered with a ready-to-use commercial 
haemostatic matrix vehicle Floseal®, on functional and morphological recovery in chronic 
(20 week evolution), hyper-acute (3 days) and an acute phase (21 days) healing periods 
(Table 2). 
The functional recovery was evaluated during 20 weeks by EPT, WRL, SFI and ankle 
cinematic tests and the morphological analysis was carried out with stereology analysis. 
The cells used in the in vivo testing of 3 of the referred published papers were an 
established ready-to-use Human MSC cell line purchased from PromoCell GmbH (C-
12971, lot-number: 8082606.7). Established human MSC cell lines are preferred for in 
vivo testing, once the numbers of MSCs obtained are higher in a shorter culture time, 
therefore the study is not dependent on donors availability and ethic committee 
authorization, and the protocol is much less time consuming which is an advantageous for 
pre-clinical trials with a large number of experimental animals.  
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Table 2 - Experimental groups performed for Neurotmesis injury study. 
Injury Group Procedure Follow-up Time Publication 
N
e
u
ro
tm
e
s
is
 
Neuro No treatment or repair 20 weeks 3rd, 4th 
End-to-end End-to-end suture repair 20 weeks 3rd, 4th 
Graft 10mm autograft 20 weeks 3rd, 4th 
End-to-
endPLCcellnonDif 
End-to-end suture+PLC 
+ HMSCs 
20 weeks 3rd 
End-to-
endPLCcellDif 
End-to-end suture+PLC 
+ Neural-like HMSC 
20 weeks 3rd 
graftPLCcellnonDif 
10mm 
autograft+PLC+HMSC 
20 weeks 3rd 
graftPLCcellDif 
10mm autograft+PLC+ 
Neural-like HMSC 
20 weeks 3rd 
End-to-EndCMC End-to-end suture+CMC 21 days 4th 
End-to-
EndCMCMSCs 
End-to-end 
suture+CMC+HMSC 
21 days 4th 
End-to-EndMSCs 
End-to-end suture 
+HMSC 
21 days 4th 
Endto-
EndFlosealMSCs 
End-to-end 
suture+Floseal+HMSC 
20 weeks 4th 
End-to-EndMSCs 
End-to-end suture 
+HMSC 
20 weeks 4th 
Endto-EndFloseal 
End-to-end 
suture+Floseal 
20 weeks 4th 
End-to-End End-to-end suture 3 days 4th 
End-to-EndCMC End-to-end suture+CMC 3 days 4th 
End-to-EndMSC 
End-to-end suture 
+HMSC 
3 days 4th 
End-to-
EndCMCMSC 
End-to-end 
suture+CMC+HMSC 
3 days 4th 
End-to-
EndFlosealMSC 
End-to-end 
suture+Floseal+HMSC 
3 days 4th 
End-to-EndFloseal 
End-to-end 
suture+Floseal 
3 days 4th 
 
The phenotype of MSCs was assessed by PromoCell. Rigid quality control tests are 
performed for each lot of PromoCell MSCs isolated from Wharton’s jelly of umbilical cord. 
MSCs are tested for cell morphology, adherence rate and viability. Furthermore, each cell 
lot is characterized by flow cytometry for a widespread marker panel. 
For the last work the cell line used for the in vivo studies was a MSC cellular system 
(UCX®) established by a private company (ECBio - Research and Development in 
Biotechnology S.A.) that settled collaboration with our group for the in vivo testing of their 
cellular product. ECBio developed proprietary technology to isolate, expand, and 
cryopreserve a well-characterized population of  human stromal cells derived from the 
umbilical cord tissue, Wharton’s jelly, named herein as UCX® cells (Santos et al., 2008). 
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UCX® cells phenotype, cell morphology, adherence rate and viability is in the overall the 
same as the MSC cell line used in the previous work. 
In what concerns to in vitro testing of the cellular systems, several analysis were 
performed, before in vivo application to our animal model. Cytogenetic analysis was 
performed to guarantee that there was no chromosomal mutation occurring during cell 
culture procedures and immunocytochemistry was used to certify that differentiation of 
HMSCs into neuroglial-like cells was successfully performed. 
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2.1. Introduction 
Axonotmesis is a well-studied nerve injury model, and the most appropriate to 
investigate the cellular and molecular behaviour of peripheral nerve regeneration. This 
permits to measure the role of the different factors and to accomplish preliminary in 
vivo testing with different therapeutic approaches (Fu et al., 1997). 
The axonotmesis approach used in this work, is performed after nerve mobilisation with 
a non-serrated clamp (Institute of Industrial Electronic and Material Sciences, 
University of Technology, Vienna, Austria) exerting a constant force of 54 N for a 
period of 30 s, 10 mm above the bifurcation into tibial and common peroneal nerves 
inducing a 3 mm lesion. This method allows to perform a standardized and 
reproducible lesion (Luís et al., 2007a). The axonotmesis or crush injury is easy to be 
induced experimentally, with low costs and has a good regenerative capacity, identical 
in rats and sub-human primates (Varejão et al., 2004). Crush injury causes axonal 
interruption but conserves the connective sheaths, the basal laminae of SCs are 
preserved, therefore allowing an optimal orientation and regrowth of the damaged 
axons (Amado et al., 2008; Luís et al., 2008b). After axonotmesis injury regeneration is 
generally successful, the reactive SCs and the preserved endoneurial tubules support 
axonal elongation along the distal nerve and assist an adequate reinnervation  (Luís et 
al., 2008b). The recovery time for this kind of injury has been highly studied (Varejão et 
al., 2003c; Varejão et al., 2004), and it was previously concluded that 8 weeks would 
not be enough as healing period for total functional and morphological recovery. 
Previous results showed that while a full recovery of nociception (WRL), SFI/SSI, and 
percentage of motor deficit (EPT) was achieved by weeks 5, 7 and 9, respectively, 
ankle kinematic parameters were still recovering their original values at week 12 post-
operatively. The same being true for several morphoquantitative parameters of 
regenerated nerve fibres (Luís et al., 2007a). Consequently Luís and colleges have 
implemented 12 weeks of healing recovery period to evaluate the functional and 
histomorphometric parameters recovery (Luís et al., 2007a; Luís et al., 2008b).  
Crush injuries do not involve surgical reconstruction but due to the required 
regeneration period, neurogenic atrophy of the innervated muscles may occur, 
therefore, therapeutic approaches to successfully decrease this recovery time are of 
extreme importance. Tissue engineering association of biomaterials, like PLC or hybrid 
chitosan, to cellular systems, like MSCs able to differentiate into neuroglial-like cells, 
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might improve peripheral nerve regeneration, in terms of motor, sensory and 
histomorphometric parameters. 
Chitosan has attracted particular attention due to its biocompatibility, biodegradability, 
and low toxicity, low cost, improvement of wound-healing and antibacterial effects 
(Amado et al., 2008; Simões et al., 2010). In addition, the potential utility of chitosan in 
nerve regeneration has been demonstrated both in vitro and in vivo (Senel et al., 
2004). In a previous study performed by our group, in vivo results showed that type III 
chitosan (hybrid chitosan) improved both morphological regeneration of nerve fibre and 
functional recovery (Amado et al., 2008).  
The MSCs may be directly injected into the neural scaffold which is enwrapped around 
the crush injury, or pre-added to the neural scaffold via injection or co-culture after 
which the biomaterial with the cellular system is implanted in the injured nerve. In the 
next two studies cells were added in both forms (Gärtner et al., 2012a; Gärtner et al., 
2012b). MSCs are a potential source for peripheral nerve repair. Human MSCs from 
Wharton’s jelly of the umbilical cord own stem cell properties (Yang et al., 2008) 
 
and it 
has been demonstrated that human MSCs can differentiate into neuroglial-like cells (Fu 
et al., 2006) or even modulate inflammatory process. In addition, these cells represent 
a non-controversial source of primitive mesenchymal progenitor cells which can be: 
harvested after birth, cryogenically stored, thawed, and expanded for therapeutic uses 
(Gärtner et al., 2013). 
MSCs isolated from the umbilical cord matrix (Wharton’s jelly) demonstrate several 
advantages, such as shorter population doubling time, easy culture in plastic culture 
flasks, good tolerance towards the immune system, therefore transplantation into non-
immunosuppressed animals does not induce acute rejection, anticancer properties, 
and most important absence of tumorigenic activity (Gärtner et al., 2013). 
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Use of hybrid chitosan membranes and human mesenchymal 
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promoting nerve regeneration in an axonotmesis rat model. 
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Use of poly(DL-lactide-e-caprolactone) membranes and 
mesenchymal stem cells from the Wharton’s jelly of the 
umbilical cord for promoting nerve regeneration in 
axonotmesis: In vitro and in vivo analysis. 
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1.4. Conclusions 
The association of biomaterials with cellular systems in peripheral nerve tissue 
engineering might improve motor and sensory recovery. SCs, MSCs, embryonic stem 
cells, marrow stromal cells are the most studied support cells candidates. It is believed 
that cellular systems implanted into the injured nerve may produce growth factors or 
extracellular matrix (ECM) molecules, or may even modulate the inflammatory process, 
to improve nerve regeneration (Amado et al., 2010; Gu et al., 2011).  
Most of the natural biomaterials used in peripheral nerve injuries are derived from 
animal sources. These materials carry the risk of transfer of viral diseases and may 
cause immunological body reactions while synthetic biomaterials do not have these 
risks (Maur cio et al., 2011). Cell culture morphology of undifferentiated MSCs and 
neuroglial-like differentiated MSCs cultured on PLC membranes, evidence that this 
biomaterial is a viable substrate for undifferentiated HMSCs culture or neuroglial-like 
differentiated HMSCs adhesion, multiplication and differentiation. 
 
In conclusion, for the in vitro studies performed with MSCs from PromoCell: 
- The karyotype analysis of the MSCs cell line derived from Wharton’s jelly of 
human umbilical cord demonstrated that this cell line in terms of number and 
structure of the somatic and sexual chromosomes has no neoplastic 
characteristics and is stable during the cell culture procedures. Also, the 
morphologic characteristics of these cells in culture, observed in an inverted 
microscope, were perfectly normal. These cells presented a star-like shape with 
a flat morphology, characteristic of MSCs. 
- The differentiated MSCs karyotype could not be established, once no dividing 
cells were obtained at passage 5, which is in agreement with the degree of 
differentiation. 
- The cell culture morphology of undifferentiated MSCs and differentiated 
neuroglial-like MSCs cultured on PLC membranes evidence that this 
biomaterial is a feasible substrate for undifferentiated MSCs culture adhesion, 
multiplication and differentiation.  
- After 96 h of culture in neurogenic medium the regular mesenchymal-like shape 
of the MSCs changed and the cells became exceedingly long. Morphologically it 
was possible to observe the formation of neuroglial-like cells after differentiation 
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which were positively stained for typical specific neuronal markers such as the 
GFAP, the GAP-43 and the NeuN confirming a clear successful differentiation. 
 
In conclusion, for the axonotmesis in vivo studies:  
- The significant improvement of axonal regeneration obtained in crushed sciatic 
nerves surrounded by chitosan type III membranes suggests that this material 
may not just work as a simple mechanical scaffold but instead may work as an 
inducer of nerve regeneration. 
- The use of human MSCs associated or not to the hybrid chitosan membranes 
showed positive effects concerning the functional recovery (evaluated by EPT 
and WRL tests), most likely due to the modulation of the inflammatory process 
during the Wallerian degeneration and the production of growth factors. 
- Employment of human MSCs alone or in combination with chitosan type III 
membrane after nerve crush injury provides a slight advantage in comparison to 
untreated controls. On the other hand, our results confirmed that chitosan type 
III membranes alone may represent a very promising clinical tool in peripheral 
nerve reconstructive surgery.  
- The use of both undifferentiated and differentiated MSCs improved the recovery 
of sensory and motor function. In both cell enriched experimental groups myelin 
sheath was thicker, suggesting that MSCs might exert a positive effects on SCs, 
the elementary key in Wallerian degeneration and following axonal 
regeneration. 
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2.1. Introduction 
Neurotmesis is the most frequent type of injury in peripheral nervous damages, which 
is characterized by a complete disorganization of the nerve anatomy. Axonal regrowth 
is impossible, but spontaneous recovery is extremely difficult without surgical 
intervention (Robinson, 2000), even after recovery it’s still not satisfactory.  
Even with all the scientific advances and clinical knowledge, the full understanding of 
nerve regeneration, especially complete functional achievement and organ 
reinnervation after nerve injury, still remain the principle goal of regenerative biology. 
(Mackinnon et al., 2001; Battiston et al., 2005). In the peripheral nervous system, 
nerves can spontaneously regenerate without any treatment if the nerve continuity is 
maintained, which happens in axonotmesis, whereas more severe type of injuries must 
be surgically treated by direct end-to-end surgical reconnection of the damaged nerve 
ends (Mackinnon et al., 1985; Amado et al., 2008; Ronchi et al., 2009).  
Whenever tension-free suturing is possible direct repair is the choice. Nevertheless, 
when there is a nerve gap resulting from loss of nerve tissue, an autologous nerve graft 
is a common choice. However there are some disadvantages with the worst being 
donor site morbidity (Mackinnon et al., 2001). Entubulation with autologous non-
nervous tissues or other kind of biomaterials could be a good alternative, where donor 
site morbidity is no longer a problem and tissue availability could be endless. Many 
studies have shown the importance of peripheral nerve repair with the use of 
entubulation technique whenever neurotmesis occurs. In these situations nerves will 
grow and regenerate from proximal towards distal nerve stump, preventing this way 
ingrowth of fibrous tissue and neuroma formation (Gärtner et al., 2013).  
In the following studies 20 weeks was the time for follow-up recovery. The recovery 
time is crucial once it is proportional to the severity of the lesion. Based on previous 
works (Luís et al., 2007b; Luís et al., 2008a) 20 weeks seemed to be the ideal time for 
these studies. 
Concerning the peripheral nerve regeneration, it is important to identify an appropriate 
vehicle to the local application of the MSCs in the injury site. This vehicle must be 
biocompatible and may be a hydrogel or a membrane that supports the adhesion, 
expansion and survival of the cellular system (Maur cio et al., 2011; Gärtner et al., 
2013). The resorption of a biomaterial should be adjusted to the regeneration process, 
which depends on its molecular weight, composition, crystal structure and thermal 
history. When associating a biomaterial to a cellular system it is also important to 
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determine properties such as hydrophobicity, surface charge and surface rugosity to 
establish its ability to support adhesion and cell growth (Harley et al., 2006). 
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ABSTRACT 
Background: Mesenchymal stem cells (MSCs) have the potential to differentiate into a 
variety of tissues and might be responsible for turnover and maintenance of adult 
tissue. It is also known that these cells migrate to damaged site, especially to hypoxia, 
inflammation and apoptosis spots, modifying the surrounding microenvironment, 
promoting repair with functional improvements. It has been suggested that MSCs have 
a reparative influence through the paracrine effect on the survivor Schwann cells and 
by modulating the regenerative process and the Wallerian degeneration.  
Methods/Design: In the present study the effects of enwrapping the site of end-to-end 
rat sciatic nerve repair with a poly(DL-lactide-ε-caprolactone) (Vivosorb®) membrane 
associated or not with undifferentiated human umbilical cord matrix MSCs (HMSCs) or 
HMSCs pre-differentiated neuroglial-like cells, was investigated. Motor and sensory 
functional recovery was evaluated throughout a healing period of 20 weeks using 
extensor postural thrust (EPT), withdrawal reflex latency (WRL) and ankle kinematic 
analysis. Histological observation was carried out on regenerated nerve fibers.  
Discussion: In vitro investigation showed the formation of typical neuroglial-like cells 
after differentiation, which was positively stained for the typical specific neuroglial 
markers. Results showed that enwrapment of the rapair site with a Vivosorb® 
membrane, with undifferentiated HMSCs or neuroglial-like cell enrichment, did not lead 
to any significant improvement in most of functional and stereological predictors of 
nerve regeneration that were assessed, with the exception of EPT which showed a 
significantly better recovery after employment of undifferentiated HMSCs enriched 
membrane. HMSCs isolated from the Wharton’s jelly of the UC delivered through PLC 
membranes might thus be regarded a potentially valuable tool to improve clinical 
outcome especially after trauma to sensory nerves induced by neurotmesis injuries 
with loss of nervous tissue which enables an end-to-end suture or a grafting procedure. 
When neurotmesis injury can be surgically reconstructed with an epineural end-to-end 
suture without tension or by grafting, the addition of a PLC membrane associated with 
a cellular system is not mandatory for a substantial improvement in functional and 
morphological recoveries. Therfore it can be concluded that this particular type of nerve 
tissue engineering approach has very limited effects on nerve regeneration after sciatic 
end-to-end nerve reconstruction or grafting in the rat.  
 
KEY WORDS: neurotmesis, end-to-end suture, stem cells, mesenchymal stem cells, 
neuroglial-like cells, nerve regeneration, Wharton jelly. 
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1. INTRODUCTION 
Traumatic injuries in Central and Peripheral Nervous (PN) System are the ones with 
less success in terms of functional motor recovery and the ones that give more 
incapacity across the world. In the absence of surgical intervention, functional 
regeneration is restricted due to scars, neuroma formation, mismatched fibers or 
extensive splitting of the re-growing axons; moreover peripheral regeneration is often 
associated to neuropathic pain, which is very limiting for the patient even more than the 
incomplete functional recovery [1]. The functional outcome gets worse with the degree 
of injury, regeneration is weaker if a nerve gap or neuroma has been developed 
leading to functional impairment [1, 2]. Temporal delay from time of trauma to the 
surgical repair is also an important factor for poor functional outcome due to irreversible 
regional muscle atrophy [3]. Neurotmesis is the most common type of injury in 
peripheral nervous injuries, and it is characterized by a complete disorganization of 
nerve anatomy, so, axonal regrowth is impossible and spontaneous recovery is 
extremely difficult without surgical intervention [4]. Despite advances in scientific and 
clinical knowledge, it is still an important aim to have a full understanding of axonal 
recovery and organ reinnervation in a nerve defect [5, 6] and new therapeutic 
approaches associated to physiotherapy besides surgical reconstruction are needed in 
order to achieve a satisfactory functional recovery [7]. Whenever tension-free suturing 
is possible direct end-to-end repair is the choice. Nevertheless, when there is a nerve 
gap resulting from loss of nerve tissue, an autologous nerve graft is a common choice. 
However there are some disadvantages with the worst being donor site morbidity [6]. 
Many studies have shown the importance of peripheral nerve repair using a tube-guide 
whenever neurotmesis occurs. In these situations nerves will grow and regenerate from 
proximal towards distal nerve stump, preventing the ingrowth of fibrous tissue and 
neuroma formation [8]. The development of cell-based therapies began a new age in 
tissue regeneration [8]. Regeneration is a physical process through which remaining 
tissues organize themselves to replace and repair injured or missing tissues in vivo. 
Stem cells from different sources are much probably the golden key for regenerative 
medicine [9]. Among these, mesenchymal stem cells (MSCs) have become one of the 
most interesting targets due to their well-known characteristics. MSCs have a high 
plasticity, proliferative and differentiation capacity together with attractive 
immunosuppressive properties [8]. Once there have been many approaches for MSCs 
culture, the Mesenchymal and Tissue Stem Cell Committee, of International Society for 
cellular therapy (ISCT), recommended several standards to define MSCs [10]. Much 
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evidence demonstrates that the therapeutic effects of these cells do not simply lie on 
the capacity to repair damage tissue, but on the ability to modulate surrounding tissue 
by secretion of various factors and activation of endogenous progenitor cells [11, 12]. 
In many studies MSCs have proven to modify the surrounding environment promoting 
functional repair decreasing inflammation and immune response [13]. Increasing 
evidence demonstrate that MSCs may play an important role in tissue regeneration 
through the secretion of soluble trophic factors which enhance and modulate the repair 
process by paracrine activation of surrounding cells. The use of cellular systems is a 
rational approach for delivering neurotrophic factors at the nerve lesion site [8]. MSCs 
can be isolated from several tissues, including bone marrow, skin, periosteum, amniotic 
fluid, umbilical cord blood and matrix and adipose tissue [8]. Bone marrow represents 
the most frequently used tissue source. MSCs from bone marrow have been applied 
for cell based therapies; however, represent several disadvantages like limited number 
of MSCs available, the heterologous and non-consistent nature of bone marrow 
preparations, the possibility of donor site morbidity, as well as decreased number of 
MSCs along the adult life. For these reasons, it is imperative to identify alternative and 
more primordial MSCs sources that would allow a safe and controlled ex vivo 
expansion for potential allogeneic application. Umbilical cord tissue-derived MSCs 
exhibit a neuronal phenotype [14-17] and have potential utility in treatment of 
neurodegenerative diseases [18, 19], indicating the versatility of this cell source. 
Interestingly, these cells are negative for the class II major histocompatibility complex 
(MHC), and have low expression MHC class I expression [16], making them a potential 
cell source for MSC-based therapies. In addition, these cells represent a non-
controversial source of primitive mesenchymal progenitor cells that can be harvested 
after birth, cryogenically stored, thawed, and expanded for therapeutic uses [7].  
MSCs have been precious for cell-based therapies, the evidence is that there are 142 
clinical trials going on and 25 are based on umbilical cord MSCs (clinical trials.gov). 
To avoid excessive connective tissue formation when re-joining nerve ends a bridging 
material is used. The best option is to use an autologous nerve; nevertheless this 
carries several limitations; like co-morbidity at donor site, loss of sensation, neuroma 
and scar formation, as well as insufficient revascularization of the graft [1, 20]. 
Whenever autografts are not possible, nerve conduits may be an option, as a good 
alternative for gaps between 3-10mm [21]. 
The ideal biomaterial for nerve conduit must fulfil several biological and 
physicochemical requirements and may be biological or synthetic. Such requirements 
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are; biocompatibility, biodegradability, permeability to ions and metabolites for the 
revascularization of the regenerated nerve, biomechanical and surface properties 
should enable and modulate the cellular system adhesion [7]. Among synthetic 
biodegradable materials, poly(DL-lactide-ε-caprolactone) (PLC) attracted particular 
attention to our research group [22-26]. The biodegradation rate of PLC is estimated to 
be approximately 16 months and the degradation products of PLC are less acidic, 
comparable, for instance with poly(L-lactide): poly(glycolide) (PLGA), which may cause 
less damage to the surrounding tissue, and they are transparent facilitating the correct 
positioning of the nerve stumps. Previous in vitro studies have shown that PLC 
membranes and tube-guides are biocompatible with nerve cells and may facilitate 
nerve cell attachment, differentiation and growth [22, 23, 27, 28]. Also, in vivo studies 
have demonstrated that PLC might improve morphological and functional recoveries, in 
axonotmesis and neurotmesis injuries of the rat sciatic nerve. The structure of the 
polymer was still well preserved, after 20 weeks, in nerves repaired by PLC [22, 23]. 
Shin and colleagues reported in 2009 a study in which they compared 3 synthetic 
bioabsorbable conduits with a reversal autograft in sciatic nerve repair. One of the 
synthetic absorbable conduits was also a PLC tube-guide which showed the best 
results comparing with the ones obtained with autograft [29]. In the present study we 
proposed to test in vivo the therapeutic value of human umbilical cord matrix MSCs 
(HMSCs) undifferentiated or differentiated into neuroglial-like cells together with a 
poly(DL-lactide-ε-caprolactone) (Vivosorb®) membrane as nerve guide, to promote 
nerve regeneration on rat sciatic nerve neurotmesis injury surgically reconstructed with 
an epineural end-to-end suture or by autologous grafting. Functional recovery after 
peripheral nerve injury and repair is rarely satisfactory [30-34]. In case of loss of 
substance a nerve autograft procedure, using commonly expendable sensory nerves, 
is required [35, 36]. However, nerve autograft leads to donor site morbidity and 
secondary sensory deficit [37]. Alternatives to peripheral nerve grafts include cadaver 
nerve segment allografts, end-to-side neurorraphy and entubulation by means of 
autologous non nervous tissues such as vein and muscles [38-44]. 
 
2. MATERIALS AND METHODS 
2.1. Poly(DL-lactide-ε-caprolactone) (PLC) membranes 
Poly(DL-lactide-ε-caprolactone) (PLC) membranes (Vivosorb®) were purchased from 
Polyganics BV, Groningen, Netherlands (FS01-006/20 Lot: FSA2009092311). 
Vivosorb® is a flexible bioresorbable polymer film, made of Poly(DL-lactide-ε-
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caprolactone) copolymer which presents retention of mechanical strength for up to 10 
weeks throughout the critical healing period. 
 
2.2. Cell Culture and in vitro differentiation of HMSC from Wharton’s jelly 
umbilical cord  
Human MSC from Wharton’s jelly umbilical cord (HMSCs) were purchased from 
PromoCell GmbH (C-12971, lot-number: 8082606.7). Cryopreserved cells were 
cultured and maintained in a humidified atmosphere with 5% CO2 at 37ºC. 
Mesenchymal stem cell medium (PromoCell, C-28010) was replaced every 48 hours. 
At 90% confluence, cells were harvested with 0.25% trypsin with EDTA (Gibco) and 
passed into a new flask for further expansion. HMSCs at a concentration of 2500 
cell/ml were cultured and after 24 hours cells exhibited 30-40% confluence. 
Differentiation was induced with MSC neurogenic medium (PromoCell, C-28015). 
Medium was replaced every 24 hours during 3 days. The formation of neuroglial-like 
cells was observed after 24 hours in an inverted microscope (Zeiss, Germany). 
 
2.3. Immunocytochemistry  
At passage 3, HMSCs were trypsinized, washed and re-suspended in mesenchymal 
stem cell medium (PromoCell, C-28010) at a concentration of 1x105cell/ml. HMSCs 
were fixed with paraformaldehyde at 4ºC for 15 min and washed with distilled water 
before permeabilization in 0.5% Triton-X100. Non-specific binding was blocked using 
blocking solution (PBS containing 1% bovine serum albumin (BSA)) for 1 hour at room 
temperature. HMSCs were then incubated 2 hours at room temperature with primary 
antibodies of rabbit anti-growth associated protein-43 (GAP-43, 1:200) (Chemicon, 
AB5220), rabbit anti-glial fibrillary acidic protein (GFAP, 1:500) (Chemicon, AB5804) 
and mouse anti-neuronal nuclei (NeuN, 1:100) (Chemicon, MAB377). After washing, 
HMSCs were incubated 15 minutes with secondary antibodies goat anti-rat IgG 
(Millipore, AP136P) and goat anti-rabbit IgG (Millipore, 12-348MN). After several 
washes in PBS, HMSCs were incubated with horseradish peroxidase (HRP)-coupled 
streptavidin for 10 min. DAB (diaminobenzidine) served as chromogen. 
 
2.4. Surgical procedure 
All the animal testing procedures are in conformity with the Directive 2010/63/EU of the 
European Parliament and with the approval of the Veterinary Authorities of Portugal in 
accordance with the European Communities Council Directive of November 1986 
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(86/609/EEC). Humane end points were followed in accordance to the OECD 
Guidance Document on the Recognition, Assessment and Use of Clinical Signs as 
Humane Endpoints for Experimental Animals Used in Safety Evaluation (2000). For the 
in vivo testing, Sasco Sprague adult rats (Charles River Laboratories, Barcelona, 
Spain) were divided in groups of 6 animals each. All animals were housed in a 
temperature and humidity controlled room with 12-12 hours light / dark cycles, two 
animals per cage (Makrolon type 4, Tecniplast, VA, Italy), and were allowed normal 
cage activities under standard laboratory conditions. The animals were fed with 
standard chow and water ad libitum. Adequate measures were taken to minimize pain 
and discomfort taking in account human endpoints for animal suffering and distress. 
Animals were housed for two weeks before entering the experiment. The neurotmesis 
injury was carried out with the animals placed prone under sterile conditions and the 
skin from the clipped lateral right thigh scrubbed in a routine fashion with antiseptic 
solution. The surgery procedure was the one previously described by Luís et al [22]. 
The right sciatic nerve was exposed and a transection (neurotmesis) injury was 
performed, immediately above terminal nerve ramification, with a straight microsurgical 
scissor. A group of 6 animals was used as control without any sciatic nerve injury 
(Group 1 – Control). In Group 2 the injured nerve was left without any repair 
intervention (Group 2 – Gap). In Group 3, immediate cooptation with 7/0 monofilament 
nylon epineural sutures of the 2 transected nerve endings was performed (Group 3 – 
End-to-End). In Group 4, the two endings of nerve transection were immediately 
sutured with a 7/0 monofilament nylon suture, and enwrapped in a PLC (Vivosorb®) 
membrane covered with a monolayer of non-differentiated HMSCs (Group 4 – End-to-
EndPLCcellnonDif), in Group 5, the two endings of nerve transection were immediately 
sutured as the previous group and enwrapped in a PLC (Vivosorb®) membrane 
covered with a monolayer of differentiated HMSCs (Group 5 – End-to-EndPLCcellDif). 
For the last three groups the sciatic nerve was bisected immediately above the terminal 
nerve ramification and at a10mm distal point. The resulting nerve graft, with a length of 
10mm, was inverted 180º and sutured with 7/0 monofilament nylon. One group was 
used as control for the graft (Group 6 – Graft), in another group the graft was 
enwrapped in a PLC (Vivosorb®) membrane covered with a monolayer of non-
differentiated HMSCs (Group 7 –GraftPLCcellnonDif) and in the last one graft was 
enwrapped in a PLC (Vivosorb®) membrane covered with a monolayer of differentiated 
HMSCs (Group 8 – GraftPLCcellDif) (Figure 1). No local or systemic signs of rejection 
or foreign body were observed in the experimental animals transplanted with PLC 
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membranes and HMSCs (undifferentiated and differentiated). There was no need of 
administrating immunosuppressive treatment to the experimental animals during the 
entire healing period of 20 weeks after surgical procedure. 
 
2.5. Functional assessment  
All animals were tested pre-operatively (week 0), and every week until week 12 and 
every 2 weeks until the end of follow-up time (20 weeks). Animals were gently handled, 
and tested in a quiet environment to minimize stress levels. 
 
2.5.1. Motor performance and nociceptive function 
The EPT was originally proposed by Thalhammer and collaborators, in 1995 [45] as a 
part of the neurological recovery evaluation in the rat after sciatic nerve injury. For this 
test, the entire body of the rat, excepting the hind-limbs, was wrapped in a surgical 
towel. Supporting the animal by the thorax and lowering the affected hind-limb towards 
the platform of a digital balance, elicits the EPT. As the animal is lowered to the 
platform, it extends the hind-limb, anticipating the contact made by the distal 
metatarsus and digits. The force in grams (g) applied to the digital platform balance 
(model TM560; Gibertini, Milan, Italy) was recorded. The same procedure was applied 
to the contra-lateral, unaffected limb. Each EPT test was repeated 3 times and the 
average result was considered. The normal (unaffected limb) EPT (NEPT) and 
experimental EPT (EEPT) values were incorporated into an equation (Equation 1) to 
derive the functional deficit (varying between 0 and 1), as described by Koka and 
Hadlock, in 2001 [46]. 
 
Motor Deficit = (NEPT – EEPT) / NEPT (Equation 1) 
To assess the nociceptive withdrawal reflex (WRL), the hotplate test was modified as 
described by Masters and collaborators [47]. The rat was wrapped in a surgical towel 
above its waist and then positioned to stand with the affected hind paw on a hot plate 
at 56ºC (model 35-D, IITC Life Science Instruments, Woodland Hill, CA). WRL is 
defined as the time elapsed from the onset of hotplate contact to withdrawal of the hind 
paw and measured with a stopwatch. Normal rats withdraw their paws from the 
hotplate within 4.3 s or less [48]. The affected limbs were tested 3 times, with an 
interval of 2 min between consecutive tests to prevent sensitization, and the three 
latencies were averaged to obtain a final result [49]. If there was no paw withdrawal 
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after 12 s, the heat stimulus was removed to prevent tissue damage, and the animal 
was assigned the maximal WRL of 12 s [50, 51]. 
 
2.5.2. Kinematic Analysis  
Ankle kinematics was carried out before nerve injury (week 0), and at the 20-week 
follow-up time. Animals walked on a Perspex track with length, width and height of 
respectively 120, 12, and 15 cm. In order to ensure locomotion in a straight direction, 
the width of the apparatus was adjusted to the size of the rats during the experiments. 
The rats’ gait was video recorded at a rate of 300 Hz images per second (Casio Exilim 
Pro EX-F1, Japan). The camera was positioned at the track half-length where gait 
velocity was steady, and 1 m distant from the track obtaining a visualization field of 14 
cm wide. The video images were stored in a computer hard disk for latter analysis 
using an appropriate software APAS® (Ariel Performance Analysis System, Ariel 
Dynamics, San Diego, USA). 2-D biomechanical analysis (sagittal plan) was carried out 
applying a two-segment model of the ankle joint, adopted from the model firstly 
developed by [25]. The rats’ ankle angle was determined using the scalar product 
between a vector representing the foot and a vector representing the lower leg. With 
this model, positive and negative values of position of the ankle joint (º) indicate 
dorsiflexion and plantarflexion, respectively. For each step cycle the following time 
points were identified: initial contact (IC), Opposite Toe off (OT), and Heel Rise (HR) 
and toe-off (TO) [25, 52, 53] and were time normalized for 100% of step cycle. The 
normalized temporal parameters were averaged over all recorded trials. A total of six 
walking trials for each animal with stance phases lasting between 150 and 400 ms 
were considered for analysis, since this corresponds to the normal walking velocity of 
the rat (20–60 cm/s) [25]. 
 
2.6. Histology and Scanning electron microscopy (SEM) 
Nerve samples (10-mm-long sciatic nerve segments distal to the crush site and from 
un-operated controls) were processed for histological analysis of myelinated nerve 
fibers [54]. Fixation was carried out using 2.5% purified glutaraldehyde and 0.5% 
saccarose in 0.1M Sorensen phosphate buffer for 6-8 hours and resin embedding was 
obtained following Glauerts' procedure [55]. Series of 2-µm thick semi-thin transverse 
sections were cut using a Leica Ultracut UCT ultramicrotome (Leica Microsystems, 
Wetzlar, Germany) and stained by Toluidine blue. Histological observation was carried 
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out on a DM4000B microscope equipped with a DFC320 digital camera and an IM50 
image manager system (Leica Microsystems, Wetzlar, Germany).   
Prior to scanning electron microscopy (SEM) analysis, the HMSCs cultured on PLC 
discs and the PLC tube-guide without HMSCs (Figures 2C and 2D) were first fixed with 
1.5% glutaraldehyde in 0.14 M sodium cacodylate buffer (pH 7.3) for 2h at 4oC. 
Afterwards, the PLC samples with and without the HMSCs were dehydrated using 
graded ethanol solutions from 60 % to 100%, 5 minutes each, and subjected to critical 
point drying. Finally, the samples were mounted on aluminum stubs using double-side 
adhesive tape and sputter coated with gold/palladium thin film, using the SPI Module 
Sputter Coater equipment for 100 seconds and with a 15mA current. The SEM / EDS 
exam was performed using a high resolution (Schottky) Environmental Scanning 
Electron Microscope with X-Ray Microanalysis and Electron Backscattered Diffraction 
analysis: Quanta 400 FEG ESEM / EDAX Genesis X4M.  
 
2.7. Statistical analysis  
The general linear model procedure was employed to undertake two-way mixed 
factorial ANOVA. The design included two between-subjects variables with either two 
conditions (grafting vs. non-grafting) or three conditions (no-cells; undifferentiated 
cells; differentiated cells) and one within-subjects factor consisting on the repeated 
measures of the outcome variables across the recovery time. Mauchly’s test was used 
to test sphericity and correction of the degrees of freedom was performed with the 
Greenhouse-Geiser’s epsilon whenever this assumption could not be demonstrated. 
Simple planned contrasts (General Linear Model, simple contrasts) were used to 
compare pooled data across all experimental groups during recovery with pre-
operative data. Pairwise comparisons between groups were carried out by employing 
the HSD Tukey’s test. All statistical procedures were performed by using the statistical 
package SPSS (version 14.0, SPSS, Inc). All data in this study is presented as mean 
± standard deviation of the mean (SD). 
 
3. RESULTS 
3.1. Confirmation of HMSCs differentiation into neuroglial-like cells  
The phenotype of HMSCs was assessed by PromoCell. Rigid quality control tests are 
performed for each lot of PromoCell mesenchymal stem cells isolated from Wharton’s 
jelly of umbilical cord. HMSCs were tested for cell morphology, adherence rate and 
viability. Furthermore, each cell lot was characterized by flow cytometry analysis for a 
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comprehensive panel of markers, such as PECAM (CD31), HCAM (CD44), CD45, and 
Endoglin (CD105). The HMSCs exhibited a mesenchymal-like shape with a flat and 
polygonal morphology. During expansion the cells became long spindle-shaped and 
colonized the whole culturing surface (Figure 2A). After 96 hours of culture in 
neurogenic medium, we observed a morphological change. The cells became 
exceedingly long and there was a formation of typical neuroglial-like cells with multi-
branches and secondary branches (Figure 2B). The differentiation was tested based on 
the expression of typical neuronal markers such as GFAP, GAP-43 and NeuN in 
neuroglial-like differentiated MSCs. Undifferentiated HMSCs were negatively labeled to 
GFAP, GAP-43 and NeuN. After 96 hours of differentiation the attained cells were 
positively stained for glial protein GFAP (Figure 3B) and for the growth-associated 
protein GAP-43. All nuclei of neuroglial-like cells were also labeled with the neuron 
specific nuclear protein NeuN demonstrating successful differentiation of HMSCs in 
neuroglial-like cells [56].  
Undifferentiated HMSCs exhibited a normal star-like shape with a flat morphology 
(Figures 2A and 2D). After in vitro differentiation, HMSCs morphology changed into 
typical neuroglial-like pattern with multi-branches and secondary branches (Figure 2B). 
Giemsa-stained cells of differentiated HMSC cell line at passage 5 were analyzed for 
cytogenetic characterization. However, no metaphases were found, therefore the 
karyotype could not be established. The karyotype of undifferentiated HMSCs was 
determined previously and no structural alterations were found demonstrating absence 
of neoplastic characteristics in these cells, as well as chromosomal stability to the cell 
culture procedures [56]. 
 
3.3. Functional analysis 
3.3.1. Nociceptive function evaluated by withdrawal reflex latency (WRL) 
Table 1 presents the data for the WRL during recovery. As expected, in the weeks 
immediately following sciatic nerve transection and repair, animals were unable to 
respond to the hot stimulus, which is compatible with complete loss of thermal and 
nociceptive sensitivity of the sole of the foot. Regaining of the foot withdrawal response 
started at the second week following sciatic nerve transection and repair. The WRL 
significantly improved during the 20-weeks recovery time although never reaching the 
normal values even at the end of the 20-weeks recovery (simple contrasts, 20 weeks 
vs. pre-injury; P=0.035). Differences in WRL recovery were found both as a result of 
grafting [F(1,31) = 7.765; P = 0.009] and as a result of HMSCs application [F(2,31) = 
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14.112; P = 0.000]. Therefore, faster and better recovery in WRL response occurred in 
animals treated with sciatic nerve end-to-end repair (End-to-End, End-to-
EndPLCcellnonDif, and End-to-EndPLCcellDif groups) compared to those receiving a 
graft (Graft, GraftPLCcellnonDif, and GraftPLCcellDif groups). Also, faster WRL 
responses were exhibited by animals that did not receive either undifferentiated (P = 
0.001) or differentiated (P = 0.000) HMSCs (End-to-End group and Graft group). No 
recovery in WRL response existed in untreated animals following sciatic nerve 
transection (Gap group).   
 
3.3.2. Motor performance by measuring extensor postural thrust (EPT) 
Animals presented a severe motor deficit immediately following sciatic nerve 
transection demonstrated by almost complete loss of EPT response in the affected 
hind limb (Table 2). EPT response in the affected side improved partially in all treated 
animals with time and a significant motor deficit still existed at week 20 after sciatic 
nerve injury (simple contrasts, 20 weeks vs. pre-injury; P = 0.000). Significantly 
different EPT responses existed during recovery from sciatic nerve transection and 
repair due to the use of HMSC cells [F(2,31) = 28.778; P = 0.000] but not due to 
grafting [F(1,31) = 0.271; P = 0.606]. Pairwise comparisons confirmed the presence of 
significant differences in EPT response following sciatic nerve injury between animals 
that were not treated with HMSC cells and those treated with undifferentiated (P = 
0.016) and differentiated (P = 0.000) cells. Also, significant differences were found in 
EPT response between animals treated with undifferentiated and differentiated HMSC 
cells (P = 0.000). Interestingly, the EPT response following sciatic nerve transection 
and repair displayed a significant interaction between the type of nerve repair (i.e. 
direct end-to-end repair or grafting) and the application of stem cells [F(2,31) = 4.910; 
P = 0.014]. Analysis of groups’ mean values regarding the EPT response throughout 
the entire 20 weeks period suggests that undifferentiated cells, but not differentiated 
cells, enhanced EPT recovery in grafting-treated animals, thus partially counteracting 
the negative effect of nerve grafting in functional recovery, comparing with direct end-
to-end sciatic nerve repair. 
 
3.4. Kinematic Analysis  
The angle and angular velocity of the ankle joint (Figures 3A and 3B) during the stance 
phase of step cycle were measured in the affected side at the end of the 20-weeks 
recovery period following sciatic nerve neurotmesis. The same measures were also 
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collected in uninjured control rats. Ankle angle was similar in all groups of animals 
recovering from sciatic nerve neurotmesis and for all instant of stance phase 
considered (Figure 3A). Similarly, no differences could be found for ankle angle at any 
studied time instant of the stance phase between groups of animals recovering from 
sciatic nerve neurotmesis and control animals, irrespectively of nerve treatment 
employed (Figure 3A).  
Regarding ankle angular velocity, univariate ANOVA found a significant effect for the 
kind of treatment for sciatic nerve neurotmesis at HR [F(6,33) = 10.414; P = 0.000] and 
TO [F(6,33) = 2.542; P = 0.039], but not at IC [F(6,33) = 1.311; P = 0.135] and OT 
[F(6,33) = 1.776; P = 0.280].  At HR, pairwise differences for values of ankle velocity 
existed between the Gap group and End-to-EndPLCcellDiff, GraftPLCcellnonDiff, and 
GraftPLCcellnonDiff groups (P > 0.05). At this time point, ankle velocity in all groups of 
sciatic nerve-injured animals was significantly different from the uninjured group. The 
same results were obtained at TO, with significant differences in the values of ankle 
velocity between uninjured animals and all the remaining groups. In this case, however, 
no differences were noticed for ankle velocity between any of sciatic nerve neurotmesis 
groups (Figure 3B).   
 
3.5. Sciatic nerve histology 
Histological analysis on semi thin sections showed that nerve fiber regeneration 
occurred in all repaired nerves. In comparison to controls (Figure 4), in all repaired 
nerves regenerated fibers showed small axons with thin myelin sheaths and 
microfasciculation (Figure 5). Microfasciculation was more evident in the graft repair 
groups (Figures 5C and 5D) in comparisons to End-to-End group (Figures 5A and 5B). 
From a histological point of view, the comparison between treatment with 
undifferentiated and differentiated HMSC did not show clear differences both after end-
to-end (Figures 5A and 5B) and graft (Figures 5C and 5D) nerve reconstruction. 
 
4. DISCUSSION 
Tissue engineering focusing on the in vitro fabrication of autologous, living tissues with 
the potential of regeneration is a promising scientific and clinical field. Peripheral nerve 
regeneration should include a multidisciplinary team able to develop biomaterials, to 
develop cell therapies, and to elaborate in vitro analysis and pre-clinical trials 
concerning animal welfare and the most appropriate animal model before the clinical 
trials and clinical application approval [57]. Transected peripheral nerves can 
Chapter II 
Results 
 
 
Andréa Louise Moutinho Gärtner | 162 
 
regenerate whenever a connection is available between the proximal and distal 
severed stumps and, when no substance loss occurs, surgical treatment consists in 
direct end-to-end suturing of the nerve ends [30-34]. However, in spite of the progress 
of microsurgical nerve repair, the outcome of nerve reconstruction is still far from being 
optimal [58]. Since during regeneration axons require neurotrophic support, they could 
benefit from the presence of a cellular system capable of responding to stimuli of the 
local environment during axonal regeneration. In case of loss of substance a nerve 
autograft procedure, using commonly expendable sensory nerves, is required [36, 59, 
60]. However, nerve autograft leads to donor site morbidity and secondary sensory 
deficit [37]. Alternatives to peripheral nerve grafts include cadaver nerve segments 
allografts, end-to-side neurorraphy and entubulation by means of autologous non 
nervous tissues such as vein and muscles [38, 40, 44, 61, 62]. Therefore one of the 
scientist’s challenges over the last thirty years has been to find an alternative to the 
autologous nerve graft [61]. Employment of a nerve conduit (i.e. a tubular structure 
designed to bridge the gap of a sectioned nerve, protect the nerve from the 
surrounding tissue, and guide the regenerating axons into the distal nerve stump) is the 
most popular alternative to nerve autografts; yet, conduits can also play an important 
role as a vehicle for neurotrophic factors and cellular systems [23, 24, 27, 38, 40, 41, 
43, 44, 62]. 
In a previously published study the therapeutic value of HMSCs on rat sciatic nerve 
after axonotmesis injury associated to the same PLC membrane (Vivosorb®), was 
evaluated. Also, in vitro characterization of the cellular system was previously 
assessed concerning nuclear magnetic resonance (NMR) analysis, 
immunocytochemistry, and intracellular ionic calcium concentration measurements 
using the epifluorescence technique where the cell viability was indirectly evaluated, 
when cultured on PLC discs (Vivosorb®). During HMSCs expansion and differentiation 
in neuroglial-like cells, the culture medium analysis by nuclear magnetic resonance 
was performed in order to evaluate the metabolic profile. It was also important to 
confirm the possibility of PLC membranes to support the expansion of HMSCs, to 
correlate the HMSCs ability to differentiate and survival capacity in the presence of the 
Vivosorb® membrane, the [Ca2+]i of undifferentiated HMSCs or neuroglial-differentiated 
HMSCs was determined by the epifluorescence technique using the Fura-2AM probe. 
The Vivosorb® membrane proved to be adequate to be used as a scaffold associated 
to undifferentiated HMSCs or neuroglial-differentiated HMSCs, so the experimental 
work could continue furthermore, with more serious injuries, namely, neurotmesis 
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without loss of nervous tissue. In vitro investigation demonstrated the formation of 
typical neuroglial cells after differentiation which was positively stained for the typical 
specific neuroglial markers such as the GFAP, the GAP-43 and NeuN. NMR showed 
clear evidence that HMSCs expansion is glycolysis-dependent but their differentiation 
requires the switch of the metabolic profile to oxidative metabolism. In vivo studies 
showed enhanced recovery of motor and sensory function in animals treated with 
transplanted undifferentiated and differentiated HMSCs that was accompanied by an 
increase in myelin sheath [56]. Crush injuries are appropriate to investigate the cellular 
and molecular mechanisms of peripheral nerve regeneration, and to assess the role of 
different factors in the regeneration process [63]. Nerve crush injury is also a well-
established model in experimental regeneration studies to investigate the impact of 
various pharmacological treatments [27, 64, 65] and should be used before testing 
therapeutic approaches in a more serious lesion, like neurotmesis. The present study 
intended to confirm the ability of PLC membranes together with undifferentiated and 
differentiated HMSCs to promote nerve regeneration, improving the functional and 
morphological recoveries even when grafting or and epineural end-to-end suture is 
possible. Results regarding the EPT response throughout the entire 20 weeks period 
suggest that undifferentiated cells, but not differentiated cells, enhanced EPT recovery 
in grafting-treated animals, thus partially counteracting the negative effect of nerve 
grafting in functional recovery, comparing with direct end-to-end sciatic nerve repair. 
Ankle angle was similar in all groups of animals recovering from sciatic nerve 
neurotmesis and for all instant of stance phase considered. Similarly, no differences 
could be found for ankle angle at any instant time of the stance phase between groups 
of animals recovering from sciatic nerve neurotmesis and control animals, 
irrespectively of nerve treatment employed. Regarding ankle angular velocity a 
significant effect for the kind of treatment for sciatic nerve neurotmesis at HR and OT, 
was found. At HR, differences for values of ankle velocity existed between the Gap 
group and End-to-EndPLCcellDiff, GraftPLCcellnonDif, and GraftPLCcellnonDif groups. 
At this time point, ankle velocity in all groups of sciatic nerve-injured animals was 
significantly different from the uninjured group. The same results were obtained at TO, 
with significant differences in the values of ankle velocity between uninjured animals 
and all the remaining groups. In this case, however, no differences were noticed for 
ankle velocity between any of sciatic nerve neurotmesis groups. Histological analysis 
showed that nerve fiber regeneration occurred in all repaired nerves. Also all repaired 
nerves regenerated fibers showed small axons with thin myelin sheaths and 
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microfasciculation was more evident in the graft repair groups in comparisons to End-
to-End groups. From a histological point of view, the comparison between treatment 
with undifferentiated and differentiated HMSC did not show clear differences both after 
end-to-end and graft nerve reconstruction. Results showed that enwrapment of the 
repaired site with a Vivosorb® membrane, with undifferentiated HMSCs or neuroglial-
like cell enrichment, did not lead to any significant improvement in most of functional 
and stereological predictors of nerve regeneration that we assessed, with the exception 
of EPT which recovered significantly better after employment of undifferentiated 
HMSCs enriched membrane. HMSCs isolated from the Wharton’s jelly of the UC 
delivered through PLC membranes might thus be regarded a potentially valuable tool 
to improve clinical outcome especially after trauma to sensory nerves after neurotmesis 
injuries with loss of nervous tissue that enables an end-to-end suture or a grafting 
procedure. When the neurotmesis injury can be surgically reconstructed with an 
epineural end-to-end suture without tension or by grafting, the addition of a PLC 
membrane associated with a cellular system is not mandatory for a substantial 
improvement in functional and morphological recoveries. It can thus be concluded that 
this particular type of nerve tissue engineering approach has very limited effects on 
nerve regeneration after sciatic end-to-end nerve reconstruction or grafting in the rat.  
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5. FIGURE AND TABLE LEGENDS 
Figure 1 - Rat sciatic nerve injury and surgical reconstruction  
Surgical approach to the rat’s sciatic nerve (A); Nerve reconstruction after induced 
neurotmesis lesion: Surgical reconstruction where the neurotmesis injury reconstructed 
with an end-to-suture is enwrapped in a PLC (Vivosorb®) membrane (B); Nerve gap of 
10mm (C); and End-to-end epineural suture (D).  
 
Figure 2 – Cell and membrane images 
Monocultures of HMSCs from Wharton’s jelly over PLC membrane exhibiting a 
mesenchymal-like shape with a flat polygonal morphology (A). Monocultures of HMSCs 
HMSCs from Wharton’s jelly over PLC membrane after 72h of culture in neurogenic 
medium, differentiated HMSCs became exceedingly long and there is a formation of 
typical neuroglial-like cells with multibranches (B) (Magnification: 100x). SEM image of 
PLC tube-guide (Magnification: 250x) (C). SEM image of HMSCs cultured over a PLC 
disc (Magnification: 1000x).  
 
Figure 3 – Kinematic plots 
Kinematic plots in the sagittal plane for angular position (º) (A) and for angular velocity 
(º/s) (B) as it moves through the stance phase, obtained at week-20 after the 
neurotmesis injury. The mean of each group is plotted. 
 
Figure 4 – Histological image 
Histological appearance of a normal rat sciatic nerve (Magnification: 1000x).  
 
Figure 5 – Histological images 
Histological appearance of regenerated nerve fiber treated with undifferentiated and 
differentiated HMSC: End-to-endPLCcellnonDif (A), End-to-endPLCcellDif (B), 
GraftPLCcellnonDif (C), GraftPLCcellDif (D) (Magnification: 1000X). 
 
Table 1 – Withdrawal Reflex Latency results 
Values in seconds (s) were obtained performing Withdrawal Reflex Latency (WRL) test 
to evaluate the nociceptive function. This test has been performed pre-operatively 
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(week-0), at week 1 and 2 and after every two weeks until the end of the 20-week 
follow-up time. Results are presented as mean and standard deviation (SD). N 
corresponds to the number of rats within the experimental group.  
 
Table 2 – Extensor Postural Thrust results 
Values of Motor Deficit were obtained performing Extensor Postural Thrust (EPT) test. 
This test has been performed pre-operatively (week-0), at week 1 and 2 and after every 
two weeks until the end of the 20-week follow-up time. Results are presented as mean 
and standard deviation (SD). N corresponds to the number of rats within the 
experimental group. 
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TABLES  
Table 1 – Withdrawal Reflex Latency results 
 Week 0 Week 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Week 14 Week 16 Week 18 Week 20 
Control             
1A 3,00 12,00 4,00 4,00 10,00 5,00 8,00 12,00 5,00 7,00 5,00 4,00 
1B 2,00 12,00 5,00 12,00 5,00 2,00 10,00 2,00 4,00 2,00 2,00 3,00 
1C 2,00 12,00 12,00 8,00 5,00 3,00 4,00 4,00 4,00 6,00 4,00 4,00 
1D 4,00 12,00 2,00 3,00 4,00 5,00 2,00 6,00 4,00 4,00 4,00 2,00 
1E 2,00 12,00 6,00 2,00 10,00 2,00 5,00 2,00 2,00 6,00 2,00 2,00 
1F 2,00 12,00 12,00 12,00 12,00 3,00 3,00 3,00 4,00 4,00 2,00 2,00 
1G 1,00 12,00 12,00 8,00 10,00 4,00 2,00 2,00 2,00 3,00 2,00 2,00 
Mean ± SD 2,29±0,95 12,0±0,00 7,57±4,31 7,00±4,12 8,00±3,21 3,43±1,27 4,86±3,08 4,43±3,64 3,57±1,13 4,57±1,81 3,00±1,29 2,71±0,95 
Gap             
2A 2,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 
2B 1,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 
2C 2,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 
2D 2,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 12,00 
Mean ± SD 1,75±0,50 12,00±0,00 12,00±0,00 12,00±0,00 12,00±0,00 48,00±0,00 12,00±0,00 12,00±0,00 12,00±0,00 12,00±0,00 12,00±0,00 12,00±0,00 
End-to-end             
3A 3,00 13,00 4,00 4,00 10,00 5,00 8,00 13,00 5,00 7,00 5,00 4,00 
3B 3,00 13,00 5,00 13,00 5,00 3,00 10,00 3,00 4,00 3,00 3,00 3,00 
3C 3,00 13,00 13,00 8,00 5,00 3,00 4,00 4,00 4,00 6,00 4,00 4,00 
3D 4,00 13,00 3,00 3,00 4,00 5,00 3,00 6,00 4,00 4,00 4,00 3,00 
3E 3,00 13,00 6,00 3,00 10,00 3,00 5,00 3,00 3,00 6,00 3,00 3,00 
3F 3,00 13,00 13,00 13,00 13,00 3,00 3,00 3,00 4,00 4,00 3,00 3,00 
3G 1,00 13,00 13,00 8,00 10,00 4,00 3,00 3,00 3,00 3,00 3,00 3,00 
Mean ± SD 3,39±0,95 13,0±0,00 7,57±4,31 7,00±4,13 8,00±3,31 3,43±1,37 4,86±3,08 4,43±3,64 3,57±1,13 4,57±1,81 3,00±1,39 3,71±0,95 
End-to-endPLCcellnonDif          
4A 3,89 13,00 13,00 13,00 11,05 13,00 13,00 9,34 7,39 7,58 5,64 3,93 
4B 4,08 10,86 10,77 8,44 7,35 7,10 5,64 5,44 5,03 4,34 4,10 3,84 
4C 3,35 13,00 13,00 7,88 9,13 8,59 8,03 7,39 7,40 6,55 6,49 5,93 
4D 4,36 13,00 13,00 13,00 13,00 13,00 13,00 5,36 8,03 7,61 7,65 7,80 
4E 3,74 13,00 13,00 10,00 4,60 13,00 6,40 3,58 3,71 5,34 5,88 6,31 
4F 5,40 13,00 13,00 13,00 13,00 13,00 10,15 10,49 7,36 5,73 5,30 4,60 
Mean ± SD 3,79±1,03 11,81±0,47 11,80±0,50 10,39±1,90 9,35±3,95 10,63±3,30 9,04±3,77 6,90±3,64 6,45±1,69 6,18±1,33 5,84±1,19 5,40±1,56 
End-to-endPLCcellDif       
5A 4,03 13,00 13,00 13,00 13,00 9,75 13,00 9,49 9,81 7,99 9,35 3,87 
5B 3,31 4,39 4,75 6,36 3,39 4,83 3,94 3,63 4,73 6,38 7,75 4,34 
5C 3,19 13,00 13,00 13,00 13,00 6,68 13,00 9,33 9,73 5,79 8,31 11,54 
5D 3,06 13,00 13,00 13,00 13,00 11,06 10,84 10,11 9,60 9,30 8,19 6,75 
5E 3,54 13,00 13,00 13,00 11,37 9,51 5,34 7,45 4,43 5,33 5,13 5,90 
5F 3,43 13,00 13,00 13,00 13,00 13,00 13,00 13,00 13,00 13,00 11,56 11,54 
Mean ± SD 3,91±0,73 10,73±3,15 10,79±3,96 11,04±3,34 10,43±3,51 8,97±3,71 9,34±3,73 8,67±3,87 8,38±3,08 7,76±3,53 8,38±3,10 7,33±3,43 
Graft    
6A 3,00 13,00 13,00 13,00 13,00 13,00 5,00 4,00 3,00 4,00 4,00 4,00 
6B 3,00 13,00 13,00 13,00 13,00 13,00 8,00 5,00 3,00 3,00 3,00 3,00 
6C 3,00 13,00 13,00 13,00 13,00 13,00 4,00 4,00 3,00 3,00 3,00 3,00 
6D 3,00 13,00 13,00 13,00 13,00 13,00 13,00 10,00 7,00 7,00 13,00 13,00 
6E 
6F 
1,00 13,00 13,00 13,00 13,00 13,00 6,00 6,00 4,00 3,00 3,00 3,00 
3,00 13,00 13,00 13,00 13,00 13,00 5,00 4,00 4,00 3,00 3,00 3,00 
Mean ± SD 1,83±0,41 13,00±0,00 13,00±0,00 13,00±0,00 13,00±0,00 13,00±0,00 6,67±3,94 5,50±3,35 4,00±1,55 3,83±1,60 4,50±3,73 4,67±3,61 
GraftPLCcellnonDif       
7A 3,88 13,00 13,00 11,37 11,06 11,04 10,39 9,03 8,77 8,19 7,64 6,30 
7B 4,03 13,00 13,00 13,00 13,00 13,00 11,74 11,14 6,44 5,60 5,88 5,39 
7C 3,36 13,00 13,00 13,00 13,00 9,54 8,34 6,67 6,34 6,13 5,73 5,53 
7D 3,87 13,00 13,00 13,00 13,00 11,96 8,81 7,37 7,47 6,56 5,77 5,38 
7E 3,18 13,00 13,00 13,00 13,00 11,75 9,66 8,83 8,30 6,83 5,93 5,34 
7F 4,48 13,00 13,00 13,00 13,00 9,35 6,93 6,16 5,58 5,03 4,73 4,80 
Mean ± SD 3,47±0,84 13,00±0,00 13,00±0,00 11,88±0,30 11,84±0,38 10,94±1,31 9,39±1,69 8,30±1,84 7,13±1,33 6,39±1,10 5,59±0,94 5,41±0,46 
GraftPLCcellDif       
8A 3,13 13,00 13,00 13,00 13,00 13,00 11,74 10,17 9,05 8,33 7,15 5,31 
8B 3,50 13,00 13,00 13,00 11,86 9,64 9,45 8,73 7,85 7,31 5,98 5,58 
8C 3,67 13,00 13,00 13,00 13,00 13,00 13,00 13,00 13,00 13,00 11,56 10,35 
8D 3,64 13,00 13,00 13,00 13,00 10,86 10,43 9,74 8,33 6,33 6,03 5,63 
8E 3,53 13,00 13,00 13,00 13,00 13,00 11,73 10,81 9,18 8,51 8,04 7,61 
8F 3,63 13,00 13,00 13,00 13,00 9,57 7,37 6,47 5,89 6,03 5,80 4,87 
Mean ± SD 3,18±0,51 13,00±0,00 13,00±0,00 13,00±0,00 11,98±0,06 11,01±1,18 10,45±1,80 9,65±1,90 8,73±3,00 8,07±3,16 7,43±3,30 6,54±3,10 
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Table 2 – Extensor Postural Thrust results 
 Week 0 Week 1 Week 3 Week 4 Week 6 Week 8 Week 10 Week 13 Week 14 Week 16 Week 18 Week 30 
Control             
1A 0,07 0,90 0,80 0,73 0,68 0,56 0,54 0,54 0,64 0,48 0,43 0,50 
1B 0,07 0,93 0,83 0,70 0,73 0,66 0,57 0,50 0,45 0,40 0,40 0,40 
1C 0,08 0,90 0,85 0,88 0,83 0,76 0,57 0,50 0,53 0,44 0,38 0,40 
1D 0,07 0,90 0,91 0,84 0,83 0,73 0,57 0,39 0,55 0,38 0,34 0,40 
1E 0,09 0,97 0,97 0,69 0,60 0,56 0,51 0,46 0,45 0,38 0,38 0,39 
1F 0,06 0,77 0,86 0,83 0,78 0,73 0,63 0,57 0,55 0,38 0,38 0,40 
1G 0,07 0,87 0,89 0,81 0,78 0,76 0,70 0,47 0,45 0,33 0,43 0,50 
Mean ± SD 0,07±0,01 0,89±0,06 0,87±0,06 0,78±0,08 0,74±0,08 0,68±0,09 0,58±0,06 0,49±0,06 0,53±0,07 0,40±0,05 0,39±0,03 0,43±0,05 
Gap             
2A 0,08 0,90 0,93 0,93 0,93 0,98 0,87 0,84 0,84 0,91 0,96 0,94 
2B 0,09 0,89 0,90 0,90 0,95 0,89 0,87 0,90 0,89 0,95 0,90 0,95 
2C 0,07 0,95 0,90 0,87 0,75 0,85 0,90 0,83 0,80 0,79 0,84 0,86 
2D 0,08 0,98 0,90 0,93 0,95 0,90 0,91 0,95 0,89 0,87 0,95 0,90 
Mean ± SD 0,08±0,01 0,93±0,04 0,91±0,01 0,90±0,03 0,89±0,10 0,91±0,05 0,89±0,03 0,88±0,06 0,86±0,04 0,88±0,07 0,91±0,06 0,91±0,04 
End-to-end             
3A 0,07 0,90 0,80 0,73 0,68 0,56 0,54 0,54 0,64 0,48 0,43 0,50 
3B 0,07 0,93 0,83 0,70 0,73 0,66 0,57 0,50 0,45 0,40 0,40 0,40 
3C 0,08 0,90 0,85 0,88 0,83 0,76 0,57 0,50 0,53 0,44 0,38 0,40 
3D 0,07 0,90 0,91 0,84 0,83 0,73 0,57 0,39 0,55 0,38 0,34 0,40 
3E 0,09 0,97 0,97 0,69 0,60 0,56 0,51 0,46 0,45 0,38 0,38 0,39 
3F 0,06 0,77 0,86 0,83 0,78 0,73 0,63 0,57 0,55 0,38 0,38 0,40 
3G 0,07 0,87 0,89 0,81 0,78 0,76 0,70 0,47 0,45 0,33 0,43 0,50 
Mean ± SD 0,07±0,01 0,89±0,06 0,87±0,06 0,78±0,08 0,74±0,08 0,68±0,09 0,58±0,06 0,49±0,06 0,53±0,07 0,40±0,05 0,39±0,03 0,43±0,05 
End-to-endPLCcellnonDif          
4A 0,03 0,97 0,94 0,98 0,97 0,88 0,80 0,84 0,79 0,73 0,50 0,13 
4B 0,06 0,97 0,98 0,98 0,99 0,99 0,85 0,85 0,80 0,61 0,45 0,50 
4C 0,36 0,99 0,93 0,98 0,91 0,91 0,90 0,83 0,87 0,64 0,60 0,38 
4D 0,14 0,97 0,86 0,98 0,93 0,94 0,90 0,88 0,83 0,64 0,60 0,08 
4E 0,03 0,95 0,88 0,88 0,90 0,83 0,77 0,76 0,75 0,57 0,39 0,15 
4F -0,05 0,90 0,87 0,98 0,95 0,99 0,79 0,80 0,64 0,51 0,31 0,03 
Mean ± SD 0,08±0,11 0,96±0,03 0,91±0,05 0,96±0,04 0,94±0,03 0,93±0,06 0,84±0,06 0,83±0,04 0,78±0,08 0,63±0,07 0,46±0,14 0,19±0,17 
End-to-endPLCcellDif       
5A 0,13 0,95 0,97 0,97 0,97 1,00 0,98 0,99 0,98 0,99 0,99 0,87 
5B 0,03 0,93 0,98 0,94 0,93 0,98 0,75 0,89 0,55 0,59 0,75 0,33 
5C -0,08 0,96 0,97 0,96 0,94 0,98 0,99 0,89 0,76 0,73 0,61 0,66 
5D 0,10 0,98 0,98 0,99 0,98 0,83 0,86 0,70 0,80 0,68 0,50 0,48 
5E 0,00 0,93 0,94 0,93 0,95 0,84 0,77 0,53 0,40 0,40 0,79 0,60 
5F 0,46 0,98 0,98 0,99 0,98 0,98 0,66 0,99 0,98 0,98 0,98 0,98 
Mean ± SD 0,11±0,19 0,11±0,19 0,97±0,03 0,96±0,03 0,96±0,03 0,94±0,08 0,84±0,13 0,83±0,19 0,75±0,33 0,75±0,33 0,77±0,33 0,64±0,37 
Graft    
6A 0,07 0,83 0,87 0,78 0,78 0,81 0,73 0,73 0,69 0,60 0,50 0,50 
6B 0,08 0,89 0,91 0,93 0,75 0,75 0,60 0,64 0,53 0,46 0,54 0,53 
6C -0,08 0,93 0,94 0,88 0,78 0,65 0,63 0,63 0,50 0,45 0,57 0,54 
6D 0,00 0,91 0,85 0,83 0,77 0,73 0,58 0,68 0,64 0,54 0,57 0,54 
6E 
6F 
0,09 0,93 0,89 0,83 0,77 0,74 0,63 0,64 0,69 0,64 0,50 0,54 
0,00 0,89 0,87 0,89 0,78 0,65 0,66 0,67 0,53 0,50 0,54 0,46 
Mean ± SD 0,03±0,07 0,90±0,04 0,89±0,03 0,85±0,05 0,77±0,01 0,73±0,06 0,64±0,05 0,66±0,03 0,60±0,09 0,53±0,08 0,54±0,03 0,53±0,03 
GraftPLCcellnonDif       
7A 0,03 0,97 0,98 0,99 0,99 0,89 0,76 0,56 0,59 0,53 0,16 0,31 
7B 0,34 0,99 0,99 0,99 0,98 0,85 0,70 0,70 0,67 0,48 0,05 0,13 
7C -0,03 0,99 0,98 0,99 0,99 0,94 0,73 0,67 0,48 0,40 0,33 0,33 
7D 0,33 0,99 0,98 0,99 0,99 1,00 0,88 0,50 0,60 0,38 0,35 0,13 
7E 0,01 0,97 0,98 0,99 0,99 0,84 0,59 0,38 0,39 0,37 0,33 0,08 
7F -0,43 0,98 0,99 0,99 0,98 0,98 0,85 0,70 0,66 0,44 0,03 0,01 
Mean ± SD 0,01±0,34 0,98±0,01 0,98±0,01 0,99±0,00 0,99±0,01 0,93±0,07 0,75±0,11 0,59±0,13 0,57±0,11 0,40±0,11 0,19±0,14 0,13±0,08 
GraftPLCcellDif       
8A -0,15 0,90 0,98 0,99 0,98 0,98 0,94 0,84 0,73 0,64 0,60 0,53 
8B 0,18 0,98 0,98 0,99 0,99 0,98 0,98 0,93 0,77 0,49 0,38 0,35 
8C 0,15 0,98 0,97 0,98 0,98 0,98 0,98 0,94 0,93 0,87 0,76 0,77 
8D -0,06 0,99 0,98 0,99 0,98 0,98 0,99 0,98 0,85 0,69 0,63 0,66 
8E 0,39 0,98 0,98 0,98 0,98 0,98 0,98 0,88 0,63 0,58 0,61 0,50 
8F -0,35 0,98 0,99 0,99 0,99 0,99 0,93 0,76 0,68 0,35 0,36 0,34 
Mean ± SD 0,34±0,04 0,97±0,03 0,98±0,01 0,99±0,01 0,98±0,01 0,98±0,00 0,97±0,03 0,89±0,08 0,76±0,11 0,59±0,31 0,54±0,18 0,51±0,19 
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FIGURES 
Figure 1 - Rat sciatic nerve injury and surgical reconstruction  
 
 
Figure 2 – Cell and membrane images 
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Figure 3 – Kinematic plots 
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Figure 4 – Histological image 
 
 
Figure 5 – Histological images 
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Abstract 
Background: Peripheral nerves possess the capacity of self-regeneration after 
traumatic injury but the extent of regeneration is often poor and may benefit from 
exogenous factors that enhance growth. Neonatal tissues as stem cell reservoirs offer 
many advantages over both embryonic and adult stem cell sources. These tissues are 
routinely discarded at parturition so little ethical controversy attends the procurement of 
the resident stem cell populations. Increasing evidence demonstrate that Mesenchymal 
Stromal Cells (MSCs) may play an important role in tissue regeneration through the 
secretion of soluble trophic factors which enhance and assist in repair by paracrine 
activation of surrounding cells. The use of cellular systems is a rational approach for 
delivering neurotrophic factors at the nerve lesion site.  
Methods/Design: In the present study, the therapeutic value of a proprietary 
population of umbilical cord tissue-derived MSCs (UCX®) was evaluated on end-to-end 
rat sciatic nerve repair. After neurotmesis, the sciatic nerve was repaired by simple 
end-to-end suture (End-to-End group) and end-to-end suture in the presence of UCX®, 
either alone or administered with a matrix vehicle, Floseal®. Both motor and sensory 
functional recoveries were evaluated along the healing period using extensor postural 
thrust (EPT), withdrawal reflex latency (WRL) and ankle kinematics analysis. After 20 
weeks animals were sacrificed and the sciatic nerves were processed for stereological 
analysis. The effect of UCX® administration on Wallerian degeneration in the hyper-
acute (3 days post-operative), and acute (21 days postoperative) phases of healing 
was also evaluated through histological analysis. Motor and sensory functional 
recoveries were evaluated at day 7, 14 and 21 post-operative.  
Discussion: Overall, the UCX® application presented positive effects in functional 
recovery in the hyper-acute, acute, and chronic phases of the regeneration process. 
The histological analysis of the acute phase study revealed that in the group treated 
with UCX® alone, the Wallerian degeneration was optimal for the subsequent process 
of regeneration. As expected it was not possible to observe regeneration of axons after 
21 days. Instead, a little retraction of the myelin membrane was observed, which could 
be caused by the nerve injury. In any case, the fibre organization was higher and the 
extent of fibrosis was lower in the UCX®-treated group The chronic phase experimental 
groups revealed that treatment with UCX® induced an increase in number of 
regenerated fibres and thickening of the myelin sheet, after a healing period of 20 
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weeks. Finally, the UCX® application presented positive effect in functional and 
morphologic recovery in the acute and chronic phase of the regeneration process.  
 
Keywords: mesenchymal stromal cells, umbilical cord tissue, neurotmesis, nerve fiber 
regeneration, myelinization, functional assessment, stereology, kinematics.  
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Introduction 
A full understanding of nerve regeneration, namely complete functional achievement 
and organ re-innervation, after nerve injury, still remains a main goal for regenerative 
biology. Peripheral nerve injury has a high regenerative potential but functional 
recovery rarely occurs after total nerve transection. Nerve regeneration is a complex 
biological phenomenon. In the peripheral nervous system nerves can spontaneously 
regenerate without any treatment if nerve continuity is maintained (axonotmesis), 
whereas more severe type of injuries must be surgically treated by direct end-to-end 
surgical reconnection of the damaged nerve ends [1-3]. 
Cell transplantation has been proposed as a method of improving peripheral nerve 
regeneration [4, 5], including Schwann cell (SC) transplantation that can enhance axon 
outgrowth and survival, both in vitro [6] and in vivo [7]. Some limitations of harvesting 
autologous SCs, such as donor nerve sacrifice and donor site morbidity, have led to 
investigate other cell types that provide similar trophic support to axon regeneration [8]. 
Mesenchymal Stromal Cells (MSCs) have become one of the most interesting targets 
since they can be harvested from different sources, including neonatal tissues, without 
ethical concerns or limitations in cell number [9]. Besides, scientific and clinical 
evidence have demonstrated that MSCs have the ability to migrate to specific sites of 
injury or of tissue regeneration where they modulate the immune and the inflammatory 
responses and mobilize intrinsic cell reservoirs through a series of distinct paracrine 
mechanisms [10]. Furthermore, MSCs are not only capable of differentiation into tri-
lineage mesenchyme cell types, such as adipocytes, chondrocytes and osteoblasts 
[11], but also into neuronal-like cells, including astrocytes, oligodendrocytes, microglia, 
neurons and neuroglial cells [12-14]. Dezawa and collaborators in 2001 showed that 
MSCs were also capable of differentiating into cells with Schwann cell properties [8, 
15].  MSCs have been isolated from various origins, including bone marrow, skin, hair 
follicle, periosteum, amniotic fluid, umbilical cord blood, placenta and adipose tissue. 
The bone marrow represents the most commonly used tissue source for adult MSCs. 
Bone marrow MSCs (BM-MSCs) have been applied for cell based therapies; however, 
due to the limited number of BM-MSCs available, the heterologous and non-consistent 
nature of bone marrow preparations, the possibility of donor site morbidity, as well as 
decreased number of BM-MSCs along the adult life, there is a need to identify 
alternative and more primordial MSCs sources that would allow for safe and controlled 
expansion for potential allogeneic utilization. Different harvesting procedures have led 
to umbilical cord tissue-derived MSCs (UC-MSCs) that exhibit a neuronal phenotype 
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[16-19] and have potential utility in treatment of neurodegenerative diseases [20, 21], 
indicating the versatility of this cell source. Interestingly, these cells, which are major 
histocompatibility complex (MHC) class II negative, not only express both an immune-
privileged and immune-modulatory phenotype, but their MHC class I expression levels 
can also be manipulated [18], making them a potential cell source for MSC-based 
therapies. In addition, these cells represent a non-controversial source of primitive 
mesenchymal progenitor cells that can be harvested after birth, cryogenically stored, 
thawed, and expanded for therapeutic uses [22].  
ECBio has developed proprietary technology to consistently isolate, expand, and 
cryopreserve a well-characterized population of  human stromal cells derived from the 
umbilical cord tissue, namely Wharton’s jelly  trademark registered as UCX® [23]. The 
isolation method has been specifically designed for clinical use and it has been recently 
adapted according to advanced therapy medicinal product (ATMP) standards, as 
defined by the guideline on the minimum quality data for certification of ATMP 
(EMA/CAT/486831/2008/corr, 2010) (results to be published elsewhere). More 
recently, the UCX® paracrine activity has been demonstrated to repress T-cell 
activation and promote the expansion of Tregs better than BM-MSCs. Accordingly, the 
xenogeneic UCX® administration in an acute inflammation model showed that UCX® 
can reduce paw edema in vivo more efficiently than BM-MSCs [24]. Finally, animals 
treated with intra-articular (i.a.) and intra-peritoneal (i.p.) infusions of UCX® showed 
faster and almost full remission of local and systemic arthritis manifestations, 
potentially demonstrating a potent paracrine induction of tissue regeneration [24]. 
Cell transplantation has indeed been proposed as a method of improving peripheral 
nerve regeneration [4, 5] but tissue engineering of peripheral nerves may involve the 
application of  biomaterials that will function as a vehicle for cell therapies, some of 
them, previously studied by the ICBAS group [1, 22, 25]. Biomaterials can support 
cellular systems to be able to either differentiate into neuroglial-like cells or to enhance 
their paracrine effects on the overall regenerative process, or can be directly involved 
in the regenerative process, improving the motor and sensory functional recovery. 
Furthermore, some biomaterials associated or not to cellular systems can also shorten 
the healing period thus avoiding regional muscular atrophy, which might be important in 
both axonotmesis and neurotmesis injuries [1, 22, 25].  Concerning peripheral nerve 
regeneration, it is important to identify an appropriate vehicle to the local application of 
the MSCs in the injury site. This vehicle must be biocompatible, support the adhesion, 
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expansion and survival of the cellular system, and may be a hydrogel, a tube-guide or 
a membrane [9, 22].  
In this experimental work, the therapeutic value of UCX® was evaluated on end-to-end 
rat sciatic nerve repair after neurotmesis. UCX® were applied either alone or 
administered with a commercially available matrix vehicle, Floseal®, associated to an 
end-to-end suture during the chronic phase of healing in order to maintain cells as long 
as possible near the injury site. Floseal® is a commercial haemostatic matrix with 
potential application in Tissue Engineering and previously used with success by the 
ICBAS research group as a vehicle for Bonelike®, a modified hydroxyapatite used in 
bone defects [26]. Floseal® is a haemostatic sealant composed of collagen-derived 
particles and topical bovine-derived thrombin which has been proven to control 
bleeding in several medical applications, like vascular surgery, adenoidectomy, 
laparoscopy and partial nephrectomy. Floseal® is easily used and it can be extruded 
from a syringe and applied topically to the bleeding area. This haemostatic agent has 
the ability to acquire irregular shapes fitting the wounded site. When the Floseal® is in 
contact with blood, the collagen particles are hydrated and swell, restricting the blood 
flow. The thrombin present converts the patient fibrinogen into a fibrin polymer, 
originating a clot around the lesion area of the nerve [26].  
 
Materials and methods 
2.1 Ethics and regulation 
Umbilical cord donations were obtained with written informed consents according to 
Directive 2004/23/EC which sets the standards of quality and safety for the donation, 
procurement, testing, processing, preservation, storage and distribution of human 
tissues and cells. All the animal testing procedures were in conformity with the 
Directive 2010/63/EU of the European Parliament and with the approval of the 
Veterinary Authorities of Portugal in accordance with the European Communities 
Council Directive of November 1986 (86/609/EEC). Humane end points were followed 
in accordance to the OECD Guidance Document on the Recognition, Assessment and 
Use of Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety 
Evaluation (2000).  
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2.2. UCX® Isolation and Culture 
Umbilical cords from full-term natural or caesarean births were obtained with informed 
consent. Cells were isolated from the umbilical cord tissue as in Santos et al. 2008 
(INPI 103843, PCT/IB2008/054067, WO/2009/044379) with a number of minor 
alterations. Briefly, after 24 hours in contact with a saline solution containing antibiotics 
and anti-mycotics, umbilical cords were cleared of blood clots and transversely 
sectioned in 2.5cm portions. These pieces were subsequently treated with a digestion 
solution containing collagenase and trypsin, for 4h at 37ºC after which cells were 
allowed to adhere to the lower surface of a poly-D-lysine coated t-flask for 30 minutes. 
After this time, the liquid media was collected and centrifuged at 200g at 4ºC for 5 
minutes, supernatant was collected and returned to the original t-flask and the pellet 
was discarded. The isolated cells were maintained in a humidified chamber at 37ºC 
and 7% CO2, cells were subject to regular medium replacements and maintained until 
80% of confluence. The MSC phenotype was confirmed by flow cytometry. Detection 
was performed with the following antibodies and their respective isotypes (all from 
BioLegend unless stated otherwise): PE anti-human CD105 (eBioScience); APC anti-
human CD73; PE anti-human CD90; APC anti-human CD44; PerCP/Cy5.5 anti-human 
CD45: FITC anti-human CD34; FITC anti-human CD31; PerCP/Cy5.5 anti-human 
CD14; Pacific Blue anti-human CD19 and pacific-blue anti-human HLA-DR. UCX® were 
maintained in culture in α-MEM (Minimum Essential Medium Eagle Alpha Modification, 
Sigma-Aldrich) with 2mM glutamine, supplemented with 20% FBS (Heat Inactivated 
Fetal Bovine Serum  Invitrogen™) at 37ºC in a 5% CO2, humid environment. For cell 
passage  PBS (Dulbecco’s Phosphate Buffered Saline, Sigma-Aldrich) was used prior 
to trypsinization to wash cells  followed by contact with TrypLE™ Select (Invitrogen™)  
a serum independent trypsin. TrypLE™ Select was inactivated by addition of PBS and 
subsequent centrifugation at 200g for 10 minutes (Sartorius, Model: 2-6). Seeding 
density was 1x104cells/cm2, unless indicated otherwise. Cell viability was evaluated 
using the trypan blue (Sigma-Aldrich) exclusion method (Figure 1A and 1B).  
 
2.2. UCX® Tri-Lineage Differentiation 
To induce adipogenic differentiation, UCX® were cultured in adipogenic differentiation 
medium for 3 days  consisting of α-MEM supplemented with 20% FBS, 2 mM L-
glutamine, 10 µg/mL insulin (Sigma-Aldrich), 200 µM indomethacin (Sigma-Aldrich), 0.5 
mM isobutylmetylxantine (Sigma-Aldrich), and 1 µM dexamethasone (Sigma-Aldrich); 
and subsequently 1 day in adipogenic maintenance medium  consisting of α-MEM 
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supplemented with 20% FBS, 2 mM L-glutamine and 10 µg/mL insulin. Medium was 
replaced every 3 days during 21 days, after which histochemical staining was 
performed. For chondrogenic differentiation, cells were grown in suspension as pellets, 
incubated in chondrogenic differentiation medium consisting on DMEM-LG (Sigma-
Aldrich), 1% FBS, 2 mM L-glutamine, 6.25 µg/mL insulin (Sigma-Aldrich), 10 ng/mL 
TGF-β1 (Tebu-bio), and 50 µM ascorbate-2-phosphate (Sigma-Aldrich). Finally, to 
induce osteogenic differentiation, cells were incubated in osteogenic differentiation 
medium which composition is α-MEM, 10% FBS, 1 g/L glucose, 2 mM glutamine, 10 
mM β-glycerol phosphate, 50 µg/mL ascorbate-2-phosphate, and 100 nM 
dexamethasone (all reagents are from Sigma-Aldrich). The medium was replaced 
every 3 days during 21 days and histochemical staining was performed. In adipogenic 
and osteogenic differentiation protocols, cells were washed and fixed with 
paraformaldehyde 4% for 20 min and stained with oil red O and alkaline phosphatase, 
respectively. For chondrogenic differentiation, cells were also fixed in 
paraformaldehyde 4%, dried, embedded in paraffin and cut into sections and finally 
stained with alcian blue. The presence of stained cells was confirmed by inverted 
microscopy with phase contrast (Leica, DMIL HC) (Figure 1C, 1D, 1E, 1F). 
 
2.3. Vehicle preparation 
Floseal® is a ready-to-use commercial hemostatic matrix, also applied in neurosurgery 
and the application kit consists of a bovine-derived gelatin matrix, a human derived 
thrombin component, applicator tips and several mixing accessories. The mixing 
accessories include a syringe with an integral female Luer connector attached, a small 
bowl, and a 5 ml syringe with needle attached. The mixing accessories are included to 
facilitate the reconstitution and mixing of the thrombin into the gelatin matrix and the 
applicator tips are included to facilitate the delivery of Floseal® to the site of the lesion. 
The gelatin matrix, manufactured by Baxter Healthcare Corporation consists of cross-
linked gelatin granules and is provided sterile in a disposable syringe. The human 
thrombin is a sterile, freeze-dried, vapor-heated and solvent detergent-treated powder 
preparation made from pooled human plasma. The sterile calcium chloride solution that 
is used for the reconstitution of the lyophilized thrombin, the resulting thrombin solution 
contains 500 IU/ml of human thrombin. Floseal® is a combination of the gelatin matrix 
and the thrombin component, is biocompatible and resorbed with 6 to 8 weeks. The 
preparation of the Floseal® prior to use followed the manufacture instructions 
(www.floseal.com). Briefly, using the 5 ml syringe with needle attached provided in the 
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Thrombin component package, the 5 ml chloride solution is transferred to the vial 
containing the thrombin. Gently, the vial is swirled until the thrombin is dissolved. The 
dissolved thrombin is aspirated from the small bowl into the syringe to the indicated 
mark (4 ml) and the gelatin matrix granules syringe is connected to the syringe 
containing the thrombin solution and the gelatin matrix – thrombin solution mixture is 
back and forth transferred between the syringes for a total 10 passes (Figure 3A, 3B). 
 
2.3. Microsurgical procedure 
Adult male Sasco Sprague Dawley rats (Charles River Laboratories, Barcelona, Spain) 
weighing 250-300 g, were randomly divided in 5 groups of 6 animals each. All animals 
were housed in a temperature and humidity controlled room with 12-12 hours light / 
dark cycles, two animals per cage (Makrolon type 4, Tecniplast, VA, Italy), and were 
allowed normal cage activities under standard laboratory conditions. The animals were 
fed with standard chow and water ad libitum. Adequate measures were taken to 
minimize pain and discomfort taking in account human endpoints for animal suffering 
and distress. Animals were housed for two weeks before entering the experiment. For 
surgery, animals   were placed prone under sterile conditions and the skin from the 
clipped lateral right thigh scrubbed in a routine fashion with antiseptic solution. The 
surgeries were performed under an M-650 operating microscope (Leica Microsystems, 
Wetzlar, Germany). Under deep anesthesia (ketamine 90 mg/Kg; xylazine 12.5 mg/Kg, 
atropine 0.25 mg/Kg i.m.), the right sciatic nerve was exposed through a skin incision 
extending from the greater trochanter to the midthigh distally followed by a muscle 
splitting incision. After nerve mobilization, a transection injury was performed 
(neurotmesis) immediately above the terminal nerve ramification using straight 
microsurgical scissors. For the acute phase study, animals   were randomly assigned 
to 3 experimental groups, in the first group (End-to-End), immediate cooptation with 7/0 
monofilament nylon epineural sutures of the 2 transected nerve endings. In the second 
group (End-to-EndUCX group) the animals received the same treatment as the 
previous group but the injury local was infiltrated with UCX® suspended in culture 
medium and the third group, was composed of 6 healthy animals   without any injury 
(Control). For these groups, animals were euthanized 21 days after the neurotmesis 
injury and surgery procedure. Animals were then randomly assigned to four 
experimental groups, and included in the chronic phase study. In one group (End-to-
End), immediate cooptation with 7/0 monofilament nylon epineural sutures of the 2 
transected nerve endings was performed, in a second group (End-to-EndFlosealUCX 
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group) nerve transaction was reconstructed by end-to-end suture, like in the first group, 
and then locally enwrapped with UCX®  mixed with Floseal®. In a third group (End-to-
EndUCX group) animals received the same treatment as the previous group but locally 
infiltrated with UCX® alone, suspended in culture medium. In a fourth group (End-to-
EndFloseal group) animals received the same treatment as the previous group but 
locally enwrapped with Floseal® alone. Also a group of 6 animals without any injury 
was included (Control). For these groups, animals were euthanized 20 weeks after the 
neurotmesis injury and surgery procedure. In both studies 5000 viable UCX® cells were 
applied / neurotmesis lesion in a volume of 20 µl of culture medium. As functional 
control for both studies, a control group of animals, without any lesion (Control group), 
was considered for the histomorphometric analysis. To prevent autotomy, a deterrent 
substance was applied to animals’ right foot [27, 28]. In order to also evaluate the effect 
of UCX® in the hyper-acute phase of the healing period, 4 more animals were 
euthanized 3 days after the surgical procedure for repairing the neurotmesis lesion for 
histological analysis: end-to-end suture (End-to-End), end-to-end suture covered by 
Floseal® (End-to-EndFloseal), end-to-end suture infiltrated with UCX® (End-to-
EndUCX), and end-to-end suture with UCX® mixed with Floseal® (End-to-
EndFlosealUCX). In this experimental group, 5000 viable UCX® cells were also applied 
in the neurotmesis lesion either suspended in 20 µl of culture medium or in the 
appropriate vehicle (Floseal®). The animals were intensively examined for signs of 
autotomy and contracture post-operative and none presented severe wounds, 
infections or contractures (Figure 2A, 2B and Figure 3C).  
 
2.4. Functional assessment  
The chronic phase groups (End-to-End; End-to-EndFlosealUCX; End-to-EndUCX; End-
to-EndFloseal, Control) were tested pre-operatively (week 0), every week up to week 
12 and every 2 weeks until the end of follow-up time (20 weeks). The acute phase 
group (End-to-End, End-to-EndUCX, and Control) were tested preoperatively (week 0), 
and at days 7, 14 and 21. Animals were gently handled, and tested in a quiet 
environment to minimize stress. No functional assessment was performed in the hyper-
acute phase experimental group. 
 
Evaluation of motor performance (EPT) and nociceptive function (WRL) 
Motor performance and nociceptive function were evaluated by measuring extensor 
postural thrust (EPT) and withdrawal reflex latency (WRL), respectively. The animals 
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were tested pre-operatively (week-0), at day 7, 14, and 21 (Acute phase study); and 
pre-operatively (week-0) and every week until week 12 and every 2 weeks until the end 
of follow-up time, 20 weeks (Chronic phase study). The EPT was originally proposed 
by Thalhammer and collaborators, in 1995 [29] as a part of the neurological recovery 
evaluation in the rat after sciatic nerve injury. For this test, the entire body of the rat, 
excepting the hind-limbs, was wrapped in a surgical towel. Supporting the animal by 
the thorax and lowering the affected hind-limb towards the platform of a digital balance, 
elicits the EPT. As the animal is lowered to the platform, it extends the hind-limb, 
anticipating the contact made by the distal metatarsus and digits. The force in grams 
(g) applied to the digital platform balance (model TM560; Gibertini, Milan, Italy) was 
recorded. The same procedure was applied to the contralateral, unaffected limb. Each 
EPT test was repeated 3 times and the average result was considered. The normal 
(unaffected limb) EPT (NEPT) and experimental EPT (EEPT) values were incorporated 
into an equation (Equation 1) to derive the functional deficit (varying between 0 and 1), 
as described by Koka and Hadlock, in 2001 [30]. 
 
Motor Deficit = (NEPT – EEPT) / NEPT (Equation 1) 
To assess the nociceptive withdrawal reflex (WRL), the hotplate test was modified as 
described by Masters and collaborators [31]. The rat was wrapped in a surgical towel 
above its waist and then positioned to stand with the affected hind paw on a hot plate 
at 56ºC (model 35-D, IITC Life Science Instruments, Woodland Hill, CA). WRL is 
defined as the time elapsed from the onset of hotplate contact to withdrawal of the hind 
paw and measured with a stopwatch. Normal rats withdraw their paws from the 
hotplate within 4.3 s or less [32]. The affected limbs were tested 3 times, with an 
interval of 2 min between consecutive tests to prevent sensitization, and the three 
latencies were averaged to obtain a final result [33]. If there was no paw withdrawal 
after 12 s, the heat stimulus was removed to prevent tissue damage, and the animal 
was assigned the maximal WRL of 12 s [34, 35]. 
 
Kinematics analysis  
Ankle kinematics was carried out prior nerve injury (week 0), and at the 20-week follow-
up time and it was only performed in the chronic phase study. A group of 6 rats 
presenting a neurotmesis injury with a gap of 10 mm where no surgical or cellular 
therapy was performed was included for data analysis (Gap group). Animals walked on 
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a Perspex track with length, width and height of respectively 120, 12, and 15 cm. In 
order to ensure locomotion in a straight direction, the width of the apparatus was 
adjusted to the size of the rats during the experiments. The rats’ gait was video 
recorded at a rate of 300 Hz images per second (Casio Exilim PRO EX-F1, Japan). 
The camera was positioned at the track half-length where gait velocity was steady, and 
1 m distant from the track obtaining a visualization field of 14 cm wide. The video 
images were stored in a computer hard disk for latter analysis using an appropriate 
software APAS® (Ariel Performance Analysis System, Ariel Dynamics, San Diego, 
USA). 2-D biomechanical analysis (sagittal plan) was carried out applying a two-
segment model of the ankle joint, adopted from the model firstly developed by Varejão 
[36]. The rats’ ankle angle was determined using the scalar product between a vector 
representing the foot and a vector representing the lower leg. With this model, positive 
and negative values of position of the ankle joint (º) indicate dorsiflexion and 
plantarflexion, respectively. For each step cycle the following time points were 
identified: initial contact (IC), Opposite Toe off (OT), and Heel Rise (HR) and toe-off 
(TO) [36-38] and were time normalized for 100% of step cycle. The normalized 
temporal parameters were averaged over all recorded trials. A total of six walking trials 
for each animal with stance phases lasting between 150 and 400 ms were considered 
for analysis, since this corresponds to the normal walking velocity of the rat (20–60 
cm/s) [36]. 
 
2.5. Sciatic nerve stereology and histological analysis  
For the chronic phase study, histomorphometric analysis was performed. Nerve 
samples obtained from the (10-mm-long sciatic nerve segments distal to the 
neurotmesis site and from un-operated controls) were processed for quantitative 
morphometry of myelinated nerve fibers [39]. Fixation was carried out using 2.5% 
purified glutaraldehyde and 0.5% saccarose in 0.1M Sorensen phosphate buffer for 6-8 
hours and resin embedding was obtained following Glauerts' procedure [40]. Series of 
2 µm thick semi-thin transverse sections were cut using a Leica Ultracut UCT 
ultramicrotome (Leica Microsystems, Wetzlar, Germany) and stained by Toluidine blue. 
Stereology was carried out on a DM4000B microscope equipped with a DFC320 digital 
camera and an IM50 image manager system (Leica Microsystems, Wetzlar, Germany). 
Systematic random sampling and D-dissector were adopted using a protocol previously 
described [41, 42]. Fiber density and total number were estimated together with fiber 
and axon diameter and myelin thickness. For the acute phase study, the animals were 
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euthanized 21 days after surgery and the samples’ histological preparation was as 
described for the histomorphometric analysis. For the hyper-acute phase study the 
nerve samples were collected at day 3, fixed in 10% buffered formalin, routinely 
processed, dehydrated and embedded in paraffin wax. Consecutive 4μm-sections were 
cut, stained with haematoxylin and eosin (HE) and submitted to histological evaluation 
where a quality analysis was performed by a single operator. 
 
2.6. Statistical analysis  
For data regarding the functional tests, means and standard deviations (SD) were 
computed and reported for each time point, including pre-operatively, and each 
experimental group. Differences between time points and between groups were tested 
by two-way analysis of variance (ANOVA) using a mixed model of within- (time of 
recovery) and between-subjects (experimental groups) factors. In case ANOVA 
revealed an overall significant main effect of experimental group (between-subjects 
factor), pairwise comparisons between the groups was undertaken using the post hoc 
Tukey’s HSD test. Statistical significance was accepted at a level of p<0.05. For 
stereology, statistical comparisons of quantitative data were subjected to one-way 
ANOVA test. Statistical significance was established as p<0.05. All statistical 
procedures were performed by using the statistical package SPSS (version 14.0, 
SPSS  Inc) except stereological data that were analyzed using the software “Statistica 
per discipline bio-mediche” (Mc raw-Hill, Milan, Italy). All data in this study is 
presented as mean ± SD. Statistical significance was accepted at p<0.05.  
 
3. Results 
3.1 UCX® are Mesenchymal Stromal Cells (MSCs) according to the ISCT  
MSCs, as defined by the International Society for Cellular Therapy (ISCT), are cells 
characterized by: a) their capacity to adhere to plastic; b) positive expression of specific 
surface markers, namely CD44, CD73, CD90, and CD105, and negative expression of  
CD14, CD19, CD31, CD34, CD45 and HLA-DR. Additionally, according to the ISCT, 
MSCs are able to undergo tri-lineage differentiation into adipocytes, chondroblasts and 
osteoblasts [43]. UCX® were expanded to P5 (12.3±2.5 generations, N=8) where the 
culture appeared homogeneous and cells presented their typical fusiform, fibroblast-
like, morphology (Figure 1C). As expected for MSC-type stromal cells, flow cytometry 
analysis showed that over 98% of the cells in the population were consistently positive 
for the cell surface markers CD44, CD73, CD90 and CD105 and less than 2% positive 
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for CD14, CD19, CD31, CD34, CD45 and HLA-DR (Figure 1B, 1C). In order to assay 
for UCX® capacity for tri-lineage differentiation, UCX® expanded to P5 were incubated 
with specific differentiation media as described in the methods section. Results showed 
that UCX® cells have the capacity for tri-lineage differentiation into adipocytes, 
chondrocytes and osteoblasts (Figure 1D, 1E, 1F). Control samples on the left column 
are cells undergoing the same culture conditions and specific staining reactions but 
without addition of differentiation factors (Figure 1C). For chondrogenic differentiation, 
the natural tendency for UCX® to form three-dimensional aggregates has become 
noticeable, even without the addition of differentiaion factors (Figure 1E). In any case, 
chondrospheres resulting from terminal chondrogenic differentiation are consistently 
larger, more regularly shaped, and strongly stain positive for alcian blue (Figure 1F). 
  
3.2. Motor deficit, Nociception function and SFI 
For the acute study groups the percentage motor deficit increased to near maximum 
values in the immediate week following sciatic nerve cut and repair, remaining elevated 
without significant recovery during the following 3 weeks [F(2,28) = 2.233, p = 0.126]. 
The EPT deficit was relatively less severe in animals treated with UCX®  during the 3 
weeks following sciatic nerve transection and direct cooptation (p < 0.05) (End-to-
EndUCX group). Immediately after the sciatic nerve cut and repair the WRL values 
increased to the test termination duration of 12 seconds in almost every animal, and 
slightly improving during the following 3 weeks. Both, the degree of acute affection in 
thermal and nociceptive sensitive function and the rate of its recovery were similar in 
both treated groups during the study period (Table 1 and Table 2).  
For the chronic study groups, data from withdrawal reflex latency (WRL) were analyzed 
through two-way Anova for repeated measures, comparing groups after sciatic 
neurotmesis treated with UCX® (End-to-EndUCX group), Floseal® (End-to-EndFloseal 
group), these two treatments combined (Endto-EndFlosealUCX group) and an end-to-
end control group (End-to-End). The results showed a significant interaction effect 
between the variables time of recovery and treatment [F(33,220) = 3.097; p = 0.000]. 
This effect was explained by differences in recovery of the WRL after sciatic nerve 
neurotmesis between the end-to-end group (End-to-End) and the remaining 
experimental groups, with the former animals showing better recovery in this test. No 
differences in WRL recovery were found between animals treated with Floseal® (End-
to-EndFloseal group), MSCs (End-to-EndUCX group) or with combined Floseal® plus 
UCX® (Endto-EndFlosealUCX group) (Table 3 and Table 4). 
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3.2. Kinematics analysis 
Ankle joint kinematics during gait was assessed in the experimental treated groups at 
the end of the 20-weeks recovery time and was compared with data from uninjured 
control animals. Ankle angle was compared between groups at four selected instants 
belonging to the stance phase and significant differences between the groups were 
found for each of these time points, except for TO. Post hoc pairwise comparisons 
showed that no differences in ankle joint angle existed between the uninjured control 
group and any of the sciatic-treated groups. However, differences in this parameter 
existed between experimental groups. At the instant of IC, the ankle joint angle was 
significantly different when comparing the End-to-End group to any of the remaining 
sciatic-treated groups (End-to-EndFlosealUCX , End-to-EndUCX and End-to-
EndFloseal) (p<0.05). At OT, which occurs around 20% of the entire stance phase 
duration, differences between groups were now found between the End-to-End and 
End-to-EndUCX (p=0.023), and End-to-EndFlosealUCX (p=0.005), as well as between 
the two latter groups (p=0.015). Further differences in ankle angle at this time point 
were observed between the End-to-End group and the group treated with UCX®  and 
Floseal® (End-to-EndFlosealUCX) (p=0.038). At the instant of HR, meaning the time 
during the stance phase of the rat’s gait cycle when the push off action begins  
significant differences in ankle joint angle existed between End-to-EndFloseal animals 
and those within the End-to-EndFlosealUCX group (p=0.008) (Figure 4).  
 
3.3. Histological and Stereological Analysis  
In the acute phase of the healing period (21 days after neurotmesis) the samples 
revealed Wallerian degeneration in varying degrees, from mild to severe, in all material 
submitted for histology, hindering the observation of axonal regeneration (Figure 5A 
and 5B). A little retraction of the myelin membrane was observed, which could be 
caused by the nerve injury. The fiber organization was higher and the extent of fibrosis 
was lower in the End-to-EndUCX group (Figure 5A and 5B). 
In the hyper-acute phase (3 days after neurotmesis), the histology of the End-to-end 
sample showed disruption of the perineurium, fascicles disorganization, proliferation of 
Schwann cells with axonal swelling and inflammatory infiltration in the endoneurium 
Scarce neutrophils and multinucleated giant cells were also identified, mainly located 
around hair shafts, probably due to the surgical technique (Figure 6A). In turn, animals 
belonging to the End-to-EndFloseal and End-to-EndFlosealUCX groups developed 
multiple foci of dystrophic calcification, often accompanied by a foreign body 
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inflammatory reaction (Figure 6B and Figure 6C). In the samples from the End-to-
EndFlosealUCX group, this finding was even more prominent and extensive, 
associated with deposition of large amount of fibrin and hemorrhage which destroyed 
the normal architecture of the nerve (Figure 6D). Mild to moderate amount of mixed 
inflammatory infiltrate along with elongated mesenchymal cells circumscribing the 
perineurium were observed in the End-to-EndUCX sample (Figure 6C). Such 
observations were indicative of an UCX® - mediated induction of  Wallerian 
degeneration necessary for proper nerve regeneration; an assumption that turned out 
to be confirmed by long-term observations (Figure 7) and stereological estimates 
(Table 5). While light microscopy analysis was restrictive, limiting our observations to 
the expected smaller size of regenerated nerve fibers relative to the controls, 
stereological analysis disclosed a significantly (p<0.05) larger axon diameter and 
thicker myelin thickness in the End-to-EndFlosealUCX group when compared to either 
End-to-EndUCX  or End-to-EndFloseal group (Table 5).   
 
4. Discussion  
Despite great progress in the fields of tissue engineering and stem cell therapy, 
translational and preclinical studies are required to accelerate the clinical application of 
alternative approaches to autologous nerve grafts for peripheral nerve repair. The 
peripheral nervous system is able to regenerate after traumatic injury but, most 
frequently, the functional outcomes following damage are poor. Nowadays, most tissue 
engineered nerve grafts are composed of a neural scaffold prepared with a variety of 
biomaterials. The introduction of active cells delivered by appropriate vehicles, could 
add on to the system an important biochemical cue, producing engineered nerve grafts 
with enhanced ability to repair more extensive peripheral nerve defects [9]. 
The rat is the animal model most frequently used in peripheral nerve regeneration 
studies because of the widespread availability of these animals as well as the 
distribution of their nerve trunks which is similar to humans [2]. Furthermore, the rat 
sciatic nerve provides a nerve trunk with adequate length and space at the mid-thigh 
for surgical manipulation and/or introduction of grafts or tube-guides [44]. 
Concomitantly, this experimental model provides a very realistic testing bench for 
lesions involving plurifascicular mixed nerves with axons of different size and type, 
competing to reach and re-innervate distal targets [2]. Peripheral nerve injuries are 
classified in two major groups, crushing injuries (axonotmesis) and complete nerve 
sections (neurotmesis) with or without loss of nerve tissue [45, 46]. The axonotmesis 
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injury is less severe and it is often used in studies concerning the physiological 
mechanisms of regeneration, while neurotmesis is mostly used in surgical strategy 
studies, such as the implementation of biomaterials associated with cellular systems 
[22, 25].  
The crucial role of stem cells, mesenchymal stem cells (MSCs) in particular, in tissue 
renewal and regeneration has been well established [47]. The International Society for 
Cellular Therapy has established minimal criteria to define MSCs. Namely, these cells 
should have the ability to adhere to plastic in optimal culture conditions, should express 
CD105, CD73, and CD90 surface markers, should not express CD45, CD34, CD14 or 
CD11b  CD79α or CD19  and HLA-DR, and should be able to differentiate into 
osteoblasts, adipocytes, and chondrocytes in vitro [43]. 
ECBio has developed and patented an isolation method that consistently isolate a 
population of stem cells from the umbilical cord tissue that fulfils the International 
Society for Cellular Therapy (ISCT) criteria for MSCs [23]. The cellular product has 
been registered under the trademark UCX®. UCX® isolated with this method have 
proven not to be immunogenic able to induce immune tolerance in vivo by repressing 
T-cell activation and promoting the expansion of Tregs and in a chronic adjuvant-
induced arthritis model, animals treated with UCX® showed faster remission of local 
and systemic arthritic manifestations [48]. More recently, the UCX® grown in 
aggregates that better mimic tissue environment have produced a secretome rich in 
trophic factors, such as HGF, TGF-β, G-CSF, VEGF-A, FGF-2, KGF and IL-6 that 
promote wound healing reactions, as demonstrated in vitro by vasculogenesis, 
motogenic and chemotactic assays; and in vivo, using a chemotaxis assay where  
UCX® were shown to recruit surrounding bone marrow MSCs known to be directly 
involved in tissue regeneration (results to be published elsewhere). 
In the present study the in vivo application of UCX® was intended to improve the 
regeneration process in the rat sciatic nerve after a neurotmesis injury which was 
surgically reconstructed using and-to-end suture. We hypothesize that UCX® can  
integrate surrounding the lesion tissue and modulate the inflammatory response 
(including the Wallerian degeneration that occurs in the hyper-acute phase) though a 
paracrine mechanisms that involves trophic factors able to promote local 
vascularization and mobilization of local cells (like the Schwann cells) involved in nerve 
regeneration [49]. From the beginning, the risk of immune rejection in our experimental 
setup was neglected. MSCs derived from the Wharton’s jelly  including the UCX® cells 
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have already been xeno-implanted before into rabbits, rats and sheep by us and other 
research groups, without eliciting any compromising immune rejection reaction [24, 50].  
In this experimental work, it was important to evaluate the immediate Wallerian 
response and early nerve regeneration in the hyper-acute and acute phases, 
respectively, given the large importance of the Wallerian degeneration for subsequent 
cellular and molecular events that will promote nerve regeneration. When an axon is 
transected, the distal cytoskeleton disintegrates, its cell membrane disappears, and the 
axon fragments. The Wallerian degeneration is accompanied by macrophages entering 
the transected area to remove myelin and axonal debris being first detected by light 
microscopy 36 to 44 hours after nerve transection in mice and rats, and reaching a 
peak around the third week. In the acute phase of the healing (21 days after 
neurotmesis), our samples revealed Wallerian degeneration in varying degrees, from 
mild to severe, hindering the observation of axonal regeneration. On the other hand, 
nerve fiber organization was higher and the extent of fibrosis was lower when sciatic 
nerves were treated with UCX®, which suggests the importance of these cells in 
improving nerve regeneration when applied in the first days after neurotmesis by 
promoting an efficient Wallerian degeneration. Theoretical repercussion of these 
histological observations performed during the hyper-acute and acute phases were 
confirmed by long-term observations and stereological estimates. While light 
microscopy analysis was limited, allowing to observe in all experimental groups just the 
expected smaller size of regenerated nerve fibers with respect to the controls, 
stereological analysis disclosed a significantly larger axon diameter and higher myelin 
thickness in the End-to-EndFlosealUCX group in comparison to End-to-EndUCX and 
End-to-EndFloseal experimental groups. These histological and histomorphometric 
analyses performed in the hyper-acute, acute and chronic phases also suggest that 
Floseal® is an appropriate vehicle to delivery UCX® to  peripheral nerve injuries. 
The myelin sheath was thicker in the regenerated nerves, suggesting that UCX® might 
exert their positive effects on Schwann cells, the key element in Wallerian degeneration 
and consequent axonal regeneration. Previous results have demonstrated that the use 
of either undifferentiated or neuroglial-like differentiated Wharton jelly MSCs did 
enhance the recovery of sensory and motor function of the rat sciatic nerve in 
axonotmesis and neurotmesis injuries [14, 51]. Both the degree of acute affection in 
thermal and nociceptive sensitive function as well as the rate of its recovery in the 
acute phase in the End-to-End group was similar to the End-to-EndUCX.  Concerning 
EPT and WRL results in the chronic phase study, no differences in recovery were 
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found between any of the treated groups. However, these tests are, to some extent, 
more dependent on the operator and therefore subject to human error. As a result, the 
use of different methods for an overall assessment of nerve function has long been 
recommended by several investigators [52]. In our lab we complement EPT and WRL 
techniques with a kinematics evaluation in order to reliably predict the potential 
therapeutic benefit of a nerve repair strategy. In this case the kinematics analysis 
showed differences in ankle joint angle between experimental groups. At the instant of 
IC, the ankle joint angle determined for animals belonging to the End-to-End group was 
significantly different from any of the remaining treated groups. At OT, which occurs 
around 20% of the entire stance phase duration, differences were now found between 
the End-to-End group and the groups treated with UCX® (End-to-EndUCX  group), and 
UCX® administered with Floseal® (End-to-EndFlosealUCX), as well as between the two 
latter groups. At the instant of HR, meaning the time during the stance phase of the 
rat’s gait cycle  when the push off action begins  significant differences in ankle joint 
angle were measured between End-to-EndFloseal animals and End-to-EndFlosealUCX 
animals. Despite ankle kinematics did not demonstrate clear differences between 
groups in terms of functional recovery, it is worthwhile noting that, 20 weeks following 
sciatic nerve neurotmesis, the ankle kinematics during gait stance phase was similar to 
that of control animals. Because it is unlikely that sciatic-injured animals can fully 
restore the normal ankle joint motion pattern during gait, we have to consider that even 
our kinematics analysis might not have sufficient sensitivity to detect small differences 
in gait performance between experimental groups.  
Additional studies will be necessary to clarify the potential of these cells to be used in 
nerve and tissue regeneration. However, the results discussed herein show a 
promising effect of UCX® in promoting myelin production by Schwann cells in surgically 
reconstructed nerves after a neurotmesis injury. A new gateway it therefore opened for 
using these cells in neurodegenerative diseases that are typified by demyelination.  
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5. FIGURES AND TABLES LEGENDS 
Figure 1 - UCX® characterization. 
Results from Flow Cytometry analysis of cell surface markers are presented as 
histograms (A) and column bars (B). Isolated UCX® presented a fusiform, fibroblast-like 
morphology in culture (C). Multi-lineage differentiation potential of UCX® was 
qualitatively analyzed by histological staining methods. Adipogenic differentiation was 
assessed with Oil Red O staining (D); chondrogenic differentiation with Alcian Blue 
staining (E); and osteogenic differentiation with Alkaline Phosphatase staining (F)s. 
Figure is representative of n=8 umbilical cords used in these studies .  
 
Figure 2 – Rat sciatic nerve injury and surgical reconstruction 
Rat sciatic nerve with a neurotmesis injury with a gap of 10 mm (A). The neurotmesis 
injury was performed and regeneration initiated after reconstruction with an end-to-end 
suture where the coaptation was performed with 7/0 monofilament nylon epineural 
sutures of the 2 transected nerve endings (B). 
 
Figure 3 – Floseal® preparation (A and B).  
The 5 ml chloride solution is transferred to a vial containing thrombin. The vial is gently 
swirled until the thrombin is dissolved. The dissolved thrombin is aspirated from the 
small bowl into the syringe to the indicated mark (4 ml) and the gelatin matrix granules 
syringe is connected to the syringe containing the thrombin solution (A) and the gelatin 
matrix – thrombin solution mixture is transferred back and forth between the syringes 
for a total 10 passages (B). Rat sciatic nerve reconstructed with an end-to-end suture 
and Floseal® (End-to-EndFloseal group). 
 
Figure 4 – Kinematic plots 
Kinematic plots in the sagittal plane for the ankle angle (º) as it moves through the 
stance phase, during the transection injury study. The mean of each group is plotted (N 
= 6). 
 
Figure 5 – Histological images acute phase 
Histological analysis of the acute phase of the healing period (day 21 after 
neurotmesis). Cross section of epon-embedded rat sciatic nerve, Toluidine Blue stain, 
400x. Images of Wallerian degeneration:  many axons with myelin degeneration 
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(arrowheads) and some regenerating axon clusters (arrows). Panels (A and B) show 
cross sections of nerves from the End-to-EndUCX group.  
 
Figure 6 – Histological images hyper-acute phase 
Histological analysis of the hyper-acute phase of the healing period (day 3 after 
neurotmesis). Cross section of paraffin-embedded rat sciatic nerve, HE, 100x: (A) End-
to-End: Destruction of perineurium and endoneurium and fascicles disorganization; (B) 
End-to-EndFloseal: multiple foci of calcification in the epineurium and fatty infiltration, 
associated with diffuse mononuclear inflammatory infiltrate; (C) End-to-EndUCX: mild 
to moderate amount of mixed inflammatory infiltrate along with elongated 
mesenchymal cells that circumscribe the perineurium; (D) End-to-EndFlosealUCX: 
multiple foci of calcification associated with fibrin deposition and hemorrhage, with 
destruction of the perineurium and endoneurium. 
 
Figure 7 – Light micrographs images 
Light micrographs of Toluidine blue-stained sciatic nerve semi-thin sections from four 
different experimental groups: Control (A) End-to-EndFlosealUCX (B) End-to-
EndFloseal (C), End-to-EndUCX  (D). Original magnification: 1,000X.  
 
Table 1 – Withdrawal Reflex Latency results for acute phase 
Values in seconds (s) were obtained performing the Withdrawal Reflex Latency (WRL) 
test to evaluate the nociceptive function. This test has been performed preoperatively 
(week-0), at day 7, day 14 and day 21, when the animals were sacrificed for 
morphological analysis. Results are presented as mean and standard error of the mean 
(SD). N corresponds to the number of animals within each experimental group.  
 
Table 2 – Extensor Postural Thrust results for acute phase 
Values of Motor Deficit were obtained performing Extensor Postural Thrust (EPT) test. 
This test has been performed preoperatively (week-0), at day 7, day 14 and day 21, 
when the animals were sacrificed for morphological analysis. Results are presented as 
mean and standard error of the mean (SD). N corresponds to the number of animals   
within each experimental group 
 
Table 3 – Withdrawal Reflex Latency results for 20 weeks follow-up 
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Values in seconds (s) were obtained performing Withdrawal Reflex Latency (WRL) test 
to evaluate the nociceptive function. This test has been performed pre-operatively 
(week-0), at week-1 and every 2 weeks after the surgical procedure until week-20, 
when the animals were sacrificed for morphological analysis. Results are presented as 
mean and standard error of the mean (SD). N corresponds to the number of animals   
within each experimental group. 
 
Table 4 – Extensor Postural Thrust results 20 weeks follow-up 
Values of Motor Deficit were obtained performing Extensor Postural Thrust (EPT) test. 
This test has been performed preoperatively (week-0), at week-1 and every 2 weeks 
after the surgical procedure until week-20, when the animals were sacrificed for 
morphological analysis. Results are presented as mean and standard error of the mean 
(SD). N corresponds to the number of animals   within each experimental group.  
 
Table 5 – Stereological quantitative assessment image 
Stereological quantitative assessment density, total number, diameter and myelin 
thickness of regenerated sciatic nerve fibers at week-20 after neurotmesis. Values are 
presented as mean ± SD 
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TABLES 
Table 1 – Withdrawal Reflex Latency results for acute phase 
 Week 0 Week 1 Week 2 Week 4 
End-to-EndUCX    
1B 3,65 12,00 12,00 9,63 
1C 3,45 12,00 12,00 12,00 
1D 3,19 12,00 10,54 7,40 
1E 3,22 12,00 12,00 11,03 
1F 3,41 12,00 12,00 10,97 
Mean ± SD 3,44±0,22 12,00±0,00 11,71±0,65 10,21±1,78 
End-to-End    
2A 3,00 12,00 4,00 4,00 
2B 2,00 12,00 5,00 12,00 
2C 2,00 12,00 12,00 8,00 
2D 4,00 12,00 2,00 3,00 
2E 2,00 12,00 6,00 2,00 
2F 2,00 12,00 12,00 12,00 
2G 1,00 12,00 12,00 8,00 
Mean ± SD 2,29±0,95 12,0±0,00 7,57±4,31 7,00±4,12 
Control    
3A 3,00 12,00 4,00 4,00 
3B 2,00 12,00 5,00 12,00 
3C 2,00 12,00 12,00 8,00 
3D 4,00 12,00 2,00 3,00 
3E 2,00 12,00 6,00 2,00 
3F 2,00 12,00 12,00 12,00 
3G 1,00 12,00 12,00 8,00 
Mean ± SD 2,29±0,95 12,0±0,00 7,57±4,31 7,00±4,12 
 
Table 2 – Extensor Postural Thrust results for acute phase 
 Week 0 Week 1 Week 2 Week 4 
End-to-EndUCX     
1B 0,21 0,98 0,98 0,97 
1C -0,07 0,97 0,98 0,98 
1D -0,14 0,80 0,98 0,98 
1E -0,05 0,97 0,98 0,98 
1F 0,17 0,98 0,97 0,98 
Mean ± SD 0,09±0,20 0,94±0,08 0,98±0,00 0,98±0,00 
End-to-End    
2A 0,07 0,90 0,80 0,73 
2B 0,07 0,93 0,83 0,70 
2C 0,08 0,90 0,85 0,88 
2D 0,07 0,90 0,91 0,84 
2E 0,09 0,97 0,97 0,69 
2F 0,06 0,77 0,86 0,83 
2G 0,07 0,87 0,89 0,81 
Mean ± SD 0,07±0,01 0,89±0,06 0,87±0,06 0,78±0,08 
Control    
3A 0,07 0,90 0,80 0,73 
3B 0,07 0,93 0,83 0,70 
3C 0,08 0,90 0,85 0,88 
3D 0,07 0,90 0,91 0,84 
3E 0,09 0,97 0,97 0,69 
3F 0,06 0,77 0,86 0,83 
3G 0,07 0,87 0,89 0,81 
Mean ± SD 0,07±0,01 0,89±0,06 0,87±0,06 0,78±0,08 
 
 
 
Chapter II 
Results 
 
 
Andréa Louise Moutinho Gärtner | 206 
 
Table 3 – Withdrawal Reflex Latency results for 20 weeks follow-up 
 Week 0 Week 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Week 14 Week 16 Week 18 Week 20 
Control             
1A 3,00 12,00 4,00 4,00 10,00 5,00 8,00 12,00 5,00 7,00 5,00 4,00 
1B 2,00 12,00 5,00 12,00 5,00 2,00 10,00 2,00 4,00 2,00 2,00 3,00 
1C 2,00 12,00 12,00 8,00 5,00 3,00 4,00 4,00 4,00 6,00 4,00 4,00 
1D 4,00 12,00 2,00 3,00 4,00 5,00 2,00 6,00 4,00 4,00 4,00 2,00 
1E 2,00 12,00 6,00 2,00 10,00 2,00 5,00 2,00 2,00 6,00 2,00 2,00 
1F 2,00 12,00 12,00 12,00 12,00 3,00 3,00 3,00 4,00 4,00 2,00 2,00 
1G 1,00 12,00 12,00 8,00 10,00 4,00 2,00 2,00 2,00 3,00 2,00 2,00 
Mean ± SD 2,29±0,95 12,0±0,00 7,57±4,31 7,00±4,12 8,00±3,21 3,43±1,27 4,86±3,08 4,43±3,64 3,57±1,13 4,57±1,81 3,00±1,29 2,71±0,95 
End-to-EndFlosealUCX    
2A 2,93 6,03 8,75 12,00 9,74 3,57 4,66 12,00 5,91 12,00 12,00 7,43 
2B 4,26 12,00 5,59 4,81 12,00 3,49 4,54 12,00 12,00 6,75 12,00 8,28 
2C 5,05 12,00 12,00 12,00 4,25 6,65 12,00 12,00 12,00 12,00 12,00 12,00 
2D 2,75 12,00 11,52 12,00 5,66 5,38 6,61 7,62 12,00 7,62 12,00 8,08 
2E 
2F 
6,53 12,00 12,00 12,00 4,42 3,74 5,83 5,62 7,56 7,83 12,00 12,00 
4,05 9,76 8,11 8,65 4,25 2,92 12,00 12,00 12,00 11,20 12,00 11,69 
Mean ± SD 4,26±1,40 10,63±2,43 9,66±2,62 10,24±2,98 6,72±3,34 4,29±1,42 7,61±0,00 10,21±2,85 10,25±2,77 9,57±2,42 12,00±0,00 9,91±2,19 
End-to-EndUCX          
3A 3,41 12,00 10,05 10,13 4,10 2,71 5,97 3,85 5,10 6,79 8,32 12,00 
3B 3,05 9,19 12,00 5,63 12,00 2,76 7,02 8,52 9,04 12,00 12,00 12,00 
3C 6,77 12,00 4,78 6,49 5,48 3,20 4,93 9,35 6,78 12,00 6,28 5,13 
3D 5,34 12,00 11,75 11,06 3,71 3,54 6,63 5,62 4,90 4,44 12,00 12,00 
3E 4,67 9,76 12,00 12,00 12,00 5,32 12,00 12,00 12,00 12,00 9,16 12,00 
3F 3,41 12,00 10,05 10,13 4,10 2,71 5,97 3,85 5,10 6,79 8,32 12,00 
3G 3,05 9,19 12,00 5,63 12,00 2,76 7,02 8,52 9,04 12,00 12,00 12,00 
Mean ± SD 4,65±1,51 10,99±1,40 10,12±3,09 9,06±2,84 7,46±4,2 3,51±1,07 7,31±2,74 7,87±3,2 7,56±2,98 9,45±3,59 9,55±2,47 10,63±3,07 
End-to-EndFloseal       
4A 4,34 12,00 12,00 12,00 12,00 12,00 10,42 12,00 12,00 12,00 12,00 12,00 
4B 6,01 12,00 12,00 5,11 12,00 4,99 7,37 9,49 12,00 12,00 9,63 12,00 
4C 4,39 12,00 12,00 12,00 6,52 12,00 12,00 9,09 6,53 12,00 12,00 12,00 
4D 3,48 12,00 12,00 12,00 8,52 12,00 12,00 12,00 8,47 9,75 12,00 12,00 
4E 6,01 12,00 12,00 4,97 6,63 12,00 10,16 12,00 12,00 12,00 12,00 7,84 
4F 3,25 12,00 12,00 7,20 6,54 7,11 12,00 3,93 9,93 4,71 7,17 5,47 
4G 4,34 12,00 12,00 12,00 12,00 12,00 10,42 12,00 12,00 12,00 12,00 12,00 
Mean ± SD 4,58±1,20 12,00±0,00 12,00±0,00 8,88±3,51 8,70±2,67 10,02±3,14 10,66±1,82 9,75±3,15 10,16±2,29 10,41±2,93 10,80±2,02 10,22±2,86 
End-to-End       
5A 3,00 12,00 4,00 4,00 10,00 5,00 8,00 12,00 5,00 7,00 5,00 4,00 
5B 2,00 12,00 5,00 12,00 5,00 2,00 10,00 2,00 4,00 2,00 2,00 3,00 
5C 2,00 12,00 12,00 8,00 5,00 3,00 4,00 4,00 4,00 6,00 4,00 4,00 
5D 4,00 12,00 2,00 3,00 4,00 5,00 2,00 6,00 4,00 4,00 4,00 2,00 
5E 2,00 12,00 6,00 2,00 10,00 2,00 5,00 2,00 2,00 6,00 2,00 2,00 
5F 2,00 12,00 12,00 12,00 12,00 3,00 3,00 3,00 4,00 4,00 2,00 2,00 
5G 1,00 12,00 12,00 8,00 10,00 4,00 2,00 2,00 2,00 3,00 2,00 2,00 
Mean ± SD 2,29±0,95 12,0±0,00 7,57±4,31 7,00±4,12 8,00±3,21 3,43±1,27 4,86±3,08 4,43±3,64 3,57±1,13 4,57±1,81 3,00±1,29 2,71±0,95 
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Table 4 – Extensor Postural Thrust results 20 weeks follow-up 
 Week 0 Week 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Week 14 Week 16 Week 18 Week 20 
Control             
1A 0,07 0,90 0,80 0,73 0,68 0,56 0,54 0,54 0,64 0,48 0,42 0,50 
1B 0,07 0,93 0,83 0,70 0,73 0,66 0,57 0,50 0,45 0,40 0,40 0,40 
1C 0,08 0,90 0,85 0,88 0,82 0,76 0,57 0,50 0,53 0,44 0,38 0,40 
1D 0,07 0,90 0,91 0,84 0,82 0,72 0,57 0,39 0,55 0,38 0,34 0,40 
1E 0,09 0,97 0,97 0,69 0,60 0,56 0,51 0,46 0,45 0,38 0,38 0,39 
1F 0,06 0,77 0,86 0,83 0,78 0,72 0,63 0,57 0,55 0,38 0,38 0,40 
1G 0,07 0,87 0,89 0,81 0,78 0,76 0,70 0,47 0,45 0,33 0,42 0,50 
Mean ± SD 0,07±0,01 0,89±0,06 0,87±0,06 0,78±0,08 0,74±0,08 0,68±0,09 0,58±0,06 0,49±0,06 0,52±0,07 0,40±0,05 0,39±0,03 0,43±0,05 
End-to-EndFlosealUCX    
2A -0,29 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
2B 0,11 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
2C 0,11 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
2D 0,06 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
2E 
2F 
-0,12 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
0,11 1,00 0,72 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
Mean ± SD 0,00±0,17 1,00±0,00 0,95±0,11 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 
End-to-EndUCX          
3A -0,46 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
3B 0,14 1,00 0,92 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
3C 0,06 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
3D 0,01 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
3E -0,21 1,00 0,83 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
3F -0,46 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
3G 0,14 1,00 0,92 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
Mean ± SD -0,09±0,24 1,00±0,00 0,95±0,08 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 
End-to-EndFloseal       
4A -0,61 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
4B -0,10 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
4C -0,52 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
4D -0,23 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
4E 0,11 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
4F 0,55 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
4G -0,61 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 
Mean ± SD -0,13±0,43 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 1,00±0,00 
End-to-End       
5A 0,07 0,90 0,80 0,73 0,68 0,56 0,54 0,54 0,64 0,48 0,42 0,50 
5B 0,07 0,93 0,83 0,70 0,73 0,66 0,57 0,50 0,45 0,40 0,40 0,40 
5C 0,08 0,90 0,85 0,88 0,82 0,76 0,57 0,50 0,53 0,44 0,38 0,40 
5D 0,07 0,90 0,91 0,84 0,82 0,72 0,57 0,39 0,55 0,38 0,34 0,40 
5E 0,09 0,97 0,97 0,69 0,60 0,56 0,51 0,46 0,45 0,38 0,38 0,39 
5F 0,06 0,77 0,86 0,83 0,78 0,72 0,63 0,57 0,55 0,38 0,38 0,40 
5G 0,07 0,87 0,89 0,81 0,78 0,76 0,70 0,47 0,45 0,33 0,42 0,50 
Mean ± SD 0,07±0,01 0,89±0,06 0,87±0,06 0,78±0,08 0,74±0,08 0,68±0,09 0,58±0,06 0,49±0,06 0,52±0,07 0,40±0,05 0,39±0,03 0,43±0,05 
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Table 5 – Stereological quantitative assessment image 
 
FIGURES 
Figure 1 - UCX® characterization. 
 
 
Figure 2 – Rat sciatic nerve injury and surgical reconstruction 
 
Group Fiber Density (N /mm2)  
Fiber Number 
(N) 
Fiber 
diameter 
(µm) 
Axon 
diameter 
(µm) 
Myelin 
thickness 
(µm) 
Control 15,905±2,87 7,666±1,90 6,66±0,12 4,26±0,07 1,19±0,03 
End-to-EndFlosealUCX 26,009±6,512 12,255±2,290 2,88±0,42 4,57±0,51 0,85±0,05 
End-to-EndFloseal 23,900±4,291 10,216±2,040 2,23±0,21 3,79±0,30 0,78±0,06 
End-to-EndUCX 28,821±1,202 12,925±2,985 2,42±0,16 3,89±0,22 0,77±0,06 
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Figure 3 – Floseal® preparation (A and B). 
 
Figure 4 – Kinematic plots 
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Figure 5 – Histological images acute phase 
 
Figure 6 – Histological images hyper-acute phase 
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Figure 7 – Light micrographs images 
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2.4. Conclusions 
Peripheral nerve injuries are broadly classified in two major groups, axonotmesis for 
crushing injuries and neurotmesis for complete nerve section with or without loss of nerve 
tissue (Stoll et al., 1989; Chaudhry et al., 1992). Neurotmesis injury is frequently used as 
a surgical strategy to explore the implementation of biomaterials associated with cellular 
systems (Luís, 2008).  
As mentioned before in this chapter, association of biomaterials, to cellular systems, such 
as MSCs able to differentiate into neuroglial-like cells, might improve peripheral nerve 
regeneration, in terms of motor, sensory and histomorphometric parameters. 
In the above mentioned works a biodegradable synthetic biomaterial PLC and a 
commercially available ready-to-use matrix vehicle, (Floseal®) were used to deliver the 
cellular system into the site of injury. 
 
In conclusion, for the neurotmesis in vivo studies: 
- The results of the 1st neurotmesis study demonstrated that enwrapment of the 
repaired site with a Vivosorb® membrane, with undifferentiated HMSCs or 
neuroglial-like cell enrichment, did not lead to any significant improvement in most 
of functional and stereological predictors of nerve regeneration that we assessed, 
with the exception of EPT which had a significantly better recovery after 
employment of undifferentiated HMSCs enriched membrane.  
- HMSCs isolated from the Wharton’s jelly of the UC delivered through PLC 
membranes might thus be regarded a potentially valuable tool to improve clinical 
outcome especially after trauma to sensory nerves after neurotmesis injuries with 
loss of nervous tissue that enables an end-to-end suture or a grafting procedure.  
- When the neurotmesis injury can be surgically reconstructed with an epineural 
end-to-end suture without tension or by grafting, the addition of a PLC membrane 
associated with a cellular system is not mandatory for a substantial improvement 
in functional and morphological recoveries.  
- In the 2nd study it was important to evaluate the immediate Wallerian response and 
early nerve regeneration in the hyper-acute and acute phases, respectively, given 
the large importance of the Wallerian degeneration for subsequent cellular and 
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molecular events that will promote nerve regeneration. Nerve fibre organization 
was higher and the extent of fibrosis was lower when sciatic nerves were treated 
with MSCs, which suggests the importance of these cells in improvement of nerve 
regeneration when applied in the first days after the neurotmesis by promoting an 
efficient Wallerian degeneration. 
- Histological and histomorphometric analysis performed in the hyper-acute, acute 
and chronic phases suggested that Floseal® is an appropriate vehicle to delivery 
UCX® cells in peripheral nerve injuries. 
- The myelin sheaths were thicker in the regenerated nerves where UCX® cells were 
applied, suggesting that MSCs might exert their positive effects on Schwann cells, 
the key element in Wallerian degeneration and the following axonal regeneration. 
- Additional studies will be necessary to clarify the potential use of these cells in 
nerve and tissue regeneration. However, the results discussed herein show a 
promising effect of UCX® in promoting myelin production by Schwann cells in 
surgically reconstructed nerves after a neurotmesis injury. A new approach 
therefore is open for the use of these cells in neurodegenerative diseases 
characterized by demyelination. 
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Discussion and conclusions 
Regeneration is the physical process where remaining tissues organize themselves to 
replace missing or injured tissues in vivo (Bongso et al., 2008), replacing previous 
function. This is the main goal of regenerative medicine.  
In what concerns to peripheral nervous system, it is able to regenerate after traumatic 
injury, but it is still frequent to see poor functional outcome. Even with all the great 
advances in tissue engineering and stem cell therapy field, “prime and excellence” is still 
far to happen, therefore translational and pre-clinical studies are essential to speed up 
future clinical applications.  
The choice of the experimental model has a great importance, rodents, particularly the rat 
and mouse, have remained during years as the chosen animal model for studies with 
peripheral nerve regeneration. It is relatively cheap, well studied, widespread available, as 
well as it’s nerve trunks distribution is similar to subhuman primates (Mackinnon et al., 
1985). The main issue of tissue engineering should be focused on the creation of 
autologous, living tissues with the potential for regeneration. Peripheral nerve 
regeneration must include a multidisciplinary team able to develop biomaterials, cell 
therapies, and to do in vitro and in vivo pre-clinical trials (Hermann et al., 2004). Although 
sciatic nerve injuries themselves are rare in humans, the rat sciatic nerve model used in 
our studies provides a very realistic testing bench for lesions involving plurifascicular 
mixed nerves with axons of different size and type competing to reach and reinnervate 
distal targets (Amado et al., 2008; Liao et al., 2012). Focal crush causes axonal 
interruption but preserves the connective sheaths (axonotmesis). After this kind of injury, 
regeneration is usually successful since axons regenerate at a steady rate along the distal 
nerve supported by the reactive Schwann cells (SCs) and by the preserved endoneural 
tubules which enhance axonal elongation and facilitate adequate reinnervation (Brohlin et 
al., 2009). Crush injuries are appropriate to investigate the cellular and molecular 
mechanisms of peripheral nerve regeneration, and to assess the role of different factors in 
the regeneration process (Mackinnon et al., 1985). Nerve crush injury is also a well-
established model in experimental regeneration studies in order to investigate the impact 
of various pharmacological treatments and cellular therapies (Sunderland et al., 2004; 
Amado et al., 2008; van Neerven et al., 2012). This injury does not implicate surgical 
reconstruction, but due to the required regeneration period, the neurogenic atrophy of the 
innervated muscles may occur. Therefore therapeutic approaches to successfully 
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decrease this recovery time are also important. For the reasons mentioned above, the first 
experimental part of this manuscript refers to this type of peripheral nerve injury. 
Most tissue engineered nerve grafts are composed of a neural scaffold prepared with a 
variety of synthetic or natural biomaterials through well-defined fabrication techniques. 
Tissue engineering of peripheral nerves associating biomaterials like chitosan, PLC 
copolyester, collagen among others (some of them, previously studied by our group) 
(Amado et al., 2008; Luís et al., 2008b;  a r ci  et al., 2011) to cellular systems (able to 
differentiate into neuroglial-like cells or modulate the inflammatory process) might improve 
nerve regeneration. This can be observed in terms of motor and sensory recovery, 
avoiding regional muscular atrophy since the healing period is shortened. The introduction 
of cellular systems represents a good option for tissue engineered nerve graft construction 
with improved ability to repair peripheral nerve injuries. SCs, MSCs, embryonic stem cells, 
bone marrow stromal cells are the best studied candidates. The cellular systems 
transplanted into the injured nerve should ideally produce growth factors or extracellular 
matrix (ECM) molecules, and modulate the inflammatory process, to improve nerve 
regeneration (Gu et al., 2011; Gärtner et al., 2013). There are evidences of the non-
immunogenic and induce immune tolerance capacity of MSCs in vivo by repressing T-cell 
activation and promoting the expansion of Tregs and in a chronic adjuvant-induced 
arthritis model, animals treated with UCX® MSCs showed faster remission of local and 
systemic arthritic manifestations (Santos et al., 2013). 
Isolation of stem cells from extra-embryonic tissues, offer many advantages over both 
embryonic and adult stem cell sources, once these tissues are routinely discarded at birth 
time, so little or no ethical controversy attends the harvest of the stem cells populations. 
Even more, the large volume of extra-embryonic tissues increases the number of 
available stem cells that can be isolated (Marcus et al., 2008). In contrast to the highly 
standardized and industrially fabricated scaffolds, the quality of stem cells varies from 
patient to patient, depending on the individual tissue characteristics, on the transport 
conditions and time of delivery of the samples from the hospital / clinic to the laboratory, 
on the processing and cryopreservation techniques. The MSCs isolated from extra-fetal 
tiss es like the Whart n’s jelly, have a m rph l gic characteristics that include a spindle 
shape, resembling fibroblast, that are plastic adherent (Porada et al., 2010). The 
International Society of Cellular Therapy (ISCT) recognized the need to define MSCs. This 
effort was made in order to distinguish between mesenchymal stromal cells and 
mesenchymal stem cells. The ISCT provided a clear and resumed definition: MSCs are 
progenitor cells for the mesenchymal lineages. These MSCs are adherent to tissue culture 
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plastic (adherent cells), have a particular surface marker phenotype (express SH2, SH3, 
SH4, CD44, and HLA-class I, and do not express markers of the hematopoietic lineages 
CD34 and CD45 or HLA-class II), and have the capacity to differentiate into three 
mesenchymal lineages in vitro (bone, cartilage, adipocytes) (Dominici et al., 2006). MSCs 
have been isolated from several sections of the umbilical cord. Our research group has 
been focused on the MSCs isolated fr m the Whart n’s jelly and  n pre-clinical studies 
regarding animal models for application of this cellular system to regeneration of the 
peripheral nervous system after axonotmesis and neurotmesis injuries. Other important 
experimental work related MSCs associated to bone, muscle (Pereira et al., 2013) and 
vascular regeneration was performed alongside with these studies. These results are not 
referred in this thesis since it is not on its scope (unpublished data). 
The aim of Ph.D. work was to explore the therapeutic value of human umbilical cord (UC) 
Whart n’s jelly derived  SCs in vitro and in vivo, associated to different materials or 
vehicles on rat sciatic nerve injuries. The in vivo application of MSCs had the intended to 
improve the regeneration process in the rat sciatic nerve after axonotmesis and 
neurotmesis injury which was surgically reconstructed using several approaches. We 
hypothesize that MSCs could integrate the microenvironment surrounding the injured 
tissue and modulate the inflammatory response through a paracrine mechanism that 
encompasses trophic factors able to promote local vessel formation and mobilize local 
cells, like SCs involved in nerve regeneration.  
 
In vitro studies 
Undifferentiated  SCs fr m h man  mbilical c rd Whart n’s jelly have been expanded 
and exhibited a normal star-like shape with a flat morphology in culture. The karyotype 
analysis of the MSCs cell line derived from human Wharton jelly demonstrated that this 
cell line has no neoplastic characteristics and was stable during the cell culture 
procedures in terms of number and structure of the somatic and sexual chromosomes 
(Gärtner et al., 2012a).  
MSCs from Whart n’s Jelly were differentiated int  ne r glial-like cells in the presence of 
neurogenic culture medium during 96 hours. They became exceedingly long and there 
was a formation of typical neuroglial-like cells with multi-branches and secondary 
branches. The differentiation was also tested based on the expression of typical neuronal 
markers such as GFAP, GAP-43 and NeuN by neural-like cells obtained from MSCs. 
Undifferentiated MSCs were negatively labeled to GFAP, GAP-43 and NeuN and after 96 
hours of differentiation the cells were positively stained for glial protein GFAP and for the 
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growth-associated protein GAP-43. All nucleus of neuroglial-like cells were also labeled 
with the neuron specific nuclear protein called NeuN showing that differentiation was 
successfully achieved (Gärtner et al., 2012a). Anyway, the in vitro expansion and 
differentiation of MSCs for clinical cell-based therapy is a very expensive and long 
process that needs standardization and future experimental work concerning the use of 
bioreactors should be considered.  
 
In vivo studies 
Several natural and synthetic biomaterials associated to cellular systems including the 
MSCs isolated from the  mbilical c rd Whart n’s jelly were tested in the rat model as a 
therapeutic approach to treat two different sciatic nerve injuries, axonotmesis and 
neurotmesis. MSCs are a potential source of growth promoting signals; transplantation of 
these cells was expected to have a positive outcome in terms of functional and 
morphologic recoveries. There are two alternatives to transplant cellular systems into 
injured nerves. The cells may be directly injected into the neural scaffold which has been 
placed in the injured site or they may be pre-added on the neural scaffold via injection or 
co-culture ( a r ci  et al., 2011). 
In the present work the first two biomaterials described were chitosan type III developed 
by our research group as a hybrid of chitosan (Shirosaki et al., 2005; Amado et al., 2008; 
Simões et al., 2010) and a commercially available Poly(DL-lactide-e-caprolactone) 
membrane, named Vivosorb®. In a group of experiments a cellular product (UCX®) derived 
from the umbilical cord matrix available from ECBIO (Soares et al., 2008) was tested 
together with a commercial vehicle (Floseal®). Both of them were applied to a neurotmesis 
injury without loss of nervous tissue, where a surgical reconstruction using an epineural 
end-to-end suture was possible. 
chitosan type III was developed as a hybrid of chitosan by adding GPTMS, which 
improves the wettability of chitosan surfaces, therefore it is expected to be more 
hydrophilic than the original chitosan (Shirosaki et al., 2005; Amado et al., 2008; Simões 
et al., 2010). Moreover Chitosan type III was developed to be more porous, with a larger 
surface to volume ratio however preserving mechanical strength and the ability to adapt to 
different shapes. Significant differences in water uptake between commonly used chitosan 
and this hybrid chitosan type III were previously reported as a consequence of the 
difference in the ability of the matrix to hold water. In fact, hybrid chitosan-based 
membranes may retain about twice as much biological fluid as chitosan (Chen et al., 
2002). The synergistic effect of a more favorable porous microstructure and 
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physicochemical properties (more wettable and higher water uptake level) of chitosan type 
III and the presence of silica ions are probably responsible for the good results in post-
traumatic nerve regeneration promotion (Shirosaki et al., 2005; Amado et al., 2008; 
Simões et al., 2010). In previous studies performed by our group (Amado et al., 2008) in 
vivo testing demonstrated that chitosan type III improved nerve fiber regeneration in 
comparison to axonotmesis control. Wettability of material surfaces may be one of the key 
elements for protein adsorption, cell attachment and migration (Hench et al., 1982).  
The positive results obtained for axonal regeneration in sciatic nerves with axonotmesis 
injuries surrounded by chitosan type III membranes suggests that this biomaterial may not 
just work as a simple mechanical device but instead may induce nerve regeneration 
(Amado et al., 2008; Simões et al., 2010). The neuroregenerative properties of chitosan 
type III may be explained by the effect on SCs proliferation, axon elongation and 
myelinization (Amado et al., 2008; Simões et al., 2010; Gärtner et al., 2012b).  
For the tests involving chitosan type III described in this thesis, the membrane was used 
to deliver human MSCs from the UC of Wharton’s jelly comparing this delivery approach 
to the direct infiltration into the injury site of MSCs in suspension. In this study the 
functional analysis revealed a gradual recovery of the injured hind limb during the 12-
week healing period in all the experimental groups with chitosan type III and MSCs. In 
fact, the application of human MSCs associated or not to the chitosan membranes 
showed positive effects concerning the functional recovery (evaluated by EPT and WRL 
tests), probably due to the modulation of the inflammatory process during the Wallerian 
degeneration and by the production of growth factors. Once more and in agreement with 
previous works (Shirosaki et al., 2005; Amado et al., 2008; Simões et al., 2010), 
statistically significant positive effects where observed relatively to the higher myelin 
thickness in the regenerated nerves enwrapped with the chitosan type III membranes 
alone. As expected, regenerated nerve fibers were organized in microfascicles and 
smaller when compared to normal control nerves. In conclusion, results of this study 
suggest that either enrichment of human MSCs alone or the combination of chitosan type 
III membrane enwrapment and human MSCs infiltration after nerve crush injury provides a 
slight advantage in comparison to untreated controls. On the other hand, our results 
confirmed that chitosan type III membranes alone may represent a very promising clinical 
tool in peripheral nerve reconstructive surgery.  
Our PLC data showed that it does not deleteriously interfere with nerve regeneration 
process, as a matter of fact, the information on the efficiency of PLC membranes for 
promoting nerve regeneration was already provided experimentally and with patients 
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( a r ci  et al., 2011). PLC becomes hydrophilic by water uptake, which increases the 
permeability of the material. This is important for nutrient control and metabolite transport 
to the surrounding healing tissue. A few weeks after implantation, the mechanical strength 
gradually decreases and loss of molecular weight occurs as a result of the hydrolysis 
process. In approximately 24 months, PLC degrades into lactic acid and hydroxycaproic 
acid which are both safely metabolized into water and carbon dioxide and/or excreted 
through the urinary tract. PCL has the advantage of not creating an acidic micro-
environment, which is favorable to the surrounding tissue (Luís et al., 2007). 
The results presented in this work (Gärtner et al., 2012a) show that the use of either 
undifferentiated or differentiated MSCs in axonotmesis and neurotmesis lesions improved 
the recovery of sensory and motor function. In the cell-enriched experimental groups we 
observed that the myelin sheath was thicker, suggesting that MSCs certainly smear a 
positive effects on SCs, the key element in Wallerian degeneration and the subsequent 
axonal regeneration (Gärtner et al., 2012a).  SCs fr m the Whart n’s jelly with capacity 
to differentiate into neuroglial-like cells may be a treasure in the peripheral nervous 
system repair. The transplanted MSCs are able to promote local blood vessel formation 
and release in locum the neurotrophic factors (Gärtner et al., 2012a; Gärtner et al., 
2012b). It could also be concluded that MSCs delivered through PLC membranes might 
thus be regarded a potentially valuable tool to improve clinical outcome especially after 
trauma to sensory nerves, after neurotmesis injuries with loss of nervous tissue.  
Whenever a nerve guide is not the essential element for the therapeutic approach, and 
MSCs are the main component for the treatment, Floseal® will be a good choice as cell 
delivery vehicle. In the neurotmesis study histological and histomorphometric analyses 
performed in the hyper-acute, acute and chronic phases suggested that Floseal® was an 
appropriate vehicle to delivery UCX® to peripheral nerve injuries.  
Additional studies will be necessary to clarify the potential of MSCs from the UC Wharton 
jelly (prepared using the technology developed by ECBIO or other protocol of isolation 
and expansion) to be used in nerve and tissue regeneration. However, the results 
discussed herein show a promising effect of MSCs in promoting myelin production by 
Schwann cells in surgically reconstructed nerves after axonotmesis and neurotmesis 
injuries. Therefore the use of these cells in neurodegenerative diseases typified by 
demyelination opens a new gateway in the field. 
The MSCs isolated from the Wharton´s jelly delivered through Floseal®, PLC, and 
chitosan type III membranes might be a potentially valuable tool to improve clinical 
outcome especially after trauma to sensory nerves, such as digital nerves. The 
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observation that in both cell-enriched experimental groups myelin sheath was thicker, 
suggests that MSCs might exert their positive effects on SCs, the key element in 
Wallerian degeneration and the following axonal regeneration. In addition, these cells 
represent a non-controversial source of primitive mesenchymal progenitor cells that can 
be harvested after birth, cryogenically stored, thawed, and expanded for therapeutic uses, 
including nerve injuries like axonotmesis and neurotmesis. The time and temperature of 
the transport (and the saline solution used) of the UC units from the hospital / clinic to the 
laboratory is crucial for a successful outcome considering MSCs isolation and proliferation 
from fresh and cryopreserved UC. It is highly recommended that the transport from the 
clinic to the hospital should be refrigerated, and the UC units should be immediately 
immersed in a sterile saline solution like HBSS or DPBS. 
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Future Perspectives 
In 2001, just a couple of months after finishing my degree in microbiology I started my 
scientific career with a scholarship in the Human Genetic Disease, Iron and Immune 
System Division of Institute for Molecular and Cell Biology (IBMC). The research topic of 
my scholarship was Hemochromatosis. A hereditary disease caused by the excessive 
absorption of iron. The accumulation of iron in organs, especially liver, heart and pancreas 
leads to an iron overload. The excess iron can poison these organs, leading to life-
threatening conditions, with the most common being liver cirrhosis.  
In 2004 with the end of the scholarship I had a proposal to start working in immunogenetic 
world! So, among other tasks, I had a special duty in transplantation procedure: Selection 
of the organ donor-recipient matching pair. 
With immunogenetic, organ and bone marrow transplantation a new interest for 
regenerative medicine began. 
Above nerve regeneration my curiosity, interest and recent scientific research knowledge 
are focused on stem cell therapies applied to regenerative medicine. Therefore I decided 
to keep on with my research work on stem cells, especially concerning the MSCs that 
might be isolated from several tissue sources other than the umbilical cord blood and 
matrix. Studying their therapeutic value on a new disease model: “liver cirrhosis”. Here by 
a fat of destiny was where I began this scientific adventure! For that reason, in the chapter 
of this thesis entitled Future Perspectives I decided to describe at a glance, the project 
that I will propose for a Pos-Doc Grant. 
 
Abstract 
The liver is a vital survival organ responsible for body homeostasis. It is well known that 
liver fibrosis development is strongly associated with the progression of chronic liver 
disease like infections by hepatitis virus B and C, alcohol abuse or nonalcoholic 
steatohepatitis. In last stage liver fibrosis progresses to cirrhosis, liver failure and portal 
hypertension which ends up requiring liver transplantation. Due to the lack donors and 
transplantation associated complications, it is imperative to seek alternative therapies. In 
the last years there has been an attempt to treat liver injury using cell therapies and tissue 
engineering strategies. Today, in the world over 21 million people live with chronic liver 
disease and 8 hundred thousand per year die. 
Chapter V 
Future Perspectives 
 
 
Andréa Louise Moutinho Gärtner | 228 
 
The main goal of this project is to evaluate and compare the therapeutic effect in vivo, of 
allogeneic and autologous Mesenchymal Stem Cells isolated from adipose tissue and 
bone marrow, in an acute liver failure induced rat model (Sasco Sprague adult rats). 
 
State of the Art 
Liver Injury 
The liver is a vital organ which comprises a wide range of functions such as 
metabolism, detoxification, biosynthesis of various biochemical components and 
storage. In adult rats the liver represents about 3% of total body weight (Martins et al., 
2007), with a very similar range in humans were it stands for about 2-2.5% (Grisham, 
2009). Liver injury can be caused by viral infection like hepatitis B and C, drugs, 
excessive alcohol consumption, in addition to many genetic, metabolic and immune 
disorders. The most common forms of liver injury are characterized by fatty liver, 
steatohepatitis, liver fibrosis / cirrhosis, which might develop into hepatocellular 
carcinoma. Alcoholic liver disease (ALD) is one of the most common diseases 
responsible for these irreversible injuries. It remains a major worldwide health problem. 
The prognosis of individual patients with ALD depends on the degree of pathological 
injury, the patient's nutritional status, the presence of secondary complications of 
advanced disease, and the patient's capacity to eliminate destructive behaviors like 
alcohol consumption or inappropriate diet routine. It is well known that liver fibrosis 
development is strongly associated with the progression of chronic liver disease like 
infections by hepatitis virus B and C, alcohol abuse or nonalcoholic steatohepatitis 
(Friedman, 2003; Nakamura et al., 2007). 
Liver fibrosis is a histological change associated to parenchyma inflammation and tissue 
necrosis; the damage causes liver stellate cells to be over active and to increase extra 
cellular matrix (ECM) synthesis, more than normal amounts of collagen fiber are deposit in 
the extra-cellular spaces of the liver cells and the ratio of fibro-connective tissue in liver 
cellular tissue increases. At this stage, the liver lobular structures are intact. There is no 
pseudo-lobule formation. The last stage of liver fibrosis clinical progression is cirrhosis, 
liver failure and portal hypertension. These symptoms are serious and the clinical 
prognosis is poor, which implies liver transplantation. Although, fibrosis and cirrhosis are 
different, they are closely related. They are two distinguished pathological conditions. 
Cirrhosis consists of two pathological features: fibro-connective tissue hypertrophy and 
pseudo-lobule formation. At the cirrhosis stage, the liver's fundamental structure is 
deformed, and the framework of the liver begins to collapse. Therefore, reversal of the 
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lesions is not possible. Liver transplantation is imperative for patient’s survival. New 
therapeutic approaches including cell therapies and tissue engineering are nowadays 
staring to be studied by several international research groups. 
 
Cell Therapy 
Stem cells (StC) participate in both tissue pathogenesis and the recovery process. StC 
are undifferentiated cells, with endless self-renewal sustained proliferation in vitro and 
multilineage differentiation capacity. They play a crucial role in many aspects of biology, 
from embryonic development to tissue repair and maintenance. This in vitro multilineage 
differentiation capacity has targeted these cells with extreme importance for use in tissue 
and cell-based therapies (Gärtner et al., 2013). Stem/progenitor cells in liver tissue 
actively participate in the repair and functional recovery process from damage caused 
by alcohol and its metabolites. 
MSCs comprise a rare population of multipotent progenitors capable of supporting 
hematopoiesis and differentiation into several lineages. Due to this ability confirmed by 
results of in vitro and in vivo studies, MSCs appear to be an attractive tool in regenerative 
medicine. The immunomodulatory function of MSCs was first reported after observation 
that they could evade immunosurveillance after cell transplantation (Parekkadan et al., 
2007). 
In animal experiments of liver transplantation, hepatocytes can clonally expand, 
suggesting that hepatocytes are themselves functional stem cells. Certain types of 
severe liver injuries, especially when the proliferative capacity of hepatocytes is 
reduced, can activate a potential stem cell compartment in the intrahepatic biliary tree. 
In alcohol-induced chronic hepatitis, a close correlation has been observed between 
the degree of progenitor/stem cell activation and the severity of inflammation and 
fibrosis. Hepatic damage studies rely on the availability of animal models, although no 
experimental model reproduces exactly the human liver damage; they may improve our 
understanding on pathogenesis and future therapies. 
 
Objectives:  
The aim of this project is to evaluate and compare the therapeutic effect in vivo, of 
alogenic and autologous MSCs isolated from adipose tissue (AT) and bone marrow (BM), 
in an acute liver failure induced rat model. 
To accomplish this goal, we aim: 
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1. To isolate and characterize rat (Sasco Sprague adult rats) MSCs from adipose 
tissue and bone marrow. 
2. To generate an animal model (Sasco Sprague adult rats) for acute liver cirrhosis, 
administrating hepatotoxic drugs.  
3. Transplant isolated MSCs by intrasplenic or intraperitoneal route in the 
experimental animals. 
4. To evaluate and compare the anti-inflammatory response of the transplanted 
MSCs. 
5. To analyze the MSCs secretome after they arrive to the liver tissue. 
In conclusion, this project aims to evaluate the paracrine function of MSCs and their 
therapeutic value when used in the treatment of acute and chronic liver failure, as well as 
the best timing to do it and to compare allogeneic with autologous therapeutic.  
 
Tasks description:  
In the first task of the work (Objective 1), we will isolation of mesenchymal stem cells 
from rat adipose tissue and bone marrow. Isolation will be done through the two 
mentioned protocols:  
1st - under deep anesthesia adipose tissue from the rats flank will be collected in sterile 
conditions. Collection procedure will be repeated a minimum of 3 times for an average of 
0.62 g of adipose tissue collected per rat. 
Adipose tissue will be minced into fragments with about 4-5 mm thickness in a medium 
solution containing DMEM, FBS and penicillin-streptomycin.  
The resulting fragments will be incubated in primary medium under standard culture 
conditions (37 °C with a 95% humidity atmosphere and 5% CO2).  
The culture medium will be replaced every day. Cells passaged will be done using 
standard trypsinization method and, cell number will be counted.  
MSCs will be passaged at least 4 times and then cryopreserved for future application.  
Cell morphology and growth will be examined under an inverted microscope. 
2nd – After euthanasia of the rat the femurs and tibias from the back limbs will be cut off 
and skin and muscles will be removed. 
Dissected structures will be immersed in 70% isopropanol for a few seconds and 
transferred to DPBS. 
The two ends of each bone will be cut and exposed with a scissor. A 3ml syringe attached 
to a 22G needle filled with DMEM will be used to flush the marrow into a 50ml tube by 
inserting the needle to one open end of the bone. After all the marrow is obtained, the 
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cells will be resuspended and passed through a 70μm cell strainer to remove the bone 
debris and blood aggregates. 
After rinsing the cell they will be resuspended MSC medium containing DMEM, FBS and 
Pen-Strep. Cell suspension will be seeded and incubated under standard culture 
conditions for 1 to 2 weeks. Medium will be changed every 48 hours. 
As soon as cells reach around 80% confluency, cell passaged will be done using standard 
trypsinization method. MSCs will be enriched using BD IMagnet cell separation method. 
Enriched MSCs will be resuspended in culture medium and seed to be maintained or 
cryopreserved for future application. 
Characterization of isolated MSCs will be done by flow cytometry against CD29, CD90, 
CD54, MHC Class I, CD45, CD106, and MHC Class II. 
 
In the second task of this work (Objective 2) we will induce an acute liver damage in a 
rat model. Cirrhosis will be induced in rats by two methods: (i) adding phenobarbital 
sodium to the drinking water during 1 week, and afterwards intraperitoneal injections of 
50% carbon tetrachloride (CCl4) (10mg/Kg body weight) twice a week during 6 weeks; (ii) 
administrating intraperitoneal injections of thioacetamide (TAA) (200mg/Kg body weight) 
twice a week during 6 weeks.  
To clarify the effectiveness of the induced injury two methods will be done in parallel: 
1st - There will be a first group of rats that will be sacrificed after the 6 week treatment with 
the hepatotoxic drugs to clarify the effectiveness of the induced injury. Cirrhosis/fibrosis 
will be detected by immunohistochemistry analysis for collagen type I and fibronectin of 
liver sections. 
2nd - In parallel with histological analysis peripheral blood serum analysis will be done 
before sacrifice and with the remaining rats. 
Peripheral blood will be collected weekly through the tail vein. 
As soon as the blood clots, samples will be centrifuged. Serum will be collected for 
analysis of serum cholinesterase (CHE), total serum bilirubin (TSB), alkaline phosphatase 
(AP), creatinin (Cr), glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic 
transaminase (GPT). 
 
The third task of the work (Objective 3) will be administration of MSCs isolated from 
both tissue sources during 1 - 4 weeks in several trials. 
MSCs will be transplanted through intraperitoneal injections. Rats will be randomly divided 
into several groups to receive ATMSCs with or without PBS, BMMSCs with or without 
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PBS and only PBS. In separate experiments rats will be sacrificed in different 
experimental times from 0 – 8 weeks after treatment. 
To clarify and analyze the tracking of cells in the liver, transplanted cells will be labeled 
with a fluorescent marker to be analyzed by fluorescent in situ hybridization (FISH) in the 
liver tissue. 
 
In the fourth task of the work (Objective 4 and 5) we will do several procedures for 
analysis of liver tissues obtained from the sacrificed rats. 
- RNA will be extracted from liver tissue and cultured ATMSCs and BMMSCs. A 
total of 2 µg RNA from each source will be used to perform RT–PCR for several 
genes of factors that regulate the development of liver organogenesis (AFP, -
fetoprotein; CK-18, cytokeratin-18; CK-19, cytokeratin-19; HGF, hepatocyte growth 
factor; HNF-3β, hepatocyte nuclear factor-3β; MMP-2, matrix metalloprotease-2; 
PPAR-γ2, peroxisome proliferator-activated receptor- γ 2;Osteopontin; Albumin; c-
Met and GAPDH). A comparative profile analysis will be done between liver tissue 
transplanted cells and cultured cells used for transplantation. 
- Analysis by fluorescent in situ hybridization (FISH) to clarify the effectiveness of 
cell tracking into the cirrhotic liver tissue 
- Azan Mallory histological staining or Immunohistochemistry for collagen type I and 
fibronectin of liver sections to define the level of liver damage reduction. 
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